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Abstract 
Flavonoids are secondary metabolites of plants which have anti-cancer, anti-inflammatory, and 
antioxidant properties. However, the intestinal microbiota can change the bioactivity and bioavailability 
of these compounds, which may trigger different levels of response to a treatment. In order to expand 
our understanding of the capacity of the gut microbiota to modify these therapeutic compounds, we 
explored the microbial degradation of quercetin, one the most abundant flavonoids in the human diet. 
First, we revealed that a non-quercetin degrader (Bacteroides thetaiotaomicron) can provide, via cross-
feeding, substrates to a quercetin-degrader (Eubacterium ramulus) for the cometabolization of the 
flavonoid. Second, through a metataxonomic analysis of fecal communities exposed to the flavonoid, we 
detected two variants related to the quercetin degrader, Flavonifractor plautii, that presented a negative 
correlation in their relative abundances upon incubation with quercetin. Lastly, a bioinformatic analysis 
of the genome of the closest relatives of these variants showed that they are discordant for the catabolism 
of an important substrate in the gastrointestinal tract, ethanolamine, which it is formed from bacterial 
and intestinal cell membranes and is abundant even in the absence of dietary compounds due to the 
constant washing away of these cells in the intestinal mucus. Overall, these observations indicate that 
flavonoid-degrading bacteria can be differentially affected by dietary and host’s substrates and 
interactions with different microbial species. Thus, the community structure and metabolic capacity of 
each individual’s gut microbiota may impact the health-related effects of these compounds. 
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Resumen 
Los flavonoides son metabolitos secundarios de plantas que tienen propiedades anticancerígenas, 
antiinflamatorias y antioxidantes. Sin embargo, la microbiota intestinal puede cambiar la bioactividad y la 
biodisponibilidad de estos compuestos, lo que puede desencadenar diferentes niveles de respuesta a un 
tratamiento. Con el fin de ampliar nuestra comprensión de la capacidad de la microbiota intestinal para 
modificar estos compuestos terapéuticas, exploramos la degradación microbiana de la quercetina, uno 
de los flavonoides más abundantes en la dieta humana. Primero, demostramos que un no degradador de 
quercetina (Bacteroides thetaiotaomicron) puede proporcionar, mediante alimentación cruzada, 
sustratos a un degradador quercetina (Eubacterium ramulus) para la cometabolización del flavonoide. 
Segundo, a través de un análisis metataxonómico de comunidades fecales expuestas al flavonoide, 
detectamos dos variantes del degradador de quercetina, Flavonifractor plautii, quienes presentaban una 
correlación negativa en sus abundancias relativas tras la incubación con quercetina. Por último, un análisis 
bioinformático del genoma de los parientes más cercanos de estas variantes mostró que son discordantes 
para el catabolismo de un sustrato importante en el tracto gastrointestinal, la etanolamina, que se forma 
a partir de las membranas celulares bacterianas e intestinales y es abundante incluso en la ausencia de 
compuestos dietarios debido al lavado constante de estas células en el moco intestinal. En general, estas 
observaciones indican que las bacterias que degradan flavonoides pueden verse afectadas de manera 
diferente por los sustratos dietarios y del huésped junto a las interacciones con diferentes especies 
microbianas.  Por lo tanto, la estructura de las comunidades y las capacidades metabólicas de la 
microbiota intestinal de cada individuo podría influenciar los efectos relacionados con la salud de estos 
compuestos. 
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I. Introduction 
The concept of the human microbiota, as first described by Joshua Lederberg, is defined as “the 
ecological community of commensal, symbiotic, and pathogenic microorganisms that literally share our 
body space” (1). The gut microbiome of healthy individuals varies significantly and only dominant bacterial 
phyla have been consistently described, these are Firmicutes, Bacteroidetes and Actinobacteria, with 
Proteobacteria and Verrucomicrobia also present in lower abundance.  
The gut microbiota plays a very important role in host metabolism. Among the mechanisms in which 
the microbiota is involved, an important one is the modulation of inflammatory pathways in the body. For 
instance, butyrate produced by some intestinal bacteria has anti-inflammatory effects, mainly by the 
suppression of the pro-inflammatory pathway of Nuclear Factor kappa beta (NF-κβ) (2). There are also 
probiotic strains that can reduce oxidative stress levels, among these, Lactobacillus curvatus HY7601, L. 
plantarum KY1032, and L. fermentum ME-3 stand out (3–5). Oxidative radicals are normally produced in 
high concentrations during food digestion and are also generated during cigarette smoking and exposure 
to contaminants, if the number of oxidative radicals surpasses the body’s capacity to neutralize them, 
these radicals start to accumulate and exert cellular damage (6). Oxidative stress also increases the activity 
of the PI 3-kinase and the myosin light chain kinase promoter that regulate the opening of the intestinal 
tight junction barrier. Thus, oxidative stress mediates the enlargement of the spaces in the gut epithelium 
allowing the translocation of normally non-invasive bacteria or their toxic products and components (e.g. 
Lipopolysaccharides [LPS]), that induce the activation of NF-κβ, perpetuating a vicious cycle of NF-κβ 
activation and impairment of the tight junction barrier (7,8). The activation of NFκβ in parts of the body 
different from the gastrointestinal tract also elicits an inflammatory response that can also alter the 
permeability of the intestinal epithelium, facilitating the translocation of luminal materials which will 
exacerbate the inflammation state. 
An approach that can counteract these harmful effects is the supplementation of dietary compounds 
like dietary fiber and phenolic compounds. Non-digestible fiber promotes the growth of beneficial 
microorganisms in the gastrointestinal tract. Some examples are: inulin, fructooligosaccharides, resistant 
starch, pectin, among others. These are metabolized to short-chain fatty acids (SCFAs), like butyrate, 
which as mentioned earlier exert many beneficial health outcomes. SCFAs activate the SCFA receptor 
GPR43 that reduces insulin sensitivity in adipose tissue and hence its fat accumulation, thereby reducing 
the uptake, synthesis, and oxidation of toxic fatty acids in other tissues (9,10). They also increase 
proliferation and inhibit apoptosis of intestinal cells (11), hinders intestinal secretion of chylomicron into 
the circulation (12), and limits inflammation perhaps through inhibition of the NF- pathway (13). 
Meanwhile, polyphenols can be found in wine, cocoa, cranberry, grape, curcumin, propolis, coffee, and 
tea; they function as antioxidants (14), strengthen intestinal barrier function (15), prevent endotoxemia 
(presence of LPS in the blood), the loss of some beneficial bacterial strains, and the development of 
diabetes (16–18). It is possible that the beneficial effects of some of these dietary compounds are exerted 
through the modulation of the microbiota. For example, the administration of cranberry extract and grape 
polyphenols is associated with an increased abundance of a genus Akkermansia that has been associated 
with beneficial metabolic effects even under a high sucrose and/or high fat diet (18–21). 
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The ingestion of foods rich in polyphenolic antioxidants can control the exposure to oxidative radicals. 
Flavonoids are an important group of natural polyphenolic substances with variations in their 3-ring basic 
structure. They are found in many fruits, vegetables, grains, pollen, among others, and are well known for 
their beneficial effects on health. However, some clinical studies have shown the health benefits of 
flavonoids, while others have not observed significant differences. It is possible that the differences 
observed lie in the capacity of absorption, distribution, excretion, response of each individual and the type 
of treatment, therefore, the type of flavonoid used, the dose, the frequency and route of the 
administration can be decisive for the success of the treatment. In addition to these factors intrinsic to 
the treatment and to the patient, there is another under-studied factor: the ability of the intestinal 
microbiota to metabolize flavonoids. Microorganisms have a great versatility to degrade compounds that 
reach the lower part of the gastrointestinal tract, in some cases, more than 90% of the flavonoid is 
degraded. The gut microbiota transforms these phenolic compounds in chemical species that might have 
a different bioactivity and/or bioavailability. Thus, the therapeutic use of flavonoids requires the 
understanding of the role of the gut microbiota as a modifier of these compounds. Specifically, the nature 
and rate of this modification may be affected by dietary substrates and interaction between bacteria. In 
the present study, we studied ecological interactions of flavonoid-degrading bacteria in simple (cocultures 
with non-flavonoid degrading bacteria) and complex (in vitro incubations of fecal matter) communities, 
using quercetin as a flavonoid type and different carbon sources, including several dietary fibers. The 
results of this research establish the importance of studying the interactions carried out by flavonoid-
degrading bacteria with dietary compounds and with flavonoid degrading and non-degrading bacteria, 
revealing factors that can affect the bioavailability and bioactivity of these compounds and therefore their 
health effects. 
Note: This introduction includes sections of the article ‘Advances in Gut Microbiome research, opening 
new strategies to cope with a Western lifestyle’. A complete copy can be found in Appendix 4. 
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II. Objectives 
Characterize the degradability of flavonoid quercetin by the gut microbiota. 
 
Specific objective 1 
To evaluate the effect of different dietary fibers on the degradation of quercetin in an in vitro model of 
simplified intestinal community (co-cultures of quercetin-degrading bacterium, E. ramulus and fiber-
degrading bacterium, B. thetaiotaomicron). 
 
Specific objective 2 
To study the capacity of degrading quercetin by fecal microbial communities of different individuals in an 
animal model of humanized microbiota. 
 
Specific objective 3 
To describe the functional potential in the intestine of the quercetin-degrading model microorganism, E. 
ramulus strain ATCC 29099. 
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III. Conceptualization 
 
The interest in the gut microbiota as an influencing factor on human health is currently a hot topic and 
is considered in the first review article ‘Advances in Gut Microbiome Research, Opening New Strategies 
to Cope with a Western Lifestyle’ (Introduction and Appendix 4). In this review, the inflammatory effect 
of the western lifestyle is discussed as well as approaches that can counteract the threat of an ongoing 
oxidative state. The role of flavonoids as compounds that can exert anti-inflammatory effects and 
potentially as modifiers of the gut microbiota is remarked. However, there is a gap in the scientific 
literature regarding the role of the gut microbiota as a modifier of these compounds. Members of the gut 
microbiota can change the bioavailability and bioactivity of flavonoids, thus altering their health-related 
effects. Flavonoids may not be used as sole carbon sources by the gut microbiota but might be 
cometabolized with other carbon sources and in fact, the literature mentions that fermentable dietary 
fibers can greatly affect the bioavailability and degradability of flavonoids (production of smaller phenolic 
compounds). In this line, we propose to study the relationship between gut microbiota, flavonoids, and 
diet. Quercetin was selected as a type flavonoid since it is an aglycone flavonoid common in human diet, 
thus, it has no sugar that could be deglycosylated and used by the microbial community obscuring the 
results. Meanwhile, dietary fiber was chosen as the dietary component because it is a common 
accompanying substrate of flavonoids and influences their degradability.  
The starting point of the experimental approach of this project was the observation that the well-
recognized quercetin degrader E. ramulus consistently failed to colonize the gastrointestinal tract of germ-
free mice when rodents were fed a diet low in fiber. Meanwhile, E. ramulus was able to colonize when 
mice were fed a diet with a high content of fiber. These germ-free mice were gavaged a synthetic microbial 
community of known microorganisms, among these, only E. ramulus failed to colonize under a fiber-
restricted diet. This was an indication that fiber could be important for the establishment of E. ramulus, 
and therefore for the metabolization of flavonoids carried out by this bacterium. The relationship between 
fiber and flavonoid-degrading bacteria was studied by two strategies, simple (pure cultures and co-
cultures) and complex (feces as inoculum for in vitro cultures) communities. In the first approach, we 
evaluated which dietary fiber, among arabinogalactan, fructooligosaccharides (FOS), galactomannan, 
inulin, pectin, gum arabic, and starch, promoted the cometabolization of quercetin by E. ramulus, and 
whether the metabolization of fiber by another bacterium stimulated E. ramulus. In the second approach, 
we studied the degradation of quercetin by fecal communities from mice fed two diets with different fiber 
contents.  
In simple communities, E. ramulus used arabinogalactan, FOS, galactomannan, inulin, and pectin as 
carbon sources for the cometabolization of quercetin, in both pure cultures as well as in cocultures with 
B. thetaiotaomicron. Interestingly, we observed that only in cocultures, E. ramulus was able to metabolize 
quercetin when starch was the only carbon source. This kind of pattern between bacteria is rarely 
document in the scientific literature, thus we highlighted these results obtained with starch in our first 
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original article titled ‘Bacteroides thetaiotaomicron Starch Utilization Promotes Quercetin Degradation 
and Butyrate Production by Eubacterium ramulus’ (Chapter 1).      
In complex communities, we expected faster rates of quercetin degradation when in vitro cultures 
were inoculated with feces from mice fed a high-fiber diet. However, in many cases incubations inoculated 
with feces from mice fed a low-fiber diet had a faster degradation of the flavonoid. We opted for looking 
for correlations between members of the microbial community with either diet and the rate of 
degradation of quercetin. Still, no significant associations were found, a possible explanation could be the 
high variability of the gut microbiota between individuals. Nevertheless, during the analysis of the 
microbial communities we observed that two species whose relative abundances increased during 
incubation with quercetin and are related to a known quercetin degrader, F. plautii, presented an 
interesting pattern of negative correlation (Chapter 2). Again, this finding has biological importance for 
the field and given its relevance, close relatives of F. plautii were included as part of the third objective, 
which aimed to describe through a bioinformatic approach the functional potential in the intestine of E. 
ramulus (Chapter 3). The important observations obtained for species related to F. plautii were then the 
focus of our second original article titled ‘Gut-derived Flavonifractor species variants are differentially 
enriched during in vitro incubation with quercetin’ which is under review in Plos One. Overall our results 
highlight the importance of the ecological interactions that flavonoid-degrading bacteria have with dietary 
substrates and with other flavonoid-degrading bacteria and members of the gut microbiota that are 
involved in fiber fermentation. Notably, these interactions could impact the anti-inflammatory properties 
of flavonoids.
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IV. Results 
Chapter 1.  Bacteroides thetaiotaomicron Starch Utilization Promotes Quercetin Degradation and 
Butyrate Production by Eubacterium ramulus 
 
Gina Paola Rodriguez-Castaño 1, Matthew R. Dorris2, Xingbo Liu2, Bradley W. Bolling2, Alejandro Acosta-
Gonzalez1, Federico E. Rey3 * 
1 Engineering Department, La Sabana University, Chia, Colombia 
2 Department of Food Science, University of Wisconsin-Madison, USA 
3 Department of Bacteriology, University of Wisconsin-Madison, USA 
Keywords: Quercetin degradation, butyrate, Eubacterium ramulus, Bacteroides thetaiotaomicron, 
cross-feeding, starch. 
Abstract 
Consumption of flavonoids has been associated with protection against cardiovascular and 
neurodegenerative diseases. Most dietary flavonoids are subjected to bacterial transformations in the gut 
where they are converted into biologically active metabolites that are more bioavailable and have distinct 
effects relative to the parent compounds. While some of the pathways involved in the breakdown of 
flavonoids are emerging, little it is known about the impact of carbon source availability and community 
dynamics on flavonoid metabolism. This is relevant in the gut where there is a fierce competition for 
nutrients. In this study, we show that the metabolism of one of the most commonly consumed flavonoids, 
quercetin, by the gut-associated bacterium Eubacterium ramulus is dependent on interspecies cross-
feeding interactions when starch is the only energy source available. E. ramulus can degrade quercetin in 
the presence of glucose but is unable to use starch for growth or quercetin degradation. However, the 
starch-metabolizing bacterium Bacteroides thetaiotaomicron, which does not metabolize quercetin, 
stimulates degradation of quercetin and butyrate production by E. ramulus via cross-feeding of glucose 
and maltose molecules released from starch. These results suggest that dietary substrates and 
interactions between species modulate the degradation of flavonoids and production of butyrate, thus 
shaping their bioavailability and bioactivity, and likely impacting their health-promoting effects in humans.  
 
Introduction 
Flavonoids are phenolic compounds produced by the secondary metabolism of plants. They are 
present in fruits, grains, and vegetables. Their basic structure consists of 15 carbon atoms arranged in 
three rings (A, B and C). Their consumption is associated with a lower risk of suffering from cardiovascular 
and neurodegenerative diseases [1]–[4]. Most polyphenols are poorly absorbed in the upper 
gastrointestinal tract (stomach, duodenum, jejunum, and ileum) and reach the colon where they are 
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metabolized by the gut microbiota into more readily absorbable phenolic acids, increasing bioavailability 
of these biologically active compounds [5], [6]. 
Among the more than 8,000 different flavonoids characterized to date, quercetin is one of the 
most common in nature. It is found in apples, onions, red wine, tea, lettuce, and tomatoes and is 
extensively metabolized in the gastrointestinal tract (>90 %; Chen et al. 2005; Hertog et al. 1992). Carbon 
dioxide is a major metabolite derived from quercetin metabolism in humans; a process that starts with 
the cleavage of the flavonoid’s C-ring by intestinal bacteria [9]. Most members of the gut microbiota that 
are known to cleave the C-ring of quercetin belong to the Clostridia class; these include Flavonifractor 
plautii, Eubacterium ramulus, and Eubacterium oxidoreducens [10]–[12]. E. ramulus is a prevalent 
bacterial species commonly found in healthy subjects at levels ranging from 107 to 109 cells/ g of dry feces 
[13]⁠. E. ramulus ferments glucose to butyrate, a major energy source of colonocytes that inhibits colon 
inflammation and carcinogenesis, and it has systemic effects lowering diet-induced insulin resistance 
[14]–[17]. In vitro studies indicate that E. ramulus requires glucose for the co-metabolization of quercetin 
[18]. Degradation of this flavonoid results in the production of 3,4-dihydroxyphenylacetic acid (DOPAC), 
which has antiproliferative activity in colon cancer cells [18]–[20]. Nevertheless, glucose is rapidly 
absorbed in the small intestine and negligible amounts reach the colon, where E. ramulus resides [21].  
Dietary compounds that can impact microbial flavonoid metabolism in the colon are those that 
resist digestion in the upper gastrointestinal tract. Most carbohydrates that reach the lower 
gastrointestinal tract are of plant origin, including plant cell-wall and storage polysaccharides [22]. Among 
these, the fraction of starch that escapes digestion in the small intestine; i.e., resistant starch, represents 
an important fermentation substrate that boosts bacterial flavonoid metabolism [23] and butyrate 
production  [24]. Starch that is incompletely digested in the upper digestive tract is naturally present in 
many foods, including bananas, rice, maize, and potatoes. For example, around 3 % of hot potato starch 
and 12 % of cold potato starch are resistant to digestion. It has been estimated that for individuals 
following a modern diet, the quantity of starch entering the colon is about 10 % of starch intake, around 
8-40 g/d [25]. Previous work indicates that undigested starch enhances bacterial metabolism of daidzein, 
a soy isoflavone [23]. Furthermore, the abundance of the flavonoid-degrading bacterium, E. ramulus, is 
positively influenced by consumption of resistant starch [26].  
In order to get insights into the fate of flavonoids in the presence of polysaccharides in the multi-
species environment of the gut, we evaluated in a simplified model of the gut microbiota the interactions 
between E. ramulus, which has a limited capacity to utilize polysaccharides, and Bacteroides 
thetaiotaomicron, which has the capacity to degrade many polysaccharides but it is unable to degrade the 
flavonoid, quercetin. We found that B. thetaiotaomicron liberates glucose and maltose from starch at 
levels that support the growth of E. ramulus and degradation of quercetin by this bacterium. Our results 
illustrate how cross-feeding between bacterial taxa can impact the metabolic fate of flavonoids in the gut. 
 
Methods and Materials  
Chemicals. Ammonium formate, 98% crystalline (Alfa Aesar), EDTA ≥98.5% w/w (Sigma-Aldrich), 
methanol HPLC-grade (Fisher Scientific), ultrapure grade water purified to 18.1 MΩ·cm using a Barnstead 
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water filtration system (Thermo Fisher Scientific), potato starch (Sigma; 102954), and quercetin dihydrate, 
97% w/w (Alfa Aesar). 
Bacterial Strains and Culture Conditions. Frozen stocks of E. ramulus strain ATCC 29099 and B. 
thetaiotaomicron VPI-5482 were diluted 1:50 in 7N minimal medium, consisting of 50 mM MOPS·KOH (pH 
7.2), 0.2 % resazurin, 2 mM tricine,  0.025 % tween 80, 20 mM C2H3NaO2, 20 mM NaCl, 14 mM NH4Cl, 0.25 
mM K2SO4, 0.5 mM MgCl2·6H2O, 0.5 mM CaCl2·2H2O, 10 µM FeSO4·7H2O, 20 mM NaHCO3, 1 mM KH2PO4, 
1µg ml-1  vitamin K3, 1.9 µM hematin, 0.2 mM histidine, 8 mM L-cysteine, 1× ATCC trace minerals, 1× ATCC 
vitamin supplement, amended with 40 mM glucose. Media were filter-sterilized (0.22 m pore diameter). 
Cultures were incubated with constant agitation at 37° C overnight (OD600 = 1.5-1.7 for E. ramulus, 1.3-1.5 
for B. thetaiotaomicron), then washed thrice with 10 ml of anaerobic 7N medium without glucose inside 
an anaerobic chamber. All centrifugations steps were done in Hungate tubes at 3,000 rpm 5 min. After 
the final centrifugation, E. ramulus’s cell suspension was resuspended in a sixth of the initial volume and 
B. thetaiotaomicron in half of the initial volume to produce concentrated cell suspensions with equivalent 
number of cells for both (an overnight culture of B. thetaiotaomicron has about 3 times more cells than 
E. ramulus). For a typical assay, about 150 μl of cell suspension was added to a 10 ml medium (this 
corresponds to about 109-1010 genome equivalents ml-1), cultures were grown at 37° C with agitation. 
Glucose was filter-sterilized and added at a final concentration of 40 mM. Starch was autoclaved and 
added at a final concentration of 1 %. Quercetin dihydrate was used at a final concentration of 0.25 mg 
ml-1 in MilliQ water, autoclaved for 20 min, let cooled for 1 h with stirring and dispensed with stirring. 
Bacteria were handled inside an anaerobic chamber under an atmosphere of nitrogen (75%), carbon 
dioxide (20%), and hydrogen (5%).  
DNA preparation. DNA extraction was performed as previously described with modifications [27]. 
Briefly, 300 μl aliquot of cultures with starch as sole carbon source was mixed with a solution containing 
500 µl of extraction buffer (200 mM Tris pH 8.0, 200 mM NaCl, 20 mM EDTA), 200 µl of 20 % SDS, 500 µl 
of a mixture of phenol:chloroform:isoamyl alcohol (25:24:1, pH 7.9) and 1.2 mg of 0.1-mm diameter 
zirconia/silica beads (BioSpecProducts). The suspension was then subjected to 3 min of bead beating 
(BioSpec Products) at room temperature (RT), spun at 8,000 rpm for 5 min at RT, and then 750 μl of the 
top layer was transferred to a 15 ml tube (BD Falcon 12 x 75 mm, #352063) for immediate column 
purification (Nucleospin, Macherey-Nagel). Column binding buffer NTl was used at 2.5 vol, 3 washes with 
washing buffer NT3 were performed and final elution was done with 25 μl of low T(10)E(0.1) buffer. 
Real-time Quantitative PCR (qPCR). qPCRs were performed using the SsoAdvanced universal 
SYBR Green supermix (2X) (BioRad, 172-5270-5275) and the BioRad CFX96 Real-Time PCR Detection 
System. Species-specific primers for the 16S rRNA gene were used at a final concentration of 0.4 mM. 
Primer sequences for B. thetaiotaomicron were 5′-GCAAACTGGAGATGGCGA-3′ and 5′-
AAGGTTTGGTGAGCCGTTA-3′ (Tm 62.5°C) [28] and for E. ramulus, 5′-CGGTACCTGACTAAGAAGC-3′ and 5′-
AGTTTCATTCTTGCGAACG-3′ (Tm: 55°C) [29]. Each culture was analyzed in triplicate. DNA extractions from 
pure cultures of B. thetaiotaomicron or E. ramulus were used to generate standard curves using 7 serial 
dilutions ranging from 442 ng ml-1 to 4.42 × 10−4 ng ml-1 and 235 mg ml-1 to 2.35 × 10−4 ng ml-1, respectively 
(quantified by the Qubit dsDNA HS assay). The qPCR run consisted of a denaturation step (95°C for 30 
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sec), an amplification step (35 cycles of 95°C for 10 sec, Tm for 15 sec and 60°C for 30 sec), and a melting 
cycle (65-95°C 0.5°C increment 2-5 sec/step). 
HPLC analyses of Quercetin and metabolites. Samples from 0 and 22 h cultures were thawed in 
ice, vortexed extensively and 400 μl were mixed with 1000 μl HPLC-grade methanol + 20 μM genistein as 
internal standard, the suspension was subjected to bead beating (BioSpecProducts) for 2 min at RT, then 
heated to 56 °C for 20 min and spun for 10 min at 18, 000 g at RT. Then 1 ml of the supernatant was 
transferred to an HPLC vial and 200 μl of 10 mM ammonium formate/0.5 M EDTA buffer (pH 3.5) was 
added. Quercetin and its metabolites were analyzed using a Dionex UltiMate 3000 HPLC equipped with 
an LPG-3400 quaternary pump, a WPS-3000 analytical autosampler, a DAD-3000 diode array detector, 
and a FLD-3100 fluorescence detector. Separations were performed on a Kinetex 5 μm EVO C18, 100 Å, 
250 × 4.6 mm column (Phenomenex, Torrance, CA, USA). Injection volumes were 5 µL. A flow rate of 1 ml 
min-1 was used throughout the 59 min run. The mobile phase was a binary gradient of (A) 10 mM 
ammonium formate and 0.3 mM ethylenediaminetetraacetic acid in water adjusted to pH 3.5 using 
concentrated HCl and (B) methanol. Solvents were vacuum filtered with 0.20 µm nylon membrane filters 
(Merk Millipore Ltd, Cork, Ireland). The gradient began at 5 % B for 5 min, increased to 30 % B over 30 
min, increased to 95 % B over 10 min, remained constant at 95 % B for 5 min, decreased to 5 % B over 2 
min, and then re-equilibrated at 5 % B for 7 min. Three-dimensional absorbance data were collected using 
the diode array detector and chromatograms of 280 nm absorbance were analyzed. Reportable values 
are shown in Table S1.1 (Appendix 1) and an example chromatogram is shown in Fig. S1.1 (Appendix 1).  
Samples were quantitated based on external calibration with injections of 10 µL over the linear 
range 1-125 µM for protocatechuic acid; 3,4-dihydroxyphenylacetic acid; 3,4-dihydroxyphenylpropionic 
acid; 3-hydroxybenzoic acid; 3-hydroxyphenylacetic acid; 3-(3-hydroxyphenyl) propionic acid; 
phenylacetic acid; quercetin; and genistein and 5-125 µM for benzoic acid. Some compounds could not 
be resolved by this method, namely 3-(3-hydroxyphenyl) propionic acid and phenylacetic acid. 
Gas chromatography-mass spectrometry measurements of butyrate. Samples were processed 
as described before [30]. Briefly, an aliquot of 50 µl of cultures incubated for 12 h with starch and 
quercetin and E. ramulus monocultures with glucose and quercetin (control) were mixed with 20 mM of 
a butyric-d7 acid, 99.5 atom % D, CDN isotopes #D-171 as internal standard, acidified with 5 µl of 33 % 
HCl, extracted twice with Diethyl Ether, then 60 µl of each sample was mixed with 2 µl of derivatizing 
reagent (N-Methyl-N-tert-butyldimethylsilyltrifluoroacetamide, MTBSTFA) and incubated at RT for 2 h. 
For detection, 1 µl of each sample was injected in a gas chromatography–mass spectrometry (GC-MS) 
instrument (Agilent 7890B/5977A GC/MSD), and an Agilent DB-1ms column was used. Oven program was: 
initial temperature, 40°C for 2.25 min; then 20°C min-1 to 200°C; next 100°C min-1 to 300°C, maintained 
for 7 min. 
Colorimetric assay for determination of Glucose and Maltose. An aliquot of each culture with 
starch as sole carbon source was centrifuged at 11,000 g 5 min and glucose and maltose levels were 
determined by a colorimetric method (Maltose and Glucose Assay Kit; Sigma-Aldrich, MO, USA) at 0, 4 
and 8 h of incubation following the manufacturer’s instructions. Standard curve: 2-10 nmoles of glucose 
per well.  
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Statistical analysis. Data was analyzed using analysis of variance (ANOVA – Minitab 18.1). 
Differences considered significant at p < 0.05. 
 
Results  
Eubacterium ramulus requires an energy source to metabolize quercetin. Glucose and starch 
were evaluated for their capacity to promote quercetin degradation by E. ramulus. The structure of 
quercetin is shown in Fig. 1.1A. We used media with no addition of a carbon source as a negative control. 
We found that glucose stimulates the degradation of quercetin by E. ramulus and the production of 3,4-
dihydroxyphenylacetic acid (DOPAC) (Fig. 1.1B) as the main metabolite derived from quercetin (Fig. 1.2 
and Table S1.1 in Appendix 1), as previously described [18]. In the presence of glucose E. ramulus also 
generates high levels of butyrate (Table 1.1). We assessed different concentrations of glucose in order to 
determine the lowest concentration of this monosaccharide required for the co-metabolization of 0.8 mM 
of quercetin. Quercetin degradation was checked by visual inspection; i.e., disappearance of the quercetin 
from the test tube, which is insoluble and has a yellow color. We also quantified quercetin and the main 
degradation product, DOPAC, by HPLC at the end of the experiment (22 h). We found that concentrations 
of glucose above 0.3 mM are required to stimulate detectable quercetin degradation (Fig. S1.2).  
Additionally, we observed a decrease in the population of E. ramulus when no carbon source was added 
but quercetin (Table S1.2 in Appendix 1), suggesting cell death. Accordingly, under these conditions little 
production of DOPAC was detected (Fig. 1.2). Monocultures of E. ramulus supplemented only with starch 
did not show growth (Fig. 1.3A and Table S1.2 in Appendix 1), as expected they accumulated little butyrate 
(Table 1.1) and DOPAC after 22 h of incubation (Fig. 1.2). There were no signs of quercetin degradation 
after 4 days of incubation (data not shown). E. ramulus did not grow on starch with or without quercetin 
(Fig. S1.3). 
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Figure 1. 1 
Structure of Quercetin (A) and 3,4-Dihydroxyphenylacetic acid (DOPAC), the main metabolite generated 
by E. ramulus from quercetin degradation (B) (National Center for Biotechnology Information. PubChem 
Database, compound 5280343 and 547, respectively [https://pubchem.ncbi.nlm.nih.gov/]. 
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Figure 1. 2 
DOPAC concentration as measured by HPLC in cultures with no carbon source, glucose (0.7 %), and starch 
(1 %). Culture tubes were inoculated with only B. thetaiotaomicron or E. ramulus or both and incubated 
for 22 h. Error bars corresponds to 3 replicates. Different letters above bars indicate significant difference 
between type of culture at p <0.05 according to LSD. 
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Figure 1. 3 
Growth of E. ramulus (A) and B. thetaiotaomicron (B) in cultures with 1 % starch as carbon source. GEq, 
Genome equivalents. Change in Geq/ml between time 0 h and 8 h. Results from independent experiments 
are presented in Table S1.2 (Appendix 1). Different letters above bars indicate significant differences 
between type of culture at p <0.05 according to LSD, data from 2 independent experiments (with 2-3 
replicates each). 
17 
 
Table 1. 1.  
Butyrate concentrations in monocultures and cocultures of E. ramulus and B. thetaiotaomicron.  
Culture and Carbon source Butyrate (mM) 
E. ramulus monoculture with Glucose 7.09 ± 0.40 
E. ramulus monoculture with Starch 0.22 ± 0.07a 
B. thetaiotaomicron monoculture with Starch 0.01 ± 0.0005b 
Coculture with Starch 3.19 ± 0.06c  
Average values for 3 replicates. Different letters after standard deviation indicate significant difference between type of culture 
(only starch cultures) at p <0.05 according to LSD. 
 
Bacteroides thetaiotaomicron starch utilization enhances butyrate production and quercetin 
degradation by Eubacterium ramulus. We examined whether the presence of the versatile 
polysaccharide-metabolizing bacterium, B. thetaiotaomicron, influenced the degradation of quercetin and 
production of butyrate by E. ramulus.  We incubated both species with quercetin and starch individually 
and in coculture. We did not observe significant degradation of quercetin by either species in monoculture 
(Fig. 1.2). However, a marked appearance of DOPAC (Fig. 1.2) and enhanced growth of E. ramulus was 
observed in cocultures (Fig. 1.3A and Table S1.2 in Appendix 1). Growth of E. ramulus was not enhanced 
in cocultures when glucose was the sole carbon source (Fig. S1.4, Appendix 1). Additionally, while butyrate 
was not produced by either species in monoculture incubated with starch, cocultures accumulated high 
levels of butyrate, ~44 % of the amount produced by E. ramulus monocultures with 40 mM glucose (Table 
1.1). On the other hand, the presence of E. ramulus did not change significantly the growth yield of B. 
thetaiotaomicron incubated with 1 % starch (Fig. 1.3B and Table S1.2 in Appendix 1).   
Bacteroides thetaiotaomicron releases glucose and maltose from starch. Lastly, we 
hypothesized that B. thetaiotaomicron promotes E. ramulus metabolism by releasing free glucose from 
starch. We quantified free glucose in cultures with starch as the sole carbon source (Table 1.2). We found 
that B. thetaiotaomicron releases free glucose at levels that are higher than what we found is necessary 
to stimulate quercetin degradation (Fig. S1.2 in Appendix 1), whereas cocultures accumulated 
approximately 50 % of the glucose of B. thetaiotaomicron monocultures (p<0.05) (Table 1.2).  Additionally, 
we detected maltose in monocultures of B. thetaiotaomicron incubated with starch at a concentration of 
0.2 mM. (±0.04 mM) at 4 h and 0.8 mM (±0.1 mM) at 8 h of incubation. In cocultures, there were lower 
concentrations of maltose, 0.08 mM (±0.02 mM) after 4h of incubation and 0.4 mM (±0.2 mM) after 8 h. 
Accordingly, maltose also stimulated the degradation of the flavonoid by E. ramulus in monoculture (data 
not shown). Altogether these results suggest that E. ramulus uses glucose and maltose released by B. 
thetaiotaomicron from starch to grow, produce butyrate and to degrade the flavonoid. 
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Table 1. 2.  
Concentration of glucose liberated from starch by E. ramulus or B. thetaiotaomicron (monocultures) or 
both organisms in coculture. 
Culture 
Free Glucose (mM) 
0 h 4 h 8 h 
E. ramulus monoculture 0.02 ±0.004a 0.02 ±0.01a 0.06 ±0.05a 
B. thetaiotaomicron monoculture 0.03 ±0.01a 1.29 ±0.43b 8.29 ±2.76b 
Coculture 0.02 ±0.01a 0.68 ±0.33c 4.62 ±1.70c 
Average values for 2 independent experiments with 2 replicates each. Different letters after parenthesis indicate significant 
difference between treatments at each time point at p <0.05 according to LSD. 
 
Discussion 
Here we evaluated how the utilization of a common carbohydrate in human diet, starch, by a 
member of the Bacteriodetes phylum changes the dynamics of flavonoid degradation and production of 
butyrate by E. ramulus. We found that metabolization of starch by B. thetaiotaomicron enhanced these 
processes in the Firmicute via cross-feeding of glucose and maltose released from the carbohydrate. 
Mahowald and coworkers observed in gnotobiotic mice co-colonized with Eubacterium rectale and B. 
thetaiotaomicron that E. rectale is better able to access nutrients and upregulates genes in the central 
carbon and nitrogen pathways in the presence of the B. thetaiotaomicron [31]. One explanation for this 
is the observation that B. thetaiotaomicron releases simple saccharides when digesting complex 
carbohydrates that then Eubacterium can access. We have observed that B. thetaiotaomicron can 
enhance the growth of E. ramulus when growing on different oligo and polysaccharides (e.g., inulin, FOS, 
and arabinogalactan; data not shown), however the most striking stimulation was on starch. B. 
thetaiotaomicron possess membrane-associated amylase activity, encoded by susG, which may allow the 
release of products of starch breakdown to the extracellular medium [32], however, not all bacteria can 
access these public goods [33]. Cross-feeding of starch-derived metabolites has also been reported for 
Bifidobacterium adolescentis, this bacterium generates resources that can be used by butyrate producers 
including Roseburia sp., Eubacterium hallii, and Anaerostipes caccae.  This cross-feeding involves end-
products (lactate or acetate) of B. adolescentis starch fermentation and potentially products released by 
partial hydrolysis of starch likely to be malto-oligosaccharides [34], however it is not clear whether glucose 
is released from starch by B. adolescentis. In our studies, supplementation of acetate to the media (20 
mM), in the absence of a usable carbohydrate, did not prompt the degradation of quercetin or the 
production of butyrate by E. ramulus.  
In this work, we evaluated a soluble form of starch.  Soluble starch could reach the colon 
entrapped in non-soluble cell-wall particles which can be released when cellulose-degrading 
microorganisms (e.g. Ruminococcus spp. or Enterococcus spp.) act on them releasing the soluble part. It 
is also possible that cellulose-degrading microorganisms could release free glucose, however, the capacity 
to degrade cellulose in humans seems to be limited [22], [35]. B. thetaiotaomicron has a great ability to 
ferment soluble starch while its ability to ferment resistant starch depends on the type of resistant starch 
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and treatment. In vitro experiments show an efficiency of >90 % for autoclaved or boiled high amylopectin 
corn starch but <1 % for raw high amylose corn starch. Thus, in the gut other players that ferment resistant 
starch more efficiently may potentially play an important role in providing resources for cross-feeding. It 
is worth noting that several butyrate-producers including E. ramulus do not have the capacity to degrade 
starch; nonetheless resistant starch is recognized as a butyrogenic substrate [24], thus we suggest that 
the acquisition of luminal products of starch breakdown (e.g., glucose and maltose) by butyrate-producing 
species may be important for the production of butyrate.  
Several studies indicate that quercetin has antibacterial activity [36], [37]. Quercetin increases the 
permeability of certain bacteria to ions [38]. Some species of bacteria have defense mechanisms against 
quercetin. For example, the plant root-colonizer, Pseudomonas putida, has an efflux pump, TtgABC, that 
has a high affinity for quercetin, as well as for certain antibiotics [39]. Cellular targets also include enzymes 
like DNA gyrase and D-alanine:D-alanine ligase, essential for DNA replication and the assembly of 
peptidoglycan precursors, respectively, in these enzymes quercetin recognizes the conserved ATP-binding 
region and compete with ATP [40], [41]. Some sugar transporters depend on ATP [42] thus the ability of 
using starch when quercetin was not present was evaluated for E. ramulus. Under these conditions E. 
ramulus was also unable to use starch. Thus, our data indicates that E. ramulus is unable to perform the 
initial breakdown of starch but possess the ability of using public goods generated by the breakdown of 
this substrate [33]. In the intestine, the ability to degrade quercetin may create a temporal niche where 
E. ramulus can access nutrients (e.g., luminal glucose) that are in the vicinity of flavonoids and that other 
flavonoid-sensitive bacteria cannot access while the concentration of the flavonoid is still high.  
Microbial-derived biologically active metabolites have a major impact on host’s health. Quercetin 
is one of the most abundant flavonoids, however it is still not clear whether its colonic degradation is 
beneficial for the host since the parent compound and bacterial products derived from its degradation all 
have bioactivity. Studies that explore the extent to which degradation of quercetin is beneficial for the 
host are needed. For this goal, carbohydrates that promote more or less the degradation of the flavonoid 
can be useful. For example, it has been shown that fructooligosaccharides administered to the diet 
accelerate the use of the flavonoids rutin, quercitrin and quercetin in cecal contents of rats relative to 
animals supplemented with non-fermentable fiber [43]. The characterization of gut microbes able to 
metabolize flavonoids will make possible in the future to stratify subjects in clinical trials based on the 
flavonoid-degrading capacity of their gut microbiotas. Furthermore, understanding how interpersonal or 
disease-associated differences in gut microbial metabolism of flavonoids impact the potential benefits 
associated with their consumption, and identifying biomarkers for these processes will help nutritionists 
formulate dietary recommendations that are matched by the metabolic potential of a subject’s gut 
microbiota with the ultimate goal of optimizing food function efficacy. 
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Chapter 2. Gut-derived Flavonifractor species variants are differentially enriched during in vitro 
incubation with Quercetin and persist in diets with different fiber contents 
Abstract 
While the health-promoting properties of flavonoids are widely studied little is known about the 
ecology of the gut bacteria that are able to transform these phenolic compounds influencing their health 
benefits. These bacteria are often studied in pure culture; however, they reside in the heterogenous colon 
environment where multiple interactions between microbes happen. In this study, a comparative 
metataxonomic analysis of complex fecal communities (n=15) supplemented with the flavonoid quercetin 
led us to describe a potential ecological phenomenon between two variants related to a flavonoid 
degrading species, Flavonifractor plautii. Fecal pellets retrieved from germ-free mice transplanted with 
human fecal samples and fed 2 diets with different fiber contents were used for fecal slurries with 
quercetin, during incubation the relative abundance of these two variants related to Flavonifractor sp. 
were inversely correlated, one variant (ASV_65f4) increased in relative abundance in half of the libraries 
and the other variant (ASV_a45d) in the other half. Mouse’s diet did not change the pattern of dominance 
of either variant, and initial relative abundances did not predict which one ended up dominating in the 
presence of the flavonoid. This pattern was also observed with 9 additional fecal samples that were used 
directly as an inoculum in in vitro cultures. Potential distinct metabolic properties of these two 
Flavonifractor-related species was evidenced, as only one species became consistently enriched in 
complex communities supplemented with acetate. Additionally, co-abundance patterns with other taxa 
showed that when one of the Flavonifractor-related species was dominant, the relative abundance of 
Desulfovibrio was significantly higher whereas the other variant was associated with higher levels of the 
succinate-utilizing genus Phascolarctobacterium, suggesting potentially distinct interactions of these 
variants within the gut microbial community and/or its metabolites. Here, we showed that the 
Flavonifractor genus harbors variants whose relative abundances may fluctuate according to the dietary 
substrates present and the interactions with the microbial community. Whether this behavior affects the 
dynamic of quercetin degradation warrants further investigation.  
 
Introduction 
Flavonoids are 3-ring phenolic compounds found in fruits and vegetables, their regular 
consumption is associated with health benefits (1,2). Among these, quercetin is one of the most abundant 
in human diet. It exerts effects in the immune, digestive, endocrine, nervous, and cardiovascular systems 
(3–6). Some gut bacteria have the capacity to cleave the central ring in the flavonoid skeleton by a process 
known as C-ring fission which generates smaller phenolic products. In the case of quercetin 
biodegradation, phloroglucinol and 3,4-dihydroxyphenylacetic acid (DOPAC) are formed (7). It is not clear 
to what extent do the health effects of flavonoids depend on their transformation to biologically active 
compounds by the gut microbiota. Vissiennon and collaborators showed that the anxiolytic activity of 
quercetin is induced by DOPAC and not by the parent compound, evidencing a case in which the microbial 
metabolite induces the beneficial effect (8). DOPAC has also antiproliferative activity in colon cancer cells 
(9) and anti-platelet aggregation activity (10). Additionally, the well-recognized quercetin-degraders, F. 
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plautii (formerly Clostridium orbiscindens) and E. ramulus, are also butyrate-producers, a short-chain fatty 
acid that is the preferred source of energy for colonocytes and essential for colon health (11–14). 
Most commonly, these flavonoid degrading bacteria are studied in pure culture, however, they 
reside in the colon where more than 1013 bacterial cells inhabit (15). In vitro fecal incubation systems 
provide a scenario where complex microbial communities can be studied in order to reveal important 
ecological interactions that can impact the biotransformation of flavonoids. In vitro fecal incubations with 
quercetin have revealed the metabolites formed during the transformation of this flavonoid; however, 
ecological interactions between quercetin-degraders and the rest of the community have been 
overlooked. Additionally, most studies have analyzed fecal samples from one donor (16,17) or pooled 
fecal samples from different donors (18–20), dismissing the importance of the gut microbiota at the 
individual level. In order to characterize key players in quercetin degradation that are common or unique 
among subjects, the evaluation of in vitro fecal incubation experiments with individual fecal samples is 
needed. However, fecal samples taken directly from individuals may be influenced by the subject's diet, 
the donor's handling of the stool sample, and transport conditions. Therefore, murine models of 
humanized microbiota provide a strategy that can minimize the interference of factors such as genetics, 
lifestyle and the diet of the individual, and can be used to study the effect of a controlled diet on the 
microbial communities. 
In this study, microbial community dynamics from different subjects were analyzed individually 
by in vitro incubations of feces with quercetin, 6 fecal samples were inoculated in human microbiota-
associated mice (HMAM) and 9 that were directly assayed. Species related to Flavonifractor, Eubacterium, 
and Intestinimonas became enriched under these conditions. A more detailed analysis revealed that two 
species variants related to the genus Flavonifractor were present in every library but after quercetin 
incubation one or the other variant but not both became enriched. Given the metabolic differences 
observed between these variants, we propose that their role in the gut microbiome is differentially 
mediated by carbon sources in the diet and interactions with other members of the community and may 
have distinct roles in the degradation of the flavonoid.   
 
Methods and Materials  
Sample collection and processing. Stool samples were collected from subjects participating in the 
Wisconsin Longitudinal Study (WLS) between November 2014 and February 2015 as previously described 
(21). Briefly, participants collected stool samples directly in sterile containers, then samples were kept at 
~4 °C until arrival to the processing laboratory within 48 hours of collection. Upon arrival, sterile straws 
were filled with the fecal material and stored at -80˚ C as previously described (22). The use of WLS fecal 
microbiota was approved by the Institutional Review Board at the University of Wisconsin-Madison. 
In vitro incubations with fecal samples from human microbiota-associated mice (HMAM) under 
different diets. Experiments involving mice were performed using protocols approved by the University 
of Wisconsin-Madison Animal Care and Use Committee. Six female C57BL/6 (B6) germ-free mice were 
gavaged with ~200 µl of fecal slurry which were prepared under anaerobic conditions in Hungate tubes 
using a 1 cm piece of straw containing the frozen fecal material and 5 ml mega media (23). Mice were 
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maintained on a chow diet for 2 weeks after humanization, then, a diet high in fiber (Teklad 2018S) was 
administered for two weeks, and then switched to a low fiber diet for two weeks (Teklad TD.97184). Three 
fecal pellets were collected for each mouse after each experimental diet (high and low in fiber) and used 
separately as inoculum for in vitro incubations. Fecal pellets were weighted and then resuspended at 0.15 
mg ml-1 final concentration with vigorous vortexing in anaerobic 7N minimal medium supplemented with 
20 mM sodium acetate (filter-sterilized through a 0.22-m pore diameter) (24). Quercetin dihydrate, 97 % 
w/w (Alfa Aesar) concentration was 0.25 mg ml-1 (0.8 mM) in the corresponding medium. Sample 
processing was done in an atmosphere of nitrogen (75%), carbon dioxide (20%), and hydrogen (5%) and 
incubation was also done under anaerobic conditions at 37° C statically. Sampling was done at 0 and 7 
days of incubation. 
In vitro incubations with human fecal samples and quercetin. Human fecal samples were directly 
used for in vitro incubations with quercetin. Samples from 9 subjects kept in frozen straws were aliquoted 
(~50 mg) on dry ice, weighted, and resuspended at 0.5 mg ml-1 final concentration with heavy vortexing 
in anaerobic 7N minimal medium supplemented with 20 mM sodium acetate (24). Quercetin 
concentration was 0.125 mg ml-1 (0.4 mM) in the corresponding medium. Controls consisted of the same 
medium plus fecal sample. Anaerobic bottles were kept statically at 37° C. When quercetin disappearance 
was visible, 10 % of the culture was transferred to another anaerobic bottle with the same medium. 
Treatments with quercetin had three replicates and controls one replicate. Sample processing was done 
in an anaerobic chamber under anaerobic conditions. Sampling was done at the end of the first and second 
incubation time once quercetin degradation was completed across all samples (72 h of incubation). In a 
second experiment, combinations of fecal matter from different subjects were tested. Two fecal samples 
used in the previous in vitro incubation experiment (from subjects #9 and #10) were selected based on 
their enrichment of one or the other Flavonifractor-related variant (ASV_65f4 or ASV_a45d). Three 
combination of these fecal samples were done as follows (#9/#10): 0/0.1, 0.1/0.1, 0.1/0 mg ml-1. 
Incubations were done again in anaerobic 7N minimal medium supplemented with 20 mM sodium acetate 
with and without quercetin using three replicates. Sampling was done at 0 and 72 h of microbial growth.  
HPLC analyses of Quercetin and metabolites. Samples were processed as previously described 
(24). Briefly, 200 μl samples were mixed with 1000 μl HPLC-grade methanol plus 20 μM genistein as 
internal standard, the suspension was bead beated (2 min), heated (56 °C for 20 min) and spun (10 min at 
18, 000 g). Then 1 ml of the supernatant was mixed with 200 μl of 10 mM ammonium formate/0.5 M 
EDTA buffer (pH 3.5). Separations were performed on a Kinetex 5 μm EVO C18, 100 Å, 250 × 4.6 mm 
column (Phenomenex, Torrance, CA, USA). Injection volumes were 10 µL. Flow rate was 1 ml min-1. Run 
time was 59 min run. The mobile phase was a binary gradient of (A) 10 mM ammonium formate and 0.3 
mM ethylenediaminetetraacetic acid in water adjusted to pH 3.5 using concentrated HCl and (B) 
methanol. Gradient was: 5 % B for 5 min, increased to 30 % B over 30 min, increased to 95 % B over 10 
min, remained constant at 95 % B for 5 min, decreased to 5 % B over 2 min, and then re-equilibrated at 5 
% B for 7 min. Chromatograms at 280 nm absorbance were analyzed.  
DNA preparation. A 300 µL aliquot of each culture was mixed with a solution containing 500 µl of 
200 mM Tris (pH 8.0), 200 mM NaCl, 20 mM EDTA, 200 µl of 20 % SDS, 500 µl of phenol:chloroform:isoamyl 
alcohol (25:24:1, pH 7.9) and 1.2 mg of 0.1-mm diameter zirconia/silica beads (BioSpecProducts). The 
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suspension was bead beated (3 min), spun at 8,000 rpm (5 min), and then top layer was transferred to a 
15 ml tube for immediate column purification with 2.5 vol of NTl buffer, 3 washes with NT3 and final 
elution with 25 μl of elution buffer (Clontech, Machery-Nagel 740609.250).  
16S rRNA gene V4 amplification and sequencing. PCR was performed using primers 515F and 
806R for the variable 4 (V4) region of the bacterial 16S rRNA gene (25). PCR reactions contained 1 ng µl-1 
DNA, 10 µM each primer, 12.5 µl 2X HotStart ReadyMix (KAPA Biosystems, Wilmington, MA, USA), and 
water to 25 μl. PCR program was 95 °C for 3 min, then 30 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C 
for 30 s, final step was 72 °C for 5 min. PCR products were purified by gel extraction from a 1.5 % low-melt 
agarose gel using a Zymoclean Gel DNA Recovery Kit (Zymo Research, Irvine, CA). Samples were quantified 
using the Qubit dsDNA HS assay (Invitrogen, Carlsbad, CA, USA) and equimolar concentrations pooled. 
The pool was sequenced with the MiSeq 2x250 v2 kit (Illumina, San Diego, CA, USA). All DNA sequences 
generated in this study will be deposited in NCBI’s Short Read Archive. 
16S rRNA Sequence Analysis. Sequences were demultiplexed on the Illumina MiSeq, and 
sequence clean-up was completed in Qiime2 Core 2018.11 (https://qiime2.org). Quality control, including 
removal of chimeras was performed with the DADA2 pipeline. The first 10 nucleotides were trimmed, and 
reads were truncated to 220 bases. DADA2 generates high-resolution tables of amplicon sequence 
variants (ASVs) which represent biological sequences in the sample differing by as little as one nucleotide 
(26). Taxonomy was assigned to ASVs using the feature-classifier classify-sklearn. The abundance of the 
resulting taxonomy assignments of ASVs was analyzed using STAMP 2.1.3 (statistical analysis of taxonomic 
and functional profiles) (27), with statistical comparisons between groups (e.x. control vs. quercetin 
treatment) performed by two-sided Welch’st-test within 95% confidence interval. A subset of 6 ASVs 
whose abundance increased in quercetin treatments were further analyzed using SILVA ACT (Alignment, 
Classification and Tree Service) (28), and 10 closest neighbors were downloaded from this analysis. ASVs 
that lack neighbors with a defined taxonomy at the genus level in SILVA ACT were subjected to BLASTn 
(https://blast.ncbi.nlm.nih.gov/) using the Whole-genome shotgun contigs (WGS) database for Clostridia 
(taxid:186801), 16s rRNA partial sequences from the most similar genomes with a defined taxonomy at 
the genus level were used for the phylogenetic analysis. This group of sequences were aligned and 
analyzed in MEGA 6.06 (29), the alignment file was used to construct a phylogenetic tree using the UPGMA 
method and a Distance Matrix for estimating evolutionary divergence between sequences  (29–31). 
Complete ids for ASV enriched in quercetin treatments and accession numbers for reference sequences 
are listed in Fig. 2.3 (only the first 4 letters of each ASV are going to be mentioned throughout the text). 
Correlations (Spearman’s rs and Bonferroni correction) and Principal component analysis (PCA) were done 
using PAST 3.23 (PAleontological STatistics) (32). 
 
Results  
Degradation of quercetin did not correlate with fiber content of diet. Germ-free mice were 
inoculated with fecal samples from 6 human subjects (HMAM mice) and fed diets with different fiber 
content, after a period of acclimatization to the diet, fecal pellets were retrieved and used for in vitro 
incubations with quercetin. The degradability of quercetin by fecal communities did not correlate with 
whether the fecal community came from mice fed a high or low content diet as shown in Table 2.1. For 
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some subjects, fecal communities that came from mice fed a diet high in fiber had a more pronounced 
quercetin degradation at day 7th of incubation and for others fecal communities that came from mice fed 
a diet low in fiber had a faster degradation. However, a PCA analysis showed that diet affected the 
composition of the microbial community (Fig. 2.1 A). Component 2 in PCA was explained by diet at 0 days 
of incubation (Fig. 2.1 A) but did not explain the grouping of component 2 at day 7th of incubation (Fig. 
S2.1 B in Appendix 2). An analysis of whether there were ASVs that explained the grouping at day 7th of 
incubation showed that the enrichment of two ASVs, ASV_65F4 and ASV_a45d, explained the grouping of 
component 2 at day 7th (Fig. 2.1 B) and not at day 0 of incubation (Fig. S2.1 A in Appendix 2), indicating an 
importance of these two ASVs after incubation with quercetin. 
 
 
Table 2. 1 
Concentration (mM) in culture of Quercetin for in vitro incubations with fecal samples from human 
microbiota-associated mice fed diets with different fiber content (day 7th of incubation). 
Subject # High Fiber Diet Low Fiber Diet 
Enrichment of 
Flavonifractor-
related variant 
Subject 1 0.004 ± 0.005 0.04 ± 0.02 ASV_a45d 
Subject 2 0.01 ± 0.01 0.48 ± 0.07 ASV_65f4 
Subject 3 0.61 ± 0.04 0.43 ± 0.01 ASV_65f4 
Subject 4 0.48 ± 0.03 0.44 ± 0.05 ASV_a45d 
Subject 5 0.38 ± 0.07 0.40 ± 0.22 ASV_65f4 
Subject 6 0.14 ± 0.05 0.03 ± 0.03 ASV_a45d 
 Note: Average quercetin concentration for all samples at day 0 of incubation was 0.76 mM 
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A 
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Figure 2. 1 
Principal component analysis (PCA) plot of the libraries from in vitro incubations with fecal samples from 
human microbiota-associated mice (HMAM) at 0 (A) and 7 days of incubation (B). In the top panel, libraries 
from HMAM mice fed a high fiber diet are shown in gray and libraries from HMAM mice fed a low fiber 
diet in black. In bottom panel, libraries that were enriched in ASV_65f4 are shown in gray and libraries 
enriched in ASV_a45d are shown in black. Each symbol represents a library (n=6, 3 replicates), different 
shapes represent libraries from a different subject: #1, star (); #2, diamond (); #3, dot (●); #4, inv. 
triangle (▼); #5, triangle (▲); and #6, square (■). 
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Amplicon Sequence Variants ASV_65F4 and ASV_a45d were differentially enriched in in vitro 
incubations with fecal samples. After quercetin treatment, it was observed that ASV_65F4 and ASV_a45d 
dominated in different libraries (Fig. 2.2). The dominance of each ASV during incubation with quercetin 
could not be explained by their initial abundances (Fig. S2.2 A and B in Appendix 2). Even though ASV_a45d 
was lower in abundance (undetectable in most cases) than ASV_65f4, it dominated in half of the libraries 
after quercetin treatment. This pattern of dominance of ASV_65F4 over ASV_a45d or vice versa was not 
affected by diet (Fig. 2.2), however, the relative abundance of ASV_65F4 seemed to be more affected by 
the diet (Fig. S2.3). Additionally, the dominance of ASV_65F4 or ASV_a45d did not explained the rate of 
degradation of quercetin (Table 2.1). 
 
Figure 2. 2 
Relative abundance of bacterial ASV_65f4 and ASV_a45d in HMAM mice fecal samples. ASV_65f4 is 
represented in gray and ASV_a45d in black. Libraries from HMAM mice fed a diet high in fiber are shown 
in solid color and mice fed a diet low in fiber are shown with line pattern. Error bars correspond to 3 
incubations done with fecal matter from the same donor individually sampled. Relative abundances 
obtained after 7 days of incubation with quercetin are shown.  
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Amplicon Sequence Variants ASV_65F4 and ASV_a45d were most related to Flavonifractor spp. 
After in vitro incubations with feces from HMAM mice, 9 human fecal samples different from the previous 
ones were directly inoculated in in vitro cultures with and without quercetin and two successive 
incubations were done. In this experiment, the main objective was not to compare between diets since 
the diet of the donors is not known but to identify bacteria that became enriched in two successive 
incubations with quercetin and whether ASV_65F4 and ASV_a45d were differentially enriched again. In 
all quercetin treatments, the main metabolite produced was DOPAC (Table S2.1 in Appendix 2). STAMP 
statistical analysis showed that 6 ASVs were identified as being enriched in one or more libraries when 
comparing quercetin treatments vs controls with no quercetin (Table S2.2 in Appendix 2), among these 6 
ASVs were ASV_65f4 and ASV_a45d. A phylogenetic analysis revealed that the closest relative for 
ASV_65f4 was F. plautii (100 % identical in the 16S rRNA region V4) and ASV_a45d was most related to 
the Flavonifractor genus (98.6 % identical to Flavonifractor sp. An4 and An82) (Fig. 2.3 and Table S2.3). 
These ASVs were the ones that increased the most in abundance when quercetin was present, together 
with another one related to E. ramulus (ASV_c588) (Fig. 2.4). The other 3 ASVs increased slightly in relative 
abundance and were related to the genera Eubacterium (Lachnospiraceae) and Intestinimonas 
(Ruminococcaceae) (Fig. 2.3 and 2.4). Although these ASVs related to Eubacterium and Intestinimonas 
genera were enriched significantly in 1 or 2 libraries, Flavonifractor-related ASVs were found to be more 
ubiquitous after quercetin incubation, with at least one variant significantly enriched in every library 
(Table S2.2 in Appendix 2). It should be noted that one of these Flavonifractor-related variants, ASV_65f4, 
showed also a significant increase when no quercetin was present in the medium (Fig. S2.4 A in Appendix 
2), indicating that this ASV is favored by the culture conditions used. Nevertheless, its relative abundance 
increased significantly more when quercetin was present (Fig. S2.4 B in Appendix 2). This behavior did not 
change when higher concentrations of fecal matter were tested (1 and 10 mg/ml). The other 
Flavonifractor variant, ASV_a45d, showed no enrichment in media with no quercetin. An important 
observation was that libraries that came from human fecal samples showed a differentially enrichment of 
ASV_65F4 and ASV_a45d after quercetin treatment (Fig. 2.5), as it happened with libraries that came from 
HMAM fecal samples (Fig. 2.2). We then further examined this pattern. 
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Figure 2. 3 
Phylogenetic analysis of taxa enriched in the presence of quercetin. Phylogenetic tree shows six ASVs 
(black dots) whose abundance increased in the presence of quercetin; distances in the tree were inferred 
using the UPGMA method (31). The optimal tree with the sum of branch length = 2.18101115 is shown. 
The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances 
used to infer the phylogenetic tree. The evolutionary distances were computed using the Maximum 
Composite Likelihood method (30) and are in the units of the number of base substitutions per site. The 
analysis involved 44 nucleotide sequences. All positions containing gaps and missing data were 
eliminated. There were a total of 225 positions in the final dataset. Evolutionary analyses were conducted 
in MEGA6 (29).   
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Figure 2. 4 
Bar plots for the relative abundances of the 6 ASVs enriched in quercetin. Human subjects are labeled 
as Subject #7, #8, #9, #10, #11, #12, #13, #14, #15 in bar plots, for better visualization intercalated libraries 
are highlighted in gray. Each library has 6 bars, 3 corresponds to replicates from first incubation and 3 
from second incubation (Subject #9 had only 2 replicates for second incubation).
34 
 
 
 
Figure 2. 5 
Relative abundance of bacterial ASV_65f4 and ASV_a45d in human fecal samples (n=9).  ASV_65f4 is 
represented in gray and ASV_a45d in black. Error bars correspond to 3 incubations done with fecal matter 
from the same donor individually sampled. Relative abundances obtained for the second incubation are 
shown.  
 
 
Amplicon Sequence Variants (ASV) related to Flavonifractor spp. were negative correlated in in 
vitro incubations with fecal samples. After observing that ASV_65f4 and ASV_a45d were differentially 
enriched in in vitro incubations done with both types of fecal samples, HMAM mice and human feces, a 
correlation analysis across the libraries of the abundances of the 6 ASVs enriched in quercetin treatments 
was performed. This analysis showed a strong negative correlation between ASV_65f4 and ASV_a45d 
after quercetin incubation (Fig. S2.5 in Appendix 2) and was not present in incubations without quercetin. 
35 
 
 
Fecal sample combinations showed dominance of ASV_65f4 over ASV_a45d. The biological 
phenomenon between ASV_65f4 and ASV_a45d was observed in fecal samples from 15 different subjects, 
thus, we aimed to continue studying this pattern in cocultures. Unfortunately, only ASV_65f4 was isolated 
in pure culture while ASV_a45d could not be isolated. Thus, an experiment combining fecal samples that 
were previously enriched in ASV_65f4 or ASV_a45d was carried out (combination of fecal samples from 
subjects #9 and #10 previously enriched in ASV_65f4 and ASV_a45d, respectively, Fig. 2.5). In this 
experiment, we expected that if the combination of fecal specimens had no effect on the Flavonifractor-
related variants, we should observe a reduction in their relative abundance corresponding only to the 
dilution factor. This means that when samples #9 and #10 were combined, the relative abundances of 
ASV_65f4 and ASV_a45d should reach 50 % of the one reached when fecal samples are not combined. 
However, it was observed that when samples #9 and #10 were combined (50:50), ASV_65f4 dominated 
reaching a relative abundance comparable to the one reached when fecal samples #9 and #10 were not 
mixed (Fig. 2.6). Meanwhile, the relative abundance of ASV_a45d was severely affected by the 
combination of fecal samples reaching a relative abundance below 1 % (Fig. 2.6).  
 
 
Figure 2. 6 
Relative abundance of bacterial ASV_65f4 and ASV_a45d in in vitro incubations with fecal samples from 
subjects #9 and #10 combined (50:50) or not (100:0 and 0:100). In vitro incubations with fecal sample 
from subject #9 (enriched in ASV_65f4) are shown in gray (right) and from subject #10 (enriched in 
ASV_a45d) are shown in black (left). 
 
 
Dominance of ASV_a45d or ASV_65f4 was associated with genera Desulfovibrio and 
Phascolarctobacterium. We also searched for organisms whose relative abundance were associated with 
the two variants. We found that when ASV_a45d dominated after incubation with quercetin, the relative 
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abundance of Desulfovibrio was significantly higher (p<0.05 in all 3 experiments) (Fig. 2.7 A). When 
present, Desulfovibrio sp. increased in relative abundance with or without quercetin, indicating its 
metabolic resilience under the culture conditions. Meanwhile, when ASV_65f4 was dominant, the relative 
abundance of the genus Phascolarctobacterium was significantly higher (p<0.05 in all 3 experiments) (Fig. 
2.7 B). This genus increased in relative abundance with or without quercetin as well. 
 
A       B 
 
Figure 2. 7 
Box plots for the relative abundances of the genera Desulfovibrio (A) and Phascolarctobacterium (B) in in 
vitro incubations with quercetin. Analysis for libraries from human subjects #7-#15 grouped by their 
enrichment in ASV_a45d (black) or ASV_65f4 (gray) is shown. Box plots were calculated with Statistical 
Analysis of Taxonomic and Functional Profiles (STAMP). 
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Discussion 
 
Quercetin is present in most fruits and its degradation produces biological active metabolites with 
effects on the host. Extending our knowledge of quercetin-degrading communities is important for 
predicting the health outcomes of flavonoid consumption. To study this matter, we used in vitro fecal 
incubation system which can isolate the effect of the microbiota on the flavonoid. In order to limit the 
enrichment of non-quercetin degraders in these incubations, a medium low in carbon sources was used 
(20 mM of acetate). Under these conditions, mostly Flavonifractor-related sequences were enriched 
across libraries, specifically ASV_65f4 and ASV_a45d. These ASVs belong to different species, sharing 96.4 
% of identity in their 16S rRNA variable region V4 (33). ASV_65f4 was 100 % identical to F. plautii in this 
region, while ASV_a45d was 98.6 % identical to Flavonifractor sp. An4 and An82, which were isolated by 
Medvecky and collaborators from chicken cecum, both are described as Flavonifractor sp. and have whole 
genome assembly projects (34). Several of the Flavonifractor strains isolated from the chicken cecum, 
including strain An4 and An82, have a predicted phloretin hydrolase gene in their genomes which 
catalyzes the hydrolytic C-C cleavage of phloretin, a flavonoid structurally similar to quercetin (35), 
generating phloroglucinol and 3-(4-hydroxyphenyl)propionic acid, this enzyme is well characterized for 
another quercetin-degrader, E. ramulus (36). This suggests that strains An4 and An82 may harbor the 
enzymatic machinery necessary for the cleavage of the C-ring in quercetin as well, as F. plautii and E. 
ramulus do (37,38). Since ASV_a45d was closely related to Flavonifractor sp. strains An4 and An82 and F. 
plautii, and was enriched in quercetin treatments with DOPAC production, even in the absence of 
ASV_65f4 and E. ramulus-related ASVs, this may indicate its metabolic capability for degrading quercetin.  
ASVs related to E. ramulus were detected only in 4 out of 9 human fecal samples and none of the 
mice samples. E. ramulus-related ASV were significantly increased by quercetin treatment only in one 
sample. This bacterium was enriched in a previous study that supplemented with quercetin the diet of 
healthy volunteers under a flavonoid-free intervention (39). However, under the culture conditions of this 
study, ASVs related to Flavonifractor were more prevalent. Another genus related to two of the ASVs 
enriched by quercetin treatments was Intestinimonas. Despite the relatedness of this bacterium with 
Flavonifractor sp., the ability to degrade quercetin was not detected in Intestinimonas butyriciproducens 
(40). However, it is not known whether this bacterium can use metabolites derived from quercetin 
degradation like phloroglucinol. In some of our incubations, the genus Coprococcus, which is reported to 
use phloroglucinol, increased in relative abundance (41). 
Correlations can be useful for identifying potential ecological interactions between microbial 
species. An interesting pattern of negative correlation was observed for Flavonifractor-related variants, 
ASV_65f4 and ASV_a45d. This may indicate a potential antagonistic interaction between these two 
species. Antagonism is more prevalent among phylogenetically and metabolically similar species. A study 
that screened 2,211 competing bacterial pairs from 8 different environments found that antagonism 
increased significantly between closely related strains and between strains that had a greater overlap in 
growth on the 31 carbon sources screened through the Biolog assay (42). Since both ASVs from our study 
are phylogenetically related and both may have the capacity to degrade quercetin, this could explain the 
observed pattern of dominance of one or the other but not both. In competition assays, it is often the 
species that starts at high initial abundance the one that dominates (43). In our experiments, initial 
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relative abundances did not predict which variant will dominate. Despite being less abundant at the initial 
point of incubation, ASV_a45d dominated over ASV_65f4 in half of the libraries after incubation with 
quercetin. However, when two fecal samples previously enriched in one or the other variant were 
combined, ASV_65f4 was always the strongest competitor and the dominant variant. Therefore, this 
evidence suggests that other processes besides initial relative abundances might be responsible for the 
dominance of the weaker competitor, ASV_a45d. For example, the explanation for this pattern of 
dominance might lay on the interactions with other species in the microbial community, thus species that 
might favor one or the other variant were searched.  
In metataxonomic studies, a limiting factor in the analysis is that gut microbial communities are 
very variable at the species level among individuals, being more homogenous at the metabolic level (44), 
then shared species among libraries are scarcer. Despite of this, we were able to identify two genera that 
were associated with the dominance of ASV_65f4 or ASV_a45d. The relative abundance of the H2S-
producing genus, Desulfovibrio, was significantly higher when ASV_a45d dominated, indicating that 
ASV_65f4 might be affected by this species or its metabolites. A subsequent genomic comparative analysis 
revealed why hydrogen sulfide (H2S) might affect this variant (see Chapter 3, ‘Functional Profiling of 
Genomes from Flavonoid-Degrading Bacteria and Their Predictive Ecological Role in the Gastrointestinal 
Tract’). Desulfovibrio sp. is an acetate utilizing bacterium which produces hydrogen sulfide (45), a very 
toxic metabolite that bacteria detoxify (46). This might be converted to thiosulfate (47) and thiosulfate to 
tetrathionate (48). When tetrathionate becomes available, there are some bacteria that can use it as an 
electron donor for ethanolamine catabolism (49), as we show in Chapter 3, ASV_65f4 might be an 
ethanolamine-utilizing species, thus, in the presence of tetrathionate the enhanced competition for this 
substrate may affect ASV_65f4. Other explanations might be that hydrogen sulfide can inhibit the action 
of phosphodiesterases (50), enzymes needed for the conversion of phosphatidylethanolamine to 
ethanolamine or it may have a direct impact on ASV_65f4. Meanwhile, when ASV_65f4 dominated, the 
abundance of a succinate-utilizing bacterium, Phascolarctobacterium, was significantly higher. Two 
species of this genus are reported to only utilize succinate as a carbon source (51,52). Succinate is not a 
major fermentation product in human feces but saccharolytic bacteria which are abundant in the 
gastrointestinal tract can produce it and may be a substrate that bacteria can specialize on in order to 
coexist with bacteria that can readily utilize other more abundant carbon sources (51). The increase in 
abundance of Phascolarctobacterium sp. when ASV_65f4 dominated suggests that succinate became 
available under these conditions. Succinate is the product of fermentation of certain bacteria that use 
acetate as a carbon source and that under O2 depletion accumulate succinate, they slowdown the 
tricarboxylic acid (TCA) cycle activity and may shift to an alternative route called glyoxylate shunt-based 
TCA cycle which uses fewer enzymes than the TCA cycle and generates glyoxylate and succinate (53,54). 
Carbon sources are a major factor affecting the rate of flavonoid degradation and the dynamic 
operations of gut bacteria. We fed two diets to HMAM mice that varied largely in their content of plant 
polysaccharides. The diet low in fiber had corn starch, maltodextrin, and sucrose, while the diet high in 
fiber had ground wheat, ground corn, wheat middlings, dehulled soybean meal, and corn gluten meal. 
The diet high in fiber has a higher content of complex carbohydrates that resist digestion in the upper gut 
that can reach the colon and promote microbial fermentation  (55). There are some studies that have 
shown the importance of dietary fiber for shaping the fate of flavonoid metabolism, for instance, mice fed 
resistant starch and FOS have higher levels of bacterial products of flavonoid metabolism (56,57). 
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Meanwhile, the abundance of E. ramulus in the gut has been shown to be positively influenced by the 
presence of dietary fiber (39). In our study, only the abundance of ASV_65f4 responded to the diet fed to 
the mice, this suggests that available carbon sources have the potential to differentially affect variants of 
Flavonifractor. Nevertheless, diet seemed to have no effect on whether ASV_65f4 or ASV_a45d 
dominated, pointing at the resilience of this pattern. The results of this study show that Flavonifractor-
related variants are differentially affected by the host diet and the microbial communities associated with 
these variants exhibit different patterns of change when one or the other variant becomes enriched. 
Whether there is competition between Flavonifractor-related variants during flavonoid consumption 
warrants further investigation. 
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Chapter 3. Functional Profiling of Genomes from Flavonoid-Degrading Bacteria and Their Predictive 
Ecological Role in the Gastrointestinal Tract 
 
Abstract 
Flavonoid research is focused on the health-promoting properties of these phenolic compounds. 
However, our understanding of gut-dwelling flavonoid-degrading bacteria is still limited and it is not 
known whether harboring certain bacterial species able to transform these compounds affects the overall 
metabolic outcomes associated with their consumption. In previous findings from our group, different 
variants of potential flavonoid-degrading bacteria were detected in a population of Wisconsin, USA. In 
order to predict the metabolic impact of harboring a specific population of flavonoid-degrading bacteria, 
we analyzed the functional profiles of different species of flavonoid-degraders, Flavonifractor plautii and 
Eubacterium ramulus, using a general annotation tool and one specialized on carbohydrate-active 
enzymes, that allows for reconstruction of complete pathways, and comparisons of orthologous gene 
clusters. This comparative genomic analysis enabled us to predict that there are groups of species with 
different carbohydrate utilization capablities, including galactose, galacturonate, and glucuronate. This is 
important since dietary compounds have been shown to impact distinctively the bioavailability of 
flavonoids. Additionally, we found one predicted glycoside hydrolase in E. ramulus that might have a 
domain with the ability to transfer hydroxyl ions between phenols, including the metabolic intermediate 
of flavonoid degradation, phloroglucinol. We also observed that a group of strains most related to E. 
ramulus might be important in the production of butyrate from protein sources. Other traits that may be 
important during opportunistic infections, such as ethanolamine utilization and presence of flagella, were 
enriched in a group of strains closely related to F. plautii. The genomic snapshot of these groups of 
flavonoid-degrading bacteria showed metabolic and structural differences (i.e. flagella) that might have 
different effects on the host and the gut microbiome. 
Introduction 
Flavonoids are 3-ring phenolic compounds produced by the secondary metabolism of plants. Their 
consumption in the human diet has been associated with health benefits on the immune, digestive, 
endocrine, nervous, and cardiovascular systems [1]–[6]. However, the intestinal microbiota has the 
capacity to transform these compounds in smaller phenolic compounds that may have different biological 
activity and bioavailability. Among the bacteria with a recognized flavonoid-degrading capability are 
Flavonifractor plautii and Eubacterium ramulus. Both of these gut bacteria are able to transform 
quercetin, one of the most abundant flavonoids in human diet, to phloroglucinol and 3,4-
dihydroxyphenylacetic acid (DOPAC) [7], [8].  
We recently showed that there are different variants of quercetin-degrading bacteria in human 
fecal sample libraries of a population of Wisconsin, USA. Two variants of each of these bacteria were 
present and became enriched after quercetin incubation (Chapter 2: “Gut-derived Flavonifractor species 
variants are differentially enriched during in vitro incubation with Quercetin”). E. ramulus variants shared 
99.5% of identity in the variable region V4 of the 16S rRNA gene, meanwhile Flavonifractor variants were 
more distant, sharing only 96.4 % of identity in this same region. The closest relative for one of these 
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variants was F. plautii (100% identical), while the other variant was more closely related to Flavonifractor 
sp. strains An4 and An82 (98,6% identical), isolated by Medvecky and collaborators from chicken cecum 
and which have whole genome assembly projects [9]. Additionally, we observed metabolic differences 
between these two Flavonifractor-related variants.  
In this study, we aimed to analyze the functional profile of the representative genomes of 
flavonoid-degraders, F. plautii YL31 and E. ramulus ATCC 29099, and their comparison to genomes of close 
relatives, including those most related to the Flavonifractor-variant enriched in fecal incubations with 
quercetin that were done in our previous work (Flavonifractor sp. strains An4 and An82). This analysis 
revealed metabolic and structural differences that were used to make ecological predictions that these 
flavonoid-degrading bacteria might present in their natural niche, the gastrointestinal tract. 
 
Methods and Materials 
Genomes used in this study. Twenty seven genome assemblies were downloaded from the NCBI 
genomes database on October 2019 (https://www.ncbi.nlm.nih.gov). A total of 5, 1, 1 and 20 genomes 
were downloaded for E. ramulus, Eubacterium rectale (non-quercetin degrader), Eubacterium 
oxidoreducens (quercetin degrader), and Flavonifractor spp., respectively. Accession numbers and 
information about completeness is presented in Table S3.1 (Appendix 3). In order to determine the species 
relationship of the genomes described as E. ramulus and Flavonifractor spp. the Average Nucleotide 
Identity (ANI) was calculated using the online tool JSpeciesWS (http://jspecies.ribohost.com/jspeciesws/) 
[10] which performs pairwise comparisons between two genomes calculating and indicating if a pair of 
genomes belongs to the same species and/or genus based on their percentage of identity. After this 
analysis, we selected all 5 genomes for E. ramulus. For Flavonifractor sp. we chose 8 genomes, 4 that 
represent the general features of the species F. plautii and 4 that represent the general features of the 
genus Flavonifractor (the 4 genomes belong to different species at a ANI percentage of 86-89%) and had 
the highest coverage in the ANI analysis (Flavonifractor sp. strains An4, An10, An82, and An306) (Fig. S3.1 
and S3.2 in Appendix 3 show the phylogenetic relatedness of F. plautii and Flavonifractor sp. strains, 
respectively). Two genomes related to E. ramulus, UHGG_MGYG-HGUT-02278 and MGYG-HGUT-01456, 
did not have gene predictions, thus predictions were done using Prodigal (prokaryotic dynamic 
programming gene finding algorithm) [11]. 
Prediction of functional profiles. Annotation of functions was done using GhostKOALA (KEGG 
Orthology And Links Annotation, https://www.kegg.jp/ghostkoala/), an automatic annotation and 
mapping service using the database ‘genus_prokaryotes’ [12]. Other analyses that were performed were 
the prediction of signal peptides with SignalP-5.0 (http://www.cbs.dtu.dk/services/SignalP/) [13] and 
prediction of glycoside hydrolases with dbCAN2 meta server (automated Carbohydrate-active enzyme 
ANnotation, http://bcb.unl.edu/dbCAN2/) (predicted at least with 2 tools) [14]. Completeness of 
pathways was screened using the KEGG Mapper Reconstruction tool 
(https://www.genome.jp/kegg/tool/map_pathway.html).   
Genome comparative analysis. Prediction of orthologous gene clusters was done using 
OrthoVenn2 (https://orthovenn2.bioinfotoolkits.net/home) [15]. Analysis for Eubacterium spp. and 
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Flavonifractor spp. genomes were run independently. We applied OrthoVenn2 clustering to identify gene 
clusters enriched in the groups most related and distantly related to E. ramulus ATCC 29099 or F. plautii 
YL31 in order to compare between groups. Proteins similar to flavonoid-degrading proteins were searched 
using the Blast tool in OrthoVenn2. For E. ramulus, Enoate Reductase (ERED) (AGS82961.1) and Phloretin 
hydrolase (AAQ12341.1), and for Flavonifractor spp. NADH oxidase (CUQ13575.1) and Phloretin hydrolase 
(OXE48401.1) were taken as reference proteins [16]. 
Evolutionary relationships of taxa. Evolutionary history was inferred using the UPGMA method 
[17]. Trees are drawn to scale, with branch lengths in the same units as those of the evolutionary distances 
used to infer the phylogenetic tree. The evolutionary distances were computed using the Maximum 
Composite Likelihood method [18] and are in the units of the number of base substitutions per site. 
Evolutionary analyses were conducted in MEGA6 [19]. 
 
Results and Discussion 
Representative genomes of F. plautii YL31 and E. ramulus ATCC 29099. Flavonoid-degrading 
bacteria influence host physiology transforming phenolic compounds with health benefits in smaller 
phenolic molecules that may have different biological activity and bioavailability compared to the parent 
compounds, but this type of bacteria are still under-characterized. This poses a limitation for the 
understanding of the interaction between gut microbiome, host, and diet. In the series of analyses that 
we performed, we first searched for the presence of complete KEGG modules, defined functional units of 
gene sets and reaction sets, in the representative genomes of F. plautii YL31 and E. ramulus ATCC 29099. 
Pathways for carbohydrate utilization, amino acid biosynthesis, secretory proteins and transport systems, 
vitamins biosynthesis, Short-Chain Fatty Acids (SCFAs) biosynthesis, antibiotic resistance, and oxygen 
tolerance are described below. 
Carbohydrate metabolism. Both F. plautii YL31 and E. ramulus ATCC 29099 have the complete 
pathways for glycolysis and citrate cycle. Additionally, E. ramulus ATCC 29099 has the complete pathway 
for galactose degradation, this capacity is reported in the literature [20]. In the other hand, F. plautii YL31 
has the pathways for the degradation of D-galacturonate and D-glucuronate. Galacturonic acid is the main 
monomer in pectin, while glucuronic acid is a glucose-derived sugar acid, which is linked via a glycosidic 
bond to other substances forming a glucuronide. Glucuronidation is a common mechanism of animal 
bodies for the detoxification of toxic substances, drugs or compounds that cannot be used as energy 
sources. Glucuronides can be hydrolyzed by bacterial beta-glucuronidases, then the aglycones are re-
absorbed and enter the enterohepatic recirculation. This cycle contributes to prolonged exposure to 
certain compounds which can have health effects on the host. For example, when bacterial glucuronidases 
remove the glucuronic acid from carcinogens (e.g. dietary heterocyclic amines) this poses a health risk 
[21], while the same bacterial activity on glucuronidated flavonoids may help intestinal cells be exposed 
to aglycon flavonoids which can have a positive health effect [22]. F. plautii YL31 does not harbor any 
glycoside hydrolase families with beta-glucuronidase activity (GH1, GH2, GH30, GH79 or GH154) (Table 
3.1). Thus, we predict that F. plautii YL31 only can use glucuronate as a carbon source when released by 
other bacteria. An analysis of other classes of glycoside hydrolases revealed that E. ramulus ATCC 29099 
had 20 different classes of glycoside hydrolases (Table 3.2) while F. plautii YL31 only had 11 (Table 3.1), 
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which may indicate that E. ramulus ATCC 29099 has more versatility for the degradation of carbohydrates 
than F. plautii YL31. Interestingly, it has been reported that F. plautii strain I2 is only capable of degrading 
the flavonoid quercetin when it is in its aglycone form while E. ramulus strain wK1 is able to degrade the 
glycosides, as well [23]. 
 
Table 3. 1.  
Comparison of predicted Glycoside Hydrolases for Flavonifractor spp. 
Glycoside Hydrolase Class YL31 
2789STDY 
ATCC 29863 An248 An4 An10 An82 An306 
5834932 
GH2 - - - - - - - + 
GH3 +P +P +P +P + + +P + 
GH4  + + + + - - - - 
GH13_4 - - - - + - + - 
GH13_9 + + + + + + + + 
GH13_11 - - - - + - + - 
GH13_20 - - - - + + + + 
GH13_31 - - - - + - + + 
GH13_39 + + + + + + + + 
GH18 +P +P +P +P +P + +P +P 
GH20 - - - - +P - - - 
GH25 +P +P +P +P + +P + + 
GH29 - - - - - - - + 
GH31 +P +P +P +P - + - - 
GH32 - - - - + - + - 
GH33 +P +P - +P - - +P - 
GH36 - - - - + - + - 
GH42 - - - - - - - - 
GH65 + + + + - + - + 
GH77 + + + + + + + + 
GH79 - - - - - - - + 
GH84 - - - - +P - - - 
GH112 - - - - - - - + 
GH125 + + + + - + - - 
+ GH predicted 
+P GH predicted and has a signal peptide  
- GH not predicted 
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Table 3. 2.  
Comparison of predicted Glycoside Hydrolases for Eubacterium spp. 
Glycoside 
Hydrolase 
Class ATCC 29099 
2789STDY56
08891 MGYG01456 MGYG02278 Strain 21 E. rectale 
GH2 + + + + + +P 
GH3 +P +P +P +P +P + 
GH13_9 + + + + + + 
GH13_14 - - - +P +P + 
GH13_18 + + + + + + 
GH13_20 + + + + + + 
GH13_31 + + + + + + 
GH13_39 + + + + + - 
GH18 + + + + + + 
GH20 + + + + + - 
GH23 + + + - - + 
GH30_5a +P +P +P +P - - 
GH32 + + + - - + 
GH35 + + + + + - 
GH36 + + + + + + 
GH39 - - - - + - 
GH42 + + + + + + 
GH43_22 - +P - - - - 
GH43_24 - - - +P - - 
GH43_37 - - - +P - - 
GH51 + + + + - + 
GH73 - + - +P - +P 
GH77 + + + + + + 
GH78 - - + - - - 
GH101 +P +P +P +P - - 
GH112 + + + + + + 
GH136 +P +P +P +P + - 
GH1 - - - - - + 
GH5_2 - - - - - +P 
GH8 - - - - - + 
GH13_11 - - - - - + 
GH13_36 - - - - - +Pb 
GH13_41 - - - - - +Pb 
GH24 - - - - - + 
GH25 - - - - - +P 
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GH31 - - - - - + 
GH43_10 - - - - - + 
GH43_12 - - - - - + 
GH53 - - - - - + 
GH94 - - - - - + 
GH133 - - - - - + 
+ GH predicted. 
+P GH predicted and has a signal peptide.  
- GH not predicted. 
a Predicted Cna B domain protein in [Clostridium] saccharolyticum (Lachnospiraceae family) (Uniprot: D9R566). 
b Predicted periplasmic amylase in E. rectale (Uniprot; GH13_36: C4ZC46 and GH13_41: C4ZGP6). 
Note: E. oxidoreducens was excluded because it had few GH predictions. 
 
 
Amino acid biosynthesis. The de novo microbial synthesis of amino acids represents a 
contribution to the host requirements for amino acids. For instance, Torrallardona and collaborators 
(2003) estimate that microbial lysine absorbed in the intestines contributes to 10 % of the requirement in 
pigs [24]. Another group has estimated this to be 5 to 9 % in healthy men under an adequate diet [25]. 
Both F. plautii YL31 and E. ramulus ATCC 29099 have complete pathways for the biosynthesis of essential 
amino acids histidine, lysine, arginine, valine, isoleucine, and leucine. Additionally, F. plautii YL31 has the 
complete pathway for the synthesis of serine and threonine and E. ramulus ATCC 29099 has the one for 
tryptophan. They also have the complete pathway for the synthesis of the conditionally essential amino 
acids, cysteine and proline.  
Secretory proteins and transport systems. An analysis of signal peptides revealed non-cytosolic 
proteins (inner membrane, periplasmic, outer membrane/extracellular). In E. ramulus ATCC 29099, about 
7.8 % of proteins had a secretory signal (270 out of 3461) while F. plautii YL31 had 8.7 % (312 out of 3592). 
Many of these proteins may be involved in the processing and/or transportation of dietary substrates, like 
carbohydrates, peptides, and amino acids. Among the non-cytosolic proteins with predicted function, E. 
ramulus ATCC 29099 had 9 predicted sugar transporters and 8 peptide/amino acid transport systems. 
Interestingly, F. plautii YL31 had a similar number of sugar transporters (8) but it had a much larger 
number of predicted peptide/amino acid transport systems, 25, which suggests that F. plautii YL31 may 
rely more on proteins for its nutrient requirements. In previous experiments, we have observed that E. 
ramulus ATCC 29099 grows well in minimal media supplemented with glucose [26] while F. plautii YL31 
requires the addition of tryptone, yeast extract, meat extract, and lysine to the same media (it doesn’t 
grow on glucose under laboratory conditions). Thus, this may indicate that the metabolism of F. plautii 
YL31 is favored toward the utilization of proteins, at least in in vitro cultures. 
Vitamin biosynthesis. The human body cannot synthesize most vitamins, thus the gut microbiota 
is an important supplier of these vitamins. Both F. plautii YL31 and E. ramulus ATCC 29099 have the 
complete pathway for the biosynthesis of the complex vitamin cobalamin, the only vitamin exclusively 
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produced by microorganisms. Additionally, E. ramulus ATCC 29099 has also almost complete pathways (1 
step missing) for the biosynthesis of thiamine, riboflavin, pantothenate, and tetrahydrofolate.  
Short-Chain Fatty Acid (SCFA) biosynthesis. Both F. plautii YL31 and E. ramulus ATCC 29099 are 
known acetate and butyrate producers [20], [27]. As expected, our analysis revealed that both have the 
pathways acetyl-CoA fermentation to butanoate II and pyruvate fermentation to acetate I and IV. Butyrate 
or butanoate is essential for colon health, it is a major energy source for colonocytes, inhibits colon 
inflammation and carcinogenesis, and has an important role in regulating processes in the adipose tissue, 
skeletal muscle cells, liver, and pancreas [28]–[32]. 
Antibiotic resistance. Both F. plautii YL31 and E. ramulus ATCC 29099 have the complete pathways 
for vancomycin resistance, a predicted two-protein system that confers macrolide resistance to 
Escherichia coli, MacAB [33], and a deaminase that can inactivate the antibiotic blasticidin-S [34]. 
Oxygen tolerance. F. plautii YL31 and E. ramulus ATCC 29099 are strict anaerobes but may have 
some protection for transient oxygen exposure, as it has been observed for other strictly anaerobic 
bacteria [35], [36]. F. plautii YL31 has a predicted peroxidase and catalase (which consume H2O2) and 
superoxide dismutases (which consume O2-) (SOD1 and SOD2). This protection against reactive species 
may help F. plautii YL31 during an opportunistic infection, few infections by this bacterium have been 
reported [37], [38]. Meanwhile, E. ramulus ATCC 29099 only has a predicted 8-oxo-dGTP diphosphatase 
involved in the detoxification of oxidized GTP, a ROS-induced oxidation of guanine which is the most 
mutagenic base. It has been observed that anaerobic microorganisms lack some oxygen stress enzymes 
but they contain novel iron-containing proteins including hemerythrin-like proteins, desulfoferrodoxin, 
rubrerythrin, new types of rubredoxins, and a new enzyme termed superoxide reductase [39]. Both F. 
plautii YL31 and E. ramulus ATCC 29099 have predicted superoxide reductases and hemerythrins.  
 
Comparison of the Genomes of F. plautii YL31 and E. ramulus ATCC 29099 to those from close 
relatives. After the analysis of the genomes of E. ramulus ATCC 29099 and F. plautii YL31, we performed 
comparisons with closed relatives. The Average Nucleotide Identity (ANI) analysis revealed which 
genomes were more closely related to these reference genomes, E. ramulus ATCC 29099 (Table S3.2 in 
Appendix 3) and F. plautii YL31 (Table S3.3 in Appendix 3). For E. ramulus, there were 2 genomes that had 
higher than 98.7% of identity with strain ATCC 29099 (the percentage for strains that belong to the same 
species is >95%), these were strains MGYG-HGUT-01456 and 2789STDY5608891. The other 2 genomes, 
MGYG-HGUT-02278 and strain 21, had only 89.2% of identity with E. ramulus ATCC 29099 but between 
them they shared 99% of identity. Thus, for subsequent analyses we considered these as two species 
clusters. For Flavonifractor spp., we also retrieved two group of genomes, one more closely related to the 
representative genome, F. plautii YL31 (F. plautii 2789STDY5834932, F. plautii ATCC 29863, and F. plautii 
An248) and another one more distant related to F. plautii YL31 (Flavonifractor sp. An4, Flavonifractor sp. 
An10, Flavonifractor sp. An82, and Flavonifractor sp. An306). This last group includes the two 
Flavonifractor sp. genomes (An4 and An82) that were most related to variant ASV_a45d from our previous 
study (Chapter 2, ‘Gut-derived Flavonifractor species variants are differentially enriched during in vitro 
incubation with Quercetin’). So, for Flavonifractor spp. we also considered two groups of genomes, each 
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with 4 genomes. After selecting these groups of genomes, we compared the presence of different classes 
of predicted glycoside hydrolases, proteins involved in the degradation of flavonoids (enoate reductase 
and phloretin hydrolase), and enriched orthologous genes. 
Glycoside hydrolases. All 5 strains of E. ramulus shared most of the glycoside hydrolase classes 
(Table 3.2). Few exceptions were GH23 and GH32 which were only present in the genomes most related 
to E. ramulus ATCC 29099. E. rectale shared less than half of the glycoside hydrolases classes with E. 
ramulus (16 out of 41). One prominent difference between E. ramulus strains and E. rectale was glycoside 
hydrolase class GH30_5 which was present in all E. ramulus strains but not in E. rectale (In E. ramulus ATCC 
29099 corresponds to ERK42643.1: 312…763). In all cases, this glycoside hydrolase had a signal peptide 
and is a predicted Cna B-type domain protein with signal peptide (Uniprot: D9R566) in [Clostridium] 
saccharolyticum (Lachnospiraceae family). Interestingly, it is mentioned that other proteins contain 
domains with a similar fold, including the C-terminal domain of the beta subunit of a transhydroxylase, a 
molybdenum-containing enzyme from Pelobacter acidigallici. This enzyme catalyzes the conversion of 
pyrogallol to phloroglucinol (one of the metabolites from flavonoid degradation), and can transfer 
hydroxyl ions between phenols [40]. It will be interesting to evaluate if this protein has this activity in E. 
ramulus. 
Another important observation was that the strains more closely related to E. ramulus ATCC 
29099, all had predicted proteins in the GH13 class (subfamilies 9, 18, 20, 31, and 39) but none had a 
signal peptide. To this class belong enzymes with amylase activity involved in the degradation of starch, 
since starch is a large polysaccharide it might be partially degraded by proteins anchored in the membrane 
instead of transporting the whole molecule inside the cell. We have previously evidenced that E. ramulus 
ATCC 29099 is not able to use starch as a carbon source [26]. Meanwhile, E. rectale is a known starch 
degrader [41], in our analyses we observed 2 predicted proteins in the class GH13 (subfamilies 36 and 41) 
with signal peptide in the genome of E. rectale, these proteins may be responsible for E. rectale amylase 
activity. Similarly, E. ramulus MGYG02278 and E. ramulus strain 21 both had a predicted protein in the 
GH13 family (subfamily 14) with a signal peptide, it is possible then that these strains might be able to use 
starch, however, experimental evidence is not yet available.  
In Flavonifractor spp., there were 12 glycoside hydrolase classes present in most of the strains 
(Table 3.1). Among these, 6 were present in all strains, 1 was present only in the group most closely related 
to F. plautii YL31, and 1 was present only in the most distant group (An4, An10, An82, and An306), the 
other vary according to the strain. This indicates that these strains might have different patterns of carbon 
metabolism which can affect the degradation of flavonoids since these compounds can be cometabolized 
with carbon sources [26], [42].  
Enriched orthologous genes in Eubacterium spp. For Eubacterium spp. we did 3 analyses in which 
we looked for enriched orthologous genes in the following groups: a) E. ramulus ATCC 29099, E. ramulus 
2789STDY5608891, and E. ramulus MGYG01456 (Table 3.3); b) E. ramulus 2789STDY5608891, E. ramulus 
ATCC29099, E. ramulus MGYG01456, E. ramulus 21, and E. ramulus MGYG02278 (Table 3.4); and c) E. 
ramulus strain 21, E. ramulus MGYG02278, E. oxidoreducens, and E. rectale (Table 3.5). In the first group 
(Table 3.3 and S3.4), the strains most closely related to E. ramulus ATCC29099 were significantly more 
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enriched in genes for L-lysine fermentation to acetate and butanoate. Metagenomic studies have revealed 
that the pathway for butyrate production from lysine has a high abundance in the human intestine [43]. 
The pathway from L-lysine to butanoyl-CoA was not present in E. ramulus strain 21, E. ramulus 
MGYG02278 or E. rectale. Thus, we predict that the presence of strains more closely related to E. ramulus 
ATCC 29099 is important for the generation of SCFAs from undigested proteins and amino acids in the 
colon. Other genes that were enriched in this group were involved in the degradation of rhamnose, 
however, this pathway was not complete and experimentally, E. ramulus ATCC 29099 does not use 
rhamnose as a carbon source [20].  
 
Table 3. 3.  
Gene clusters enriched in E. ramulus 2789STDY5608891/E. ramulus ATCC29099/E. ramulus MGYG01456. 
Cluster Count Name p-value 
Cluster 1 4 L-lysine catabolic process to butyrate 3.27E-05 
Cluster 2 2 rhamnose catabolic process  0.00157155 
Cluster 3 2 pyridoxal phosphate biosynthetic process 0.00017873 
 
 
When we analyzed what orthologous genes were enriched in all E. ramulus strains vs E. 
oxidoreducens and E. rectale (Table 3.4 and S3.5), we observed that genes for vitamin B1 (thiamine) 
binding and biosynthesis and tetrahydrofolate biosynthesis were enriched. As mentioned before, E. 
ramulus ATCC 29099 has almost complete pathways for the biosynthesis of these vitamins. Other genes 
that were enriched are involved in sporulation. The genus Eubacterium is known as asporogenous, this 
means that it harbors an incomplete set of genes for sporulation [44]. Although E. ramulus strains seem 
to have genes that E. rectale lack (pspIIQ, spmA, and spmB), it still does not have the complete set of 
genes.  
At last, we looked for genes enriched in E. ramulus strain 21, E. ramulus MGYG02278, E. 
oxidoreducens, and E. rectale (Table 3.5 and S3.6) that were not enriched in the group most closely related 
to E. ramulus ATCC 29099. We found that genes for the biosynthesis of capsule and polysaccharides that 
formed the capsule were significantly enriched. There is no experimental evidence that points to the 
presence or lack of capsule in this group of bacteria, if they do produce it, the significance of this can be 
broad. Capsule-forming bacteria can influence host immunological responses, they might evade 
complement and/or antimicrobial peptides produced by the host’s immune system and they can also 
exclude intestinal pathogens by inhibiting their attachment to host cells. Capsule may also improve 
bacterial fitness, for example, by providing protection from bacteriophages, and it can also affect other 
host-microbe and microbe-microbe interactions, as well as the formation of biofilms [45].
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Table 3. 4.  
Gene clusters enriched in E. ramulus 2789STDY5608891/E. ramulus ATCC29099/E. ramulus 
MGYG01456/E. ramulus 21/E. ramulus MGYG02278. 
Cluster Count Name p-value 
Cluster 1 3 thiamine pyrophosphate binding  0.00021166 
Cluster 2 6 thiamine diphosphate biosynthetic process 7.69E-05 
Cluster 3 4 tetrahydrofolate biosynthetic process  0.00068406 
Cluster 4 27 sporulation resulting in formation of a cellular spore 1.07E-12 
 
Table 3. 5.  
Gene clusters enriched in E. ramulus 21/E. ramulus MGYG02278/E. oxidoreducens/E. rectale. 
Cluster Count Name p-value 
Cluster 1 3 polysaccharide biosynthetic process  5.45E-05 
Cluster 2 2 capsule polysaccharide biosynthetic process 0.0005179 
 
 
Enriched orthologous genes in Flavonifractor spp. For Flavonifractor spp., we analyzed 
orthologous genes enriched in the group more closely related to F. plautii YL31 (Table 3.6 and S3.7) and 
those enriched in the group more distantly related to F. plautii YL31 (Table 3.7 and S3.8). The F. plautii 
YL31-related group was enriched in several genes involved in ethanolamine utilization (Table 3.6 and 
S3.7). Ethanolamine can be used as carbon, nitrogen, and energy source, its catabolic process requires 
cobalamin (as mentioned before F. plautii YL31 has the complete biosynthesis pathway for this vitamin) 
and occurs in microcompartments called metabolosomes, which are protein-based organelle-like 
structures that protect the cell from the potential toxic effects of volatile intermediates; in the case of 
ethanolamine, acetaldehyde is produced. Ethanolamine is abundant in the gut thanks to the action of 
phosphodiesterases on the phosphatidylethanolamine on bacterial and mammalian cell membranes and 
could also originate from plant cells in the diet [46]. 
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Table 3. 6.  
Gene clusters enriched in F. plautii YL31/ F. plautii 2789STDY5834932/ F. plautii ATCC 29863/ F. plautii 
An248. 
Cluster Count Name p-value 
Cluster 1 11 ethanolamine catabolic process 6.00E-07 
Cluster 2 4 ornithine metabolic process 0.00028198 
Cluster 3 3 polyhedral organelle 0.00255864 
Cluster 4 5 bacterial-type flagellum-dependent swarming motility 2.33E-08 
Cluster 5 5 chemotaxis 4.62E-07 
Cluster 6 4 protein secretion 3.91E-06 
Cluster 7 4 bacterial-type flagellum-dependent cell motility 1.14E-05 
 
 
We noticed that both groups (closely and distantly related to F. plautii YL31) had ethanolamine 
utilization genes but F. plautii YL31-related group had these genes enriched, thus we reconstruct the 
operons for ethanolamine and 1,2-propanediol utilization (Fig. 3.1). Propanediol catabolic process also 
occurs in metabolosomes, produces a toxic volatile intermediate (propionaldehyde), requires cobalamin, 
and the pathway has homolog proteins to ethanolamine catabolic pathway that can be misannotated by 
automatic servers. The reconstruction of these operons revealed two ethanolamine operons (Eut operon 
1 and 2) (Fig. 3.1) most similar to the reported Eut2 operon, which instead of the EutD 
phosphotransacetylase (PTAC) it encodes a homolog to the PduL PTAC, and in place of the EutR regulatory 
enzyme, it has a two-component regulatory system consisting of a signal transduction histidine kinase and 
a response regulator [47]. Eut operon 2 has more eut genes that encode for structural proteins for the 
microcompartment [48] than Eut operon 1 but both have the essential proteins for ethanolamine 
utilization, EutBC protein, which is an ethanolamine ammonia lyase that converts ethanolamine into 
acetaldehyde and ammonia, the reactivating enzyme EutA that acts on EutBC, the aldehyde 
dehydrogenase (AldDH) EutE for converting acetaldehyde to acetyl-CoA that enters the tricarboxylic acid 
cycle and other processes, and the PduL PTAC homolog for the formation of acetate. The F. plautii YL31-
related group harbors Eut operon 1 and 2 while the group more distant related to F. plautii YL31 only has 
Eut operon 1 (Fig. 3.1). Eut operons 1 and 2 locate in different parts of the genome and their proteins are 
highly similar but not identical (data not shown).  
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Figure 3. 1 
Representative BMC Loci for Flavonifractor spp. Cartoon representation of Ethanolamine utilization 
operon (Eut operon 1 and 2) and 1,2-propanediol utilization operon (Pdu operon). Genes are drawn on F. 
plautii YL31 genome using Benchling [Biology Software] (2019). Eut operon 1 is 12,247 bp, Pdu operon is 
22,527 bp, and Eut operon 2 is 18,769 bp. Abbreviations are as follows: AlcDH, Alcohol dehydrogenase; 
AldDH, Aldehyde dehydrogenase; PTAC, phosphotransacylase; BMC, bacterial microcompartment; pdtaS, 
two-component system, sensor histidine kinase; pdtaR, two-component system, response regulator. 
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Genes are color-coded according to their annotation: light blue, BMC-containing proteins; red, aldehyde 
dehydrogenase; green, alcohol dehydrogenase; solid pink, pduL-type phosphotransacylase; light purple, 
re-activating proteins; dark blue, signature enzymes (ethanolamine ammonia lyase subunits and 
propanediol dehydratase subunits); brown, regulatory element including two-component signaling 
elements; yellow, transporter; gray, other Eut or Pdu proteins. Circles show the presence (filled circle) or 
absence (white circle) of proteins in the strains depicted in the phylogenetic tree. The phylogenetic tree 
is as in Fig. 3.2. Table S3.9 (Appendix 3) contains all accession number for each protein in each strain. 
 
 
Metabolosomes have different substrates and functions but their main function is dictated by the 
aldehyde-generating enzyme. In the case of ethanolamine and 1,2-propanediol, the presence of 
ethanolamine ammonia-lyase and 1,2-propanediol dehydratase, respectively, it is considered the 
signature enzymes that defines the substrate of the metabolosome [49]. Thus, we predict that the group 
with the two Eut operons it is more efficient in utilizing ethanolamine but we cannot discard that one of 
the operons might be also used for other processes, for example, in some cases class II aldolases were 
observed close to the operon as reported for other Eut operons [47]. The presence of ethanolamine 
catabolism in these strains might give an advantage under nutrient scarcity in the gastrointestinal tract 
since this compound is present in the membrane of epithelial intestinal cells which are constantly washed 
away in the mucus. It is possible that this pathway might be used during opportunistic infections.   
Pdu operon was also found in members of both groups (Fig. 3.1). Some Pdu proteins were 
predicted using the automatic annotation server, however, some were missing an annotation; thus, we 
performed a similarity matrix between the possible proteins of F. plautii YL31 Pdu operon with the 
proteins encode in the Pdu operon of Salmonella enterica subsp. enterica serovar Typhimurium str. LT2, 
which has a well-established Pdu operon (Table S3.10 in Appendix 3). This process enabled us to 
reconstruct the Pdu operon in F. plautii YL31 genome (Fig. 3.1). This operon was found in all members of 
the F. plautii YL31-related group and only 2 members of the group more distantly related to F. plautii YL31 
(Flavonifractor sp. strains An306 and An82). 1,2-propanediol catabolism is also important in the 
gastrointestinal tract since it is a microbial fermentation product that can be produced during the 
fermentation of rhamnose or fucose, sugars found in plant cell walls, bacterial capsules, and the 
glycoconjugates of eukaryotic cells (Badia, Ros, & Aguilar, 1985). 
F. plautii YL31-related group was also enriched in the pathway for the degradation of L-ornithine 
(Table 3.6 and S3.7). This group can generate ornithine from the degradation of arginine and they have 
the complete pathway for the formation of acetyl-CoA from ornithine. Other enriched genes in this group 
encode proteins involved in the formation of flagella, flagellar proteins that interact with chemotaxis 
proteins, components of the flagellar motor that determine the direction of flagellar rotation, and the 
secretion of flagellar proteins (Table 3.6 and S3.7). The core set of flagellar genes [50] (26 genes) was 
identified in the 4 genomes belonging to the F. plautii YL31-related group, except for one of the genes 
that encode for a rod protein, FlgB, which was not found in F. plautii 2789STDY5834932. It has been 
reported that this genus can be motile or non-motile. Thus, we predict that F. plautii is one of the motile 
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species in this genus [27]. The breakdown of intestinal barrier has been associated with high levels of 
flagellin, a bacterial flagellar protein. In a healthy state, the host immunological defense downregulates 
the microbiome’s production of flagella [51]. However, it is possible that this trait might be displayed 
during an opportunistic infection.  
The group more distantly related to F. plautii YL31, to which strains An4, An10, An82, An306 
belong to, was enriched in genes for galactose metabolism (Table 3.7 and S3.8). F. plautii YL31 and its 
close relatives do not possess the metabolic route for galactose degradation whereas strains An4, An10, 
An82, An100 do have the complete pathway. Thus, we propose that a strategy for the isolation of 
ASV_a45d from our previous study (Chapter 2) might be the use of galactose in the culture media. These 
strains might be important in dairy-rich diet since lactose is a disaccharide formed from one molecule of 
glucose plus one of galactose. Additionally, this group was enriched in riboflavin and Mo-molybdopterin 
cofactor biosynthetic processes but none of the strains have the complete pathways.  
Flavonoid-degrading genes. Knowledge about the proteins involved in the degradation of 
flavonoids is still limited. In E. ramulus, enoate reductase (ERED) and phloretin hydrolase (Phy) have been 
experimentally confirmed. While in F. plautii, phloretin hydrolase (Phy) is predicted and the most probable 
homologue protein to enoate reductase is a NADH oxidase but there is no experimental evidence [16]. All 
E. ramulus strains harbored a protein highly similar to ERED and only E. ramulus strain 21 lacked a Phy 
protein (Fig. 3.2A and Table S3.11 and S3.12 in Appendix 3). For Flavonifractor spp., all strains closely 
related to F. plautii YL31 possess a protein very similar to the NADH oxidase and to the predicted Phy (Fig. 
3.2B and Table S3.13 and S3.14 in Appendix 3). On the other hand, among the Flavonifractor strains that 
do not belong to the species F. plautii, all strains had a protein similar to Phy but only Flavonifractor sp. 
strains An82 and An306 had proteins highly similar to the NADH oxidase (Fig. 3.2B and Table S3.13 and 
S3.14 in Appendix 3). It is worth noting that predicted Phy proteins of strains An4, An10, An82, and An306 
are 90-95% identical to the reference Phy (Table S3.14 in Appendix 3), meanwhile the predicted Phy for 
E. oxidoreducens is only 83% identical to the one from E. ramulus (Table S3.12 in Appendix 3). This suggests 
that Flavonifractor species might have a group of similar proteins involved in the degradation of 
flavonoids. 
 
Table 3. 7.  
Gene clusters enriched in Flavonifractor sp. An4/ Flavonifractor sp. An10/ Flavonifractor sp. An82/ 
Flavonifractor sp. An306. 
Cluster Count Name p-value 
Cluster 1 4 Mo-molybdopterin cofactor biosynthetic process 8.54E-07 
Cluster 2 3 riboflavin biosynthetic process 0.00044437 
Cluster 3 2 galactose metabolic process 0.00249661 
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Figure 3. 2 
Heatmap showing presence (gray) or absence (white) of proteins involved in flavonoid degradation in 
Eubacterium spp. (A) and Flavonifractor spp. (B) genomes. Optimal tree with the sum of branch length = 
0.11524341 is shown for A and 0.05375762 for B. The analysis in A involved 7 nucleotide sequences: E. 
ramulus ATCC 29099 (ATCC29099), E. ramulus MGYG-HGUT-01456 (MGYG 01456), E. ramulus MGYG-
HGUT-02278 (MGYG 02278), E. ramulus 2789STDY5608891 (STDY5608891), E. ramulus strain 21 (Strain 
21), E. rectale (E.rectale), and E. oxidoreducens (E. oxidoreducens). The analysis in B involved 8 nucleotide 
sequences: F. plautii 2789STDY5834932 (STDY5834932), F. plautii An248 (An248), F. plautii ATCC 29863 
(ATCC29863), F. plautii YL31 (YL31), Flavonifractor sp. An306 (An306), Flavonifractor sp. An82 (An82), 
Flavonifractor sp. An4 (An4), and Flavonifractor sp. An10 (An10). All positions containing gaps and missing 
data were eliminated. There were a total of 1341 positions in the final dataset for A and 1008 positions in 
the final dataset for B. ERED, Enoate reductase; Phy, Phloretin hydrolase. Table S3.10-S3.13 (Appendix 3) 
show Blast results. 
 
It must be said that strains An4 and An82 share an identical variable region V4 of the 16S rRNA 
gene but at the level of genome they only share 89% of identity, thus they belong to different species. In 
previous experiments in our laboratory, a sequence variant (ASV_a45d) identical to Flavonifractor sp. 
strains An82 and An4 in this variable region of the rRNA gene was enriched in in vitro fecal incubations 
with quercetin. Efforts to reconstruct the genome of ASV_a45d must take place in order to reveal which 
is the most closely related species. Meanwhile, the capacity of degrading quercetin of these strains must 
be confirmed in pure culture. If proven experimentally, this would mean that different species of the 
Flavonifractor genus are able to degrade flavonoids. And that they might have different metabolic and 
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structural traits, such as presence of flagella and use of carbon sources including host-derived compounds. 
Thus, they might have a different impact on the host and the gut microbiome. 
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General Discussion 
In this study, we revealed aspects that are important for the microbial of ecology of quercetin-
degrading bacteria, F. plautii and E. ramulus. To extend our understanding of the role of these bacteria in 
the complex interaction between host diet and gut microbiota, we first screened whether different dietary 
fibers have an impact on the quercetin-degrading capacity of E. ramulus. We observed that inulin, FOS, 
and arabinogalactan promoted the degradation of quercetin by this bacterium. However, in order to 
provide conditions more similar to the natural niche of this bacterium, we incorporated in our 
experiments another human gut symbiont, B. thetaiotaomicron, which it is a known versatile 
polysaccharide degrader but does not degrade quercetin. This simple model of gut microbiota revealed 
that non-quercetin degraders can promote the degradation of quercetin by E. ramulus in the presence of 
substrates that this bacterium is not able to use by its own (i.e. starch). As a consequence of this 
interaction, the production of butyrate, an important metabolite for colon health, was also enhanced. We 
therefore propose that the butyrogenic effect of starch [1] is partially mediated by the use of starch 
breakdown products by butyrate producers. This same effect that B. thetaiotaomicron had on the 
metabolism of E. ramulus was not observed with F. plautii (data not shown), indicating that flavonoid-
degrading bacteria have different capacities of interacting with the gut microbiota and distinct nutrient 
requirements (at least under the laboratory conditions tested).   
 After these experiments with pure cultures and cocultures, we evaluated the degradation of 
quercetin by complex fecal communities in in vitro experiments. Our original objective was to observe if 
interindividual (fecal microbial communities from different subjects) differences in quercetin degradation 
exist. We did observe these differences (data not shown) but these were not consistent across different 
assays. An explanation might be that fecal matter individually sampled can have different number of 
bacterial cells per gram and/or concentration of carbon sources intrinsic to the feces. Nevertheless, these 
experiments showed another important insight about quercetin-degrading bacteria: the population that 
we sampled (Wisconsin, USA) harbors different variants closely related to known quercetin-degrading 
bacteria that showed distinct features. Under the conditions of our fecal incubation system, we found 
that some species from Flavonifractor spp. were more prevalent, thus we focused our analysis on them. 
There were two variants (named ASV_65f4 and ASV_a45d) that belong to different species of the genus 
Flavonifractor that presented a negative correlation in their relative abundances upon incubation with 
quercetin. One of the variants was closely related to the known quercetin-degrader, F. plautii, it had 100% 
identity with F. plautii in the variable region V4 of the rRNA gene. In order to continue studying these 
variants, we attempted to isolate them using the same media culture we use to grow F. plautii in pure 
culture. However, we could only retrieve the variant ASV_65f4 even from samples that became highly 
enriched with the variant ASV_a45d, which is more distantly related to F. plautii. This indicates that 
isolation attempts for variant ASV_a45d must use a different strategy. As we wanted to study the relation 
between both variants, we combined fecal matters that were previously enriched with one or the other 
variant. This approach shows that under these conditions, ASV_65f4 was a stronger competitor and 
indeed initial relative abundances of this variant were higher across all the 15 fecal samples that we 
studied. However, we propose that ASV_a45d might have an advantage over ASV_65f4 under certain 
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circumstances that might be given by the available carbon sources and/or interactions with the rest of the 
microbial community.  
It has been widely described that the gut microbial community among different subjects have 
limited redundancy at the taxonomic level [2]. Additionally, some of our fecal samples were inoculated in 
HMAM mice that were subjected to an abrupt change in diet that impacted the taxonomic profile of the 
microbial community. In the other hand, we used media culture that lacked common sugars, this can 
restrict the enrichment of many bacteria. These factors can make difficult to establish the shared 
microbiota across experiments that correlated positively or negatively with the relative abundance of 
variants ASV_65f4 or ASV_a45d. Nevertheless, we observed that the genus Desulfovibrio was negatively 
correlated with ASV_65f4, which was the strongest competitor between the two Flavonifractor-related 
variants. Desulfovibrio sp. is an acetate-utilizing bacterium which produces hydrogen sulfide. This 
metabolite is very toxic and could impact ASV_65f4 directly. Another possibility is that when some 
bacteria detoxify hydrogen sulfide, they convert it to thiosulfate and from this tetrathionate can be 
generated. When tetrathionate becomes available, there are some microorganisms that can use it as an 
electron donor for ethanolamine catabolism. In our genomic comparison analysis, we revealed that the 
group of genomes most closely related to ASV_65f4 harbors the genetic potential for ethanolamine 
catabolism, this indicates that the presence of tetrathionate may increase the competition for this 
substrate which can affect ASV_65f4. Ethanolamine might be an important carbon source in our in vitro 
system as well as in the gastrointestinal tract since it can be formed from dead cell membranes.  
Another important characteristic that we revealed in the group of genomes most closely related 
to ASV_65f4 was that they harbor a core set of flagellar genes while the group most related to ASV_a45d 
does not. This is an important difference since the presence of flagella and the utilization of ethanolamine 
(abundant in mammalian cells) can help during opportunistic infections, which have been reported for F. 
plautii. Meanwhile, for E. ramulus, we highlight the enriched genes for butyrogenesis from lysine in the 
group of genomes most closely related to E. ramulus ATCC 29099, this process is important in the 
gastrointestinal tract for the production of short-chain fatty acids from proteins and has been described 
in few species [3].  
Overall, we showed aspects of the microbial ecology of known quercetin-degraders and related 
species among these the use of different substrates and interactions with the microbial community that 
are important for the understanding of the dynamic of quercetin degradation in the gastrointestinal tract. 
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Conclusions and Future Research Perspectives 
 
Gut microbiome research aims at understanding how the microbiota modulates the health of 
individuals considering lifestyles, diet and disease risk. Eventually, the field of microbial flavonoid 
degradation may lead to the characterization of biomarkers that will indicate the degree of the capacity 
of an individual’s gut microbiota to degrade flavonoids with the goal of personalizing food intake based 
on the metabolic profile of the individual. It is possible that for some disease states (i.e. anxiety), the 
degradation of flavonoids will be desired while for other conditions a minimal degradation of the flavonoid 
might give a better outcome. The main conclusion drew from this study is that flavonoid-degrading 
bacteria cannot be understood in isolation but that these bacteria carry out complex interactions with 
abiotic and biotic components of their environment, including accompanying substrates of flavonoids and 
members of the microbial community. This means that there are factors that might influence the 
metabolic capability of these bacteria. Ultimately, the different interactions of flavonoid-degrading 
bacteria will affect the bioavailability and bioactivity of flavonoids, and these must be considered when 
using flavonoids as therapeutic compounds, for example, for people that are constantly exposed to high 
levels of oxidative stress (alcohol consumption, smoking and/or western diet) or that suffered from an 
inflammatory disease. In the future, it may be necessary to stratify subjects in clinical trials based on the 
flavonoid-degrading capacity of their gut microbiotas in order to understand the influence of the 
microbiome on the health outcome. 
For future perspectives, it is important to evaluate fecal communities from other human 
populations in search for variants of quercetin-degrading bacteria and analyze if there are common 
variants across different populations. Attempts for the isolation of these variants must continue and we 
propose that in order to exclude the variant most closely related to F. plautii, galactose might be used as 
the only carbon source in the culture media. Through genome comparisons, it was shown that this 
substrate is not used by F. plautii but other strains of Flavonifractor sp. might use it.  Upon isolation of 
different variants, their capacity for degrading flavonoids must be evaluated in pure culture. The rate of 
degradation of flavonoids might be tested using different dietary sources. Additionally, the utilization of 
ethanolamine for quercetin degradation by species of Flavonifractor is another topic that needs 
experimental evidence.  
We also consider important to evaluate whether E. ramulus’s predicted GH30_5 protein has a 
transhydroxylase activity involved in the transfer of hydroxyl ions between phenols. This might reveal 
another important protein in flavonoid metabolism. 
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Appendix 1. Supplemental Material Chapter 1 
Bacteroides thetaiotaomicron Starch Utilization Promotes Quercetin Degradation and Butyrate 
Production by Eubacterium ramulus 
 
Figure S1.1. Chromatogram for calibration of standards. Reference compounds had the following 
retention times: 13.2 min for 3,4-dihydroxybenzoic acid (PCA, 1), 15.4 min for 3,4-dihydroxyphenylacetic 
acid (DOPAC, 2), 22.4 min for 3,4-dihydroxyphenylpropionic acid (3), 23.7 min for 3-hydroxybenzoic acid 
(4), 24.1 min for 3-hydroxyphenylacetic acid (5), 33.9 min for 3-(3-hydroxyphenyl)propionic acid + 
phenylacetic acid (6), 38.0 min for benzoic acid (7), 41.7 min for rutin (8), 43.6 min for quercetin (9), and 
44.0 for genistein (10). Concentration of each analyte 100 µM.
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Figure S1.2. Quercetin degradation assay inoculated with E. ramulus with different concentrations 
of glucose (0.1, 0.3, 0.6, and 0.9 mM) at 22 h of incubation. Degradation was monitored through the 
visualization of the yellow color of quercetin. No transformation of quercetin, yellow; transformation, 
transparent. Tubes correspond to representative results from 3 replicates. 
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Figure S1.3. Lack of growth of E. ramulus in media supplemented with 1 % starch as carbon source 
with (black) and without Quercetin (gray). GEq, Genome equivalents.  
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Figure S1.4. Growth of E. ramulus in monocultures and cocultures supplemented with 40 mM of 
glucose as carbon source with and without quercetin. GEq, Genome equivalents.  
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Table S1.1. HPLC reportable values for Quercetin and related compounds in monocultures and cocultures at 22 h. 
Substrate Culture Qq Dd Cc Ec Ff Hh I + Ji Kk 
No Carbon source B. thetaiotaomicron  155.47 <0.99 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
No Carbon source B. thetaiotaomicron  190.82 <0.99 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
No Carbon source B. thetaiotaomicron  197.20 <0.99 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
Glucose B. thetaiotaomicron  201.67 3.93 5.11 <0.99 <0.99 <0.99 <4.99 <4.99 
Glucose B. thetaiotaomicron  199.52 4.13 5.50 <0.99 <0.99 <0.99 <4.99 <4.99 
Glucose B. thetaiotaomicron  179.65 4.10 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
Starch B. thetaiotaomicron  226.80 3.63 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
Starch B. thetaiotaomicron  183.53 3.60 5.08 <0.99 <0.99 <0.99 <4.99 <4.99 
Starch B. thetaiotaomicron  192.92 3.63 5.03 <0.99 <0.99 <0.99 <4.99 <4.99 
No Carbon source E.ramulus 170.27 26.25 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
No Carbon source E.ramulus 172.08 22.29 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
No Carbon source E.ramulus 168.88 20.73 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
Glucose E.ramulus 18.44 113.76 10.55 <0.99 <0.99 <0.99 <4.99 <4.99 
Glucose E.ramulus 2.98 132.62 9.81 <0.99 <0.99 <0.99 <4.99 <4.99 
Glucose E.ramulus 6.06 131.26 10.34 <0.99 <0.99 <0.99 <4.99 <4.99 
Starch E.ramulus 162.91 47.63 6.36 <0.99 <0.99 1.21 <4.99 <4.99 
Starch E.ramulus 203.09 41.97 5.67 <0.99 <0.99 <0.99 <4.99 <4.99 
Starch E.ramulus 173.60 36.92 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
No Carbon source Coculture 171.92 21.89 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
No Carbon source Coculture 165.69 27.51 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
No Carbon source Coculture 166.26 26.97 <4.99 <0.99 <0.99 <0.99 <4.99 <4.99 
Glucose Coculture 25.56 117.58 12.21 <0.99 <0.99 <0.99 <4.99 <4.99 
Glucose Coculture 22.79 117.77 12.56 <0.99 <0.99 <0.99 <4.99 <4.99 
Glucose Coculture 18.70 121.08 11.93 <0.99 <0.99 <0.99 <4.99 <4.99 
Starch Coculture 34.33 138.66 6.42 <0.99 <0.99 <0.99 <4.99 <4.99 
Starch Coculture 39.18 141.16 6.05 <0.99 <0.99 <0.99 <4.99 <4.99 
Starch Coculture 25.34 158.65 6.37 <0.99 <0.99 <0.99 <4.99 <4.99 
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qQ, Quercetin; dD, 3,4-dihydroxyphenylacetic acid (DOPAC, in bold); cC, 3,4-dihydroxybenzoic acid (PCA); eE, 3,4-dihydroxyphenylpropionic acid; fF, 3-hydroxybenzoic acid; hH, 3-
hydroxyphenylacetic acid; iI+J, 3-(3-hydroxyphenyl) propionic acid + phenylacetic acid; kK, benzoic acid. Concentration in µM. A number after the symbol “<” indicates less than 
the minimum detectable value. 
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Table S1.2. Change in Genome equivalents of E. ramulus and B. thetaiotaomicron in cultures with 
1 % starch as carbon source (experiment independent from the one shown in Fig. 2) and no carbon source. 
Experiment  Change in Geq/ml 
  No Carbon Source Starch 
Monoculture E. ramulus -8.63×108 ±4.7×108 a -3.17E×109 ±5.3×109 b 
 B. thetaiotaomicron - 2.07×1011 ±1.8×1010 a 
Coculture E. ramulus - 2.20E×1010 ±2.6×109 b 
 B. thetaiotaomicron - 2.78×1011 ±1.5×1010 a 
 GEq, Genome equivalents 
a Change in Geq/ml between time 0 h and 8 h.  
b Change in Geq/ml between time 0 h and 12 h.  
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Appendix 2. Supplemental Material Chapter 2 
Gut-derived Flavonifractor species variants are differentially enriched during in vitro 
incubation with Quercetin and persist in diets with different fiber contents  
A 
 
 
B 
 
Figure S2.1. Principal component analysis (PCA) plot of the libraries from in vitro incubations with 
fecal samples from human microbiota-associated mice (HMAM) at 0 (A) and 7 days of incubation (B). In 
the top panel, libraries that were enriched in ASV_65f4 are shown in gray and libraries enriched in 
ASV_a45d are shown in black. In bottom panel, libraries from HMAM mice fed a high fiber diet are shown 
in gray and libraries from HMAM mice fed a low fiber diet in black. Each symbol represents a library (n=6, 
3 replicates), different shapes represent libraries from a different subject: #1, star (); #2, diamond (); 
#3, dot (●); #4, inv. triangle (▼); #5, triangle (▲); and #6, square (■). 
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Figure S2.2. Initial relative abundances for ASV_65f4 (A) and ASV_a45d (B) in in vitro incubations 
with fecal samples from human microbiota-associated mice (HMAM) 0 days of incubation). Libraries that 
were enriched in ASV_65f4 are shown in gray and libraries enriched in ASV_a45d are shown in black.  
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Figure S2.3. Relative abundances for ASV_65f4 libraries from in vitro incubations at 7th day of 
incubation with fecal samples from human microbiota-associated mice (HMAM) fed different diets. 
Libraries from HMAM mice fed a high fiber diet are shown in gray and libraries from HMAM mice fed a 
low fiber diet are shown in black. Libraries shown correspond only to those enriched in ASV_65f4 (subjects 
#2, #3, and #5).  
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Figure S2.4. Proportion of sequences (%) for ASV_65f4 in in vitro incubations with human fecal 
from subject #9. STAMP Bar plots for controls at 0 vs 72 h of incubation (A) and Quercetin treatment vs 
controls at 72 h (B).  
 
 
 
 
 
Figure S2.5. Univariate correlations between levels of six fecal taxa (ASVs) enriched in the 
presence of quercetin in vitro. Presence of an ellipse represents values below p=0.05. Spearman’s rs and 
Bonferroni correction were applied. Dark gray is a positive correlation, light gray is a negative correlation. 
Only treatments with quercetin were analyzed (first and second incubation). 
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Table S2.1. Concentration (mM) in culture of Quercetin and metabolites related to flavonoid 
degradation for in vitro incubations with human fecal samples. 
Subject DOPAC PCA C E H I + M K Quercetin 
#1 0.362 <0.021 0.015 0.067 <0.004 <0.021 0.024 <0.004 
#2 0.385 0.025 <0.004 <0.004 <0.004 <0.021 <0.021 <0.004 
#3 0.351 0.025 <0.004 0.006 0.009 <0.021 <0.021 <0.004 
#4 0.385 0.027 <0.004 <0.004 <0.004 <0.021 <0.021 <0.004 
#5 0.356 0.024 <0.004 0.008 <0.004 <0.021 <0.021 <0.004 
#6 0.399 0.025 <0.004 <0.004 <0.004 <0.021 <0.021 0.005 
#8 0.377 <0.021 0.036 0.004 0.005 <0.021 <0.021 <0.004 
#9 0.325 0.022 0.005 0.006 0.008 <0.021 <0.021 <0.004 
3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxybenzoic acid (PCA); 3,4-dihydroxyphenylpropionic acid (C); 3-
hydroxybenzoic acid (E); 3-hydroxyphenylacetic acid (H); 3-(3-hydroxyphenyl) propionic acid (M) + phenylacetic acid (I); benzoic 
acid (K). A number after the symbol “<” indicates less than the minimum detectable value. Results from 2 replicates. Sample #7 
was not measured. Samples were measured after completion of quercetin degradation (72 h). 
 
Table S2.2. Distribution of Amplicon Sequence Variants (ASVs) significantly enriched in quercetin 
treatments vs. controls derived from in vitro incubations with human fecal samples.  
 Human subject 
ASV #1 #2 #3 #4 #5 #6 #7 #8 #9 
65f4 + + + + + + + + + 
a45d Ns Ns - + - + + - Ns 
76b3 - + - Ns - - Ns - Ns 
f8d4 + Ns - - - - + Ns Ns 
ace8 - - - - - - - - + 
c588 - Ns - Ns Ns 
 
- - + 
+ p < 0.05 
-  not present 
Ns p > 0.05 
p-values calculated with STAMP (Parks et al., 2014).
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Table S2.3. Estimates of Evolutionary Divergence between ASVs and Reference sequences. The number of base substitutions per site from 
between sequences are shown. Analyses were conducted using the Maximum Composite Likelihood model (Tamura et al., 2004). The analysis 
involved 44 nucleotide sequences. All positions containing gaps and missing data were eliminated. There were a total of 225 positions in the final 
dataset. Evolutionary analyses were conducted in MEGA6 (Tamura et al., 2013). 
 
 
 
 
Organism or ASV 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
1 65f46d8c10965a970fcc6949e8c793f6
2 a45db01884f321cd22dcf0f2f1c20738 0.04
3 76b37e21d00e3a7fe96be478db34f3fd 0.06 0.05
4 f8d470aa418ce2d620ef4cd7323ae59d 0.07 0.06 0.03
5 ace82a789a667f4a647ceeddf99ec8f4 0.16 0.18 0.17 0.18
6 c588b62f0de4eb4d078a18ac941fad67 0.16 0.17 0.17 0.17 0.00
7 Flavonifractor_plautii_Y18187 0.00 0.04 0.06 0.07 0.16 0.16
8 Flavonifractor_plautii_EU874848 0.00 0.04 0.06 0.07 0.16 0.16 0.00
9 Flavonifractor_plautii_AY730662 0.00 0.04 0.06 0.07 0.16 0.16 0.00 0.00
10 Flavonifractor_AWSS01000025 0.00 0.04 0.06 0.07 0.16 0.16 0.00 0.00 0.00
11 Flavonifractor_plautii_AGCK01000014 0.00 0.04 0.06 0.07 0.16 0.16 0.00 0.00 0.00 0.00
12 Flavonifractor_sp._An82_NFHG01000054.1:55-285 0.03 0.01 0.04 0.05 0.17 0.17 0.03 0.03 0.03 0.03 0.03
13 Flavonifractor_sp._An306_NFIQ01000164.1:558-787 0.03 0.02 0.05 0.06 0.18 0.18 0.03 0.03 0.03 0.03 0.03 0.02
14 Flavonifractor_sp._An4_NFIL01000023.1:55-285 0.03 0.01 0.04 0.05 0.17 0.17 0.03 0.03 0.03 0.03 0.03 0.00 0.02
15 Pseudoflavonifractor_capillosus_ATCC_29799_AY136666.1 0.04 0.04 0.07 0.08 0.17 0.17 0.04 0.04 0.04 0.04 0.04 0.04 0.05 0.04
16 Intestinimonas_FMGM01000011 0.07 0.06 0.03 0.00 0.18 0.17 0.07 0.07 0.07 0.07 0.07 0.05 0.06 0.05 0.08
17 Intestinimonas_HE974967 0.07 0.06 0.03 0.00 0.18 0.17 0.07 0.07 0.07 0.07 0.07 0.05 0.06 0.05 0.08 0.00
18 Intestinimonas_uncultured_KY285278 0.07 0.06 0.01 0.02 0.18 0.18 0.07 0.07 0.07 0.07 0.07 0.05 0.06 0.05 0.08 0.02 0.02
19 Intestinimonas_butyriciproducens_MJII01000001.3039866 0.07 0.06 0.03 0.00 0.18 0.17 0.07 0.07 0.07 0.07 0.07 0.05 0.06 0.05 0.08 0.00 0.00 0.02
20 Intestinimonas_butyriciproducens_KC311367 0.07 0.06 0.03 0.00 0.18 0.17 0.07 0.07 0.07 0.07 0.07 0.05 0.06 0.05 0.08 0.00 0.00 0.02 0.00
21 Intestinimonas_timonensis_LN870298 0.07 0.06 0.03 0.03 0.19 0.18 0.07 0.07 0.07 0.07 0.07 0.05 0.06 0.05 0.08 0.03 0.03 0.03 0.03 0.03
22 Eubacterium_ramulus_CYYA01000009 0.16 0.17 0.17 0.17 0.00 0.00 0.16 0.16 0.16 0.16 0.16 0.17 0.18 0.17 0.17 0.17 0.17 0.18 0.17 0.17 0.18
23 Eubacterium_ramulus_AJ011522 0.16 0.17 0.17 0.17 0.00 0.00 0.16 0.16 0.16 0.16 0.16 0.17 0.18 0.17 0.17 0.17 0.17 0.18 0.17 0.17 0.18 0.00
24 Eubacterium_ramulus_CYYA01000009(2) 0.16 0.17 0.17 0.17 0.00 0.00 0.16 0.16 0.16 0.16 0.16 0.17 0.18 0.17 0.17 0.17 0.17 0.18 0.17 0.17 0.18 0.00 0.00
25 Eubacterium_ramulus_LG085505 0.16 0.17 0.17 0.17 0.00 0.00 0.16 0.16 0.16 0.16 0.16 0.17 0.18 0.17 0.17 0.17 0.17 0.18 0.17 0.17 0.18 0.00 0.00 0.00
26 Eubacterium_ramulus_ATCC_29099_AWVJ01000187 0.16 0.17 0.17 0.17 0.00 0.00 0.16 0.16 0.16 0.16 0.16 0.17 0.18 0.17 0.17 0.17 0.17 0.18 0.17 0.17 0.18 0.00 0.00 0.00 0.00
27 Eubacterium_oxidoreducens_FMXR01000001 0.18 0.20 0.18 0.17 0.07 0.07 0.18 0.18 0.18 0.18 0.18 0.19 0.20 0.19 0.19 0.17 0.17 0.17 0.17 0.17 0.17 0.07 0.07 0.07 0.07 0.07
28 Eubacterium_rectale_AY169428 0.15 0.17 0.16 0.17 0.05 0.05 0.15 0.15 0.15 0.15 0.15 0.16 0.17 0.16 0.16 0.17 0.17 0.17 0.17 0.17 0.16 0.05 0.05 0.05 0.05 0.05 0.06
29 Clostridium_butyricum_AB022592 0.24 0.26 0.26 0.25 0.20 0.19 0.24 0.24 0.24 0.24 0.24 0.25 0.26 0.25 0.23 0.25 0.25 0.25 0.25 0.25 0.26 0.19 0.19 0.19 0.19 0.19 0.19 0.19
30 Eubacterium_multiforme_LV535406 0.23 0.26 0.26 0.26 0.19 0.19 0.23 0.23 0.23 0.23 0.23 0.25 0.25 0.25 0.21 0.26 0.26 0.26 0.26 0.26 0.26 0.19 0.19 0.19 0.19 0.19 0.18 0.18 0.08
31 Eubacterium_barkeri_FNOU01000044 0.17 0.18 0.17 0.18 0.17 0.16 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.18 0.18 0.17 0.18 0.18 0.19 0.16 0.16 0.16 0.16 0.16 0.20 0.21 0.22 0.20
32 Eubacterium_rangiferina_EU124830 0.14 0.16 0.16 0.16 0.06 0.06 0.14 0.14 0.14 0.14 0.14 0.16 0.16 0.16 0.16 0.16 0.16 0.17 0.16 0.16 0.17 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.19 0.19 0.17
33 Eubacterium_callanderi_AM902700 0.21 0.21 0.20 0.20 0.15 0.15 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.15 0.15 0.15 0.15 0.15 0.16 0.18 0.23 0.20 0.05 0.17
34 Eubacterium_pyruvativorans_AJ310135 0.30 0.32 0.32 0.32 0.25 0.25 0.30 0.30 0.30 0.30 0.30 0.31 0.30 0.31 0.28 0.32 0.32 0.33 0.32 0.32 0.34 0.25 0.25 0.25 0.25 0.25 0.26 0.25 0.21 0.21 0.24 0.25 0.25
35 Eubacterium_oxidoreducens_AF202259 0.18 0.20 0.19 0.18 0.08 0.07 0.18 0.18 0.18 0.18 0.18 0.20 0.20 0.20 0.20 0.18 0.18 0.18 0.18 0.18 0.18 0.07 0.07 0.07 0.07 0.07 0.00 0.06 0.19 0.19 0.21 0.07 0.17 0.27
36 Eubacterium_nitritogenes_AB018185 0.23 0.25 0.25 0.25 0.18 0.17 0.23 0.23 0.23 0.23 0.23 0.24 0.24 0.24 0.21 0.25 0.25 0.25 0.25 0.25 0.26 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.07 0.01 0.20 0.18 0.20 0.21 0.18
37 Eubacterium_aggregans_AF073898 0.17 0.18 0.17 0.18 0.17 0.16 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.18 0.18 0.17 0.18 0.18 0.19 0.16 0.16 0.16 0.16 0.16 0.20 0.21 0.22 0.20 0.00 0.17 0.05 0.24 0.21 0.20
38 Eubacterium_limosum_AB298909 0.21 0.21 0.20 0.20 0.15 0.15 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.15 0.15 0.15 0.15 0.15 0.16 0.18 0.23 0.20 0.05 0.17 0.00 0.25 0.17 0.20 0.05
39 Eubacterium_plexicaudatum_AF157054 0.17 0.18 0.18 0.18 0.06 0.06 0.17 0.17 0.17 0.17 0.17 0.18 0.19 0.18 0.18 0.18 0.18 0.19 0.18 0.18 0.18 0.06 0.06 0.06 0.06 0.06 0.06 0.04 0.21 0.20 0.20 0.08 0.18 0.26 0.07 0.19 0.20 0.18
40 Eubacterium_brachy_ATCC_33089_AXUD01000014 0.31 0.32 0.32 0.32 0.25 0.26 0.31 0.31 0.31 0.31 0.31 0.30 0.30 0.30 0.29 0.32 0.32 0.32 0.32 0.32 0.34 0.26 0.26 0.26 0.26 0.26 0.27 0.28 0.25 0.26 0.23 0.25 0.23 0.12 0.28 0.26 0.23 0.23 0.28
41 Eubacterium_infirmum_AGWI01000033 0.29 0.30 0.30 0.31 0.25 0.24 0.29 0.29 0.29 0.29 0.29 0.30 0.28 0.30 0.26 0.31 0.31 0.31 0.31 0.31 0.31 0.24 0.24 0.24 0.24 0.24 0.25 0.25 0.24 0.20 0.24 0.24 0.23 0.09 0.26 0.20 0.24 0.23 0.25 0.11
42 Eubacterium_nodatum_ATCC_33099_AZKM01000010 0.34 0.34 0.34 0.34 0.30 0.30 0.34 0.34 0.34 0.34 0.34 0.36 0.35 0.36 0.33 0.34 0.34 0.34 0.34 0.34 0.32 0.30 0.30 0.30 0.30 0.30 0.32 0.29 0.29 0.29 0.28 0.32 0.27 0.13 0.33 0.29 0.28 0.27 0.31 0.18 0.16
43 Eubacterium_saphenum_ATCC_49989_ACON01000003 0.29 0.30 0.30 0.30 0.24 0.25 0.29 0.29 0.29 0.29 0.29 0.30 0.28 0.30 0.29 0.30 0.30 0.30 0.30 0.30 0.30 0.25 0.25 0.25 0.25 0.25 0.25 0.24 0.24 0.24 0.22 0.25 0.21 0.13 0.26 0.24 0.22 0.21 0.25 0.12 0.11 0.19
44 Bifidobacterium_adolescentis_AAXD02000034 1.19 1.24 1.34 1.32 1.13 1.13 1.19 1.19 1.19 1.19 1.19 1.25 1.20 1.25 1.23 1.32 1.32 1.39 1.32 1.32 1.36 1.13 1.13 1.13 1.13 1.13 1.10 1.17 1.19 1.18 1.23 1.16 1.25 1.12 1.10 1.15 1.23 1.25 1.17 1.16 1.13 1.28 1.1560459981449+A1:AS455
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Appendix 3. Supplemental material Chapter 3 
Functional profiling of genomes from flavonoid-degrading bacteria and their predictive ecological role 
in the gastrointestinal tract 
 
Figure S3.1. Evolutionary relationships of F. plautii strains. The evolutionary history was inferred 
using the UPGMA method. The optimal tree with the sum of branch length = 0.01324911 is shown. The 
evolutionary distances were computed using the Maximum Composite Likelihood method and are in the 
units of the number of base substitutions per site. The analysis involved 9 nucleotide sequences: F. plautii 
MC1, F. plautii An248, F. plautii 1001175st1_C9, F. plautii DSM 6740, F. plautii 2789STDY5608854, F. 
plautii 2789STDY5834932, F. plautii ATCC 29863, F. plautii 1_3_50AFAA, and F. plautii YL31. All positions 
containing gaps and missing data were eliminated. There were a total of 1465 positions in the final dataset 
corresponding to the 16S rRNA gene. Genomes selected for subsequent analyses are labeled with a black 
circle. 
 1001175st1 C9
 An248
 DSM 6740
 2789STDY5608854
 MC1
 ATCC 29863
 2789STDY5834932
 1 3 50AFAA
 YL31
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Figure S3.2. Evolutionary relationships of Flavonifractor sp. strains. The evolutionary history was 
inferred using the UPGMA method. The optimal tree with the sum of branch length = 0.05920312 is 
shown. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary 
distances used to infer the phylogenetic tree. The analysis involved 11 nucleotide sequences: 
Flavonifractor sp. strains An4, An9, An10, An52, An82, An91, An92, An100, An112, An135, An306. All 
positions containing gaps and missing data were eliminated. There were a total of 230 positions in the 
final dataset. Genomes selected for subsequent analyses are labeled with a black circle. 
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Table S3.1. Genomes used in this study. 
Organism name Strain Genome Id Size (bp) Assembly level Genome representation 
Flavonifractor plautiia YL31 GCA_001688625.2 3,818,478 Complete Genome full 
Flavonifractor plautii 2789STDY5834932 GCA_001406055.1 4,115,051 Scaffold full 
Flavonifractor plautii ATCC 29863 GCA_000239295.1 3,820,124 Scaffold full 
Flavonifractor plautii DSM 6740 GCA_004345805.1 4,431,208 Scaffold full 
Flavonifractor plautii An248 GCA_002159865.1  3,761,516 Contig full 
Flavonifractor plautii MC1 GCA_901212615.1 3,923,577 Scaffold full 
Flavonifractor plautii 1001175st1_C9 GCA_005844565.1 4,011,075 Scaffold full 
Flavonifractor plautii 1_3_50AFAA GCA_000760655.1 4,383,642 Scaffold full 
Flavonifractor plautii 2789STDY5608854 GCA_001404915.1 4,250,184 Scaffold full 
Flavonifractor sp. An4 GCA_002161245.1 3,350,225 Contig full 
Flavonifractor sp. An9 GCA_002161245.1 3,350,225 Contig full 
Flavonifractor sp. An10 GCA_002161215.1 3,882,968 Contig full 
Flavonifractor sp. An52 GCA_002159385.1 2,834,090 Contig full 
Flavonifractor sp. An82 GCF_002159265.1 3,668,665 Contig full 
Flavonifractor sp. An91 GCA_002159225.1 3,603,995 Contig full 
Flavonifractor sp. An92 GCA_002159175.1 3,490,035 Contig full 
Flavonifractor sp. An100 GCA_002161175.1 3,040,137 Contig full 
Flavonifractor sp. An112 GCA_002161085.1 2,958,951 Contig full 
Flavonifractor sp. An135 GCA_002160795.1 3,889,952 Contig full 
Flavonifractor sp. An306 GCA_002159455.1 3,902,886 Contig full 
Eubacterium ramulusa ATCC 29099 GCA_000469345.1 3,447,136 Scaffold full 
Eubacterium ramulus 2789STDY5608891 GCA_001406295.1 3,307,376 Scaffold full 
Eubacterium ramulus 21 GCA_003122485.1  3,487,636 Contig full 
Eubacterium ramulus MGYG-HGUT-01456 GCA_902375155.1  3,447,136 Scaffold full 
Eubacterium ramulus MGYG-HGUT-02278 GCA_902385375.1 3,656,239 Scaffold full 
Eubacterium oxidoreducensa DSM 3217 GCA_900104415.1 2,912,287 Scaffold full 
Eubacterium rectalea ATCC 33656 GCA_000020605.1 3,449,685 Complete Genome full 
a representative genome 
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Table S3.2. Average Nucleotide Identity (ANIm) and aligned percentage for E. ramulus genomes. 
  MGYG-HGUT-02278 MGYG-HGUT-01456 Strain 21 2789STDY5608891 ATCC 29099 
MGYG-HGUT-02278 * 89.22 [40.21] 99.05 [79.89] 89.04 [39.42] 89.22 [40.21] 
MGYG-HGUT-01456 89.21 [41.98] * 89.20 [40.53] 98.75 [80.31] 100.00 [99.70] 
Strain 21 99.05 [82.87] 89.19 [40.09] * 89.00 [39.88] 89.19 [40.09] 
2789STDY5608891 89.04 [43.10] 98.75 [84.14] 89.01 [42.44] * 98.75 [84.14] 
ATCC 29099 89.21 [41.98] 100.00 [99.70] 89.20 [40.53] 98.75 [80.31] * 
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Table S3.3. Average Nucleotide Identity (ANIm) and aligned percentage for 20 genomes belonging to Flavonifractor spp.  
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Table S3.4. Protein list for each orthologous gene clusters for the genomes of E. ramulus 
2789STDY5608891, E. ramulus ATCC29099, and E. ramulus MGYG01456. 
  
# 
cluste
r_na
me 
protei
n_nu
mber 
swiss
_pro
t_id 
go_annotation protein_list 
cluste
r2536 
3 
E3PR
K0 
GO:0019475; P:L-lysine 
catabolic process to acetate; 
IEA:UniProtKB-UniPathway 
EramulusATCC|ERK46210.1;Eramulus2789STDY|CUN14552.1;EramulusMGYG0145
6|CABKSU010000112.1_56 
cluste
r2628 
3 
Q9X
BQ8 
GO:0019475; P:L-lysine 
catabolic process to acetate; 
IEA:UniProtKB-UniPathway 
EramulusATCC|ERK46208.1;Eramulus2789STDY|CUN14590.1;EramulusMGYG0145
6|CABKSU010000112.1_54 
cluste
r2694 
3 
E3PR
J9 
GO:0019475; P:L-lysine 
catabolic process to acetate; 
IEA:UniProtKB-UniPathway 
EramulusATCC|ERK46209.1;Eramulus2789STDY|CUN14574.1;EramulusMGYG0145
6|CABKSU010000112.1_55 
cluste
r2778 
3 
E3PR
K1 
GO:0019475; P:L-lysine 
catabolic process to acetate; 
IEA:UniProtKB-UniPathway 
EramulusATCC|ERK46211.1;Eramulus2789STDY|CUN14537.1;EramulusMGYG0145
6|CABKSU010000112.1_57 
cluste
r1258 
6 
E3PR
K0 
GO:0019475; P:L-lysine 
catabolic process to acetate; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000002.1_59;Eoxidoreducens|SDB19416.1;Era
mulus21|PWE86865.1;Eramulus2789STDY|CUM90605.1;EramulusMGYG01456|CA
BKSU010000018.1_53;EramulusATCC|ERK43036.1 
cluste
r2730 
3 
C6DJ
R5 
GO:0019299; P:rhamnose 
metabolic process; 
IEA:UniProtKB-UniRule 
EramulusATCC|ERK41761.1;Eramulus2789STDY|CUN23050.1;EramulusMGYG0145
6|CABKSU010000033.1_13 
cluste
r2803 
3 
Q65
Q26 
GO:0019301; P:rhamnose 
catabolic process; 
IEA:UniProtKB-UniPathway 
EramulusATCC|ERK47447.1;Eramulus2789STDY|CUN23570.1;EramulusMGYG0145
6|CABKSU010000080.1_12 
87 
 
cluste
r2789 
3 
Q9K
CM0 
GO:0019301; P:rhamnose 
catabolic process; 
IEA:UniProtKB-UniPathway 
EramulusATCC|ERK47449.1;Eramulus2789STDY|CUN23587.1;EramulusMGYG0145
6|CABKSU010000080.1_14 
cluste
r2259 4 
B8FZ
R3 
GO:0042823; P:pyridoxal 
phosphate biosynthetic 
process; IEA:UniProtKB-
UniRule 
EramulusATCC|ERK46173.1;Eramulus2789STDY|CUN15211.1;EramulusMGYG0145
6|CABKSU010000112.1_21;Erectale|ACR76680.1 
cluste
r2260 4 
B8FZ
R4 
GO:0042823; P:pyridoxal 
phosphate biosynthetic 
process; IEA:UniProtKB-
UniRule 
EramulusATCC|ERK46174.1;Eramulus2789STDY|CUN15191.1;EramulusMGYG0145
6|CABKSU010000112.1_22;Erectale|ACR76681.1 
88 
 
Table S3.5. Protein list for each orthologous gene clusters for the genomes of E. ramulus 2789STDY5608891, E. ramulus ATCC29099, E. 
ramulus MGYG01456, E. ramulus 21, and E. ramulus MGYG02278. 
# 
clust
er_n
ame 
protei
n_nu
mber 
swis
s_pr
ot_i
d 
go_annotation protein_list 
clust
er103
5 
6 
O26
801 
GO:0030976; F:thiamine 
pyrophosphate binding; 
IEA:InterPro 
EramulusMGYG02278|CABMEW010000001.1_122;Eoxidoreducens|SDB28922.1;
Eramulus21|PWE86535.1;Eramulus2789STDY|CUM93990.1;EramulusMGYG014
56|CABKSU010000021.1_85;EramulusATCC|ERK42627.1 
clust
er137
9 
6 
O26
801 
GO:0030976; F:thiamine 
pyrophosphate binding; 
IEA:InterPro 
EramulusMGYG02278|CABMEW010000001.1_123;Eoxidoreducens|SDB28910.1;
Eramulus21|PWE86536.1;Eramulus2789STDY|CUM94028.1;EramulusMGYG014
56|CABKSU010000021.1_84;EramulusATCC|ERK42626.1 
clust
er144
3 
6 
Q56
317 
GO:0030976; F:thiamine 
pyrophosphate binding; 
IEA:InterPro 
EramulusMGYG02278|CABMEW010000002.1_153;Eoxidoreducens|SDB33464.1;
Eramulus21|PWE87698.1;Eramulus2789STDY|CUM72979.1;EramulusMGYG014
56|CABKSU010000006.1_37;EramulusATCC|ERK43358.1 
clust
er109
2 
6 
Q9K
9G5 
GO:0009229; P:thiamine 
diphosphate biosynthetic process; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000007.1_33;Eoxidoreducens|SDB27697.1;E
ramulus21|PWE87606.1;Eramulus2789STDY|CUN14904.1;EramulusMGYG01456
|CABKSU010000112.1_38;EramulusATCC|ERK46191.1 
clust
er101
8 
6 
Q97L
Q9 
GO:0009229; P:thiamine 
diphosphate biosynthetic process; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000009.1_82;Eramulus21|PWE86015.1;Era
mulus2789STDY|CUM86707.1;EramulusMGYG01456|CABKSU010000057.1_74;E
ramulusATCC|ERK49886.1;Erectale|ACR74026.1 
clust
er102
1 
6 
P614
22 
GO:0009229; P:thiamine 
diphosphate biosynthetic process; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000001.1_199;Eramulus21|PWE86603.1;Era
mulus2789STDY|CUN26534.1;EramulusMGYG01456|CABKSU010000063.1_69;Er
amulusATCC|ERK51838.1;Erectale|ACR76259.1 
clust
er121
9 
6 
Q97
EL4 
GO:0009229; P:thiamine 
diphosphate biosynthetic process; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000001.1_196;Eramulus21|PWE86600.1;Era
mulus2789STDY|CUN26564.1;EramulusMGYG01456|CABKSU010000063.1_66;Er
amulusATCC|ERK51835.1;Erectale|ACR76261.1 
89 
 
clust
er130
8 
6 
A6LT
L5 
GO:0009229; P:thiamine 
diphosphate biosynthetic process; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000009.1_80;Eramulus21|PWE86013.1;Era
mulus2789STDY|CUM86750.1;EramulusMGYG01456|CABKSU010000057.1_72;E
ramulusATCC|ERK49884.1;Erectale|ACR74028.1 
clust
er138
7 
6 
A0Q
1U9 
GO:0009229; P:thiamine 
diphosphate biosynthetic process; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000001.1_202;Eramulus21|PWE86606.1;Era
mulus2789STDY|CUN26517.1;EramulusMGYG01456|CABKSU010000063.1_71;Er
amulusATCC|ERK51842.1;Erectale|ACR76258.1 
clust
er144
8 
6 
Q89
3R0 
GO:0009229; P:thiamine 
diphosphate biosynthetic process; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000001.1_197;Eramulus21|PWE86601.1;Era
mulus2789STDY|CUN26552.1;EramulusMGYG01456|CABKSU010000063.1_67;Er
amulusATCC|ERK51836.1;Erectale|ACR76260.1 
clust
er110
3 
6 
F4JY
E9 
GO:0046654; P:tetrahydrofolate 
biosynthetic process; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000008.1_129;Eoxidoreducens|SDB27740.1;
Eramulus21|PWE86909.1;Eramulus2789STDY|CUM88513.1;EramulusMGYG014
56|CABKSU010000064.1_66;EramulusATCC|ERK49454.1 
clust
er145
2 
6 
P596
57 
GO:0046654; P:tetrahydrofolate 
biosynthetic process; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000008.1_132;Eoxidoreducens|SDB27717.1;
Eramulus21|PWE86911.1;Eramulus2789STDY|CUM88575.1;EramulusMGYG014
56|CABKSU010000064.1_63;EramulusATCC|ERK49451.1 
clust
er151
2 
6 
B1L1
S1 
GO:0046654; P:tetrahydrofolate 
biosynthetic process; 
IEA:UniProtKB-UniRule 
EramulusMGYG02278|CABMEW010000003.1_154;Eoxidoreducens|SDB03615.1;
Eramulus21|PWE88095.1;Eramulus2789STDY|CUM71334.1;EramulusMGYG014
56|CABKSU010000082.1_45;EramulusATCC|ERK47260.1 
clust
er151
8 
6 
Q05
621 
GO:0046654; P:tetrahydrofolate 
biosynthetic process; 
IEA:UniProtKB-UniPathway 
EramulusMGYG02278|CABMEW010000008.1_131;Eoxidoreducens|SDB27725.1;
Eramulus21|PWE86910.1;Eramulus2789STDY|CUM88556.1;EramulusMGYG014
56|CABKSU010000064.1_64;EramulusATCC|ERK49452.1 
clust
er104
9 
6 
C0H
450 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000007.1_75;Eramulus21|PWE87646.1;Era
mulus2789STDY|CUN04726.1;EramulusMGYG01456|CABKSU010000104.1_40;Er
amulusATCC|ERK46456.1;Erectale|ACR76162.1 
clust
er105
8 
6 
P336
58 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000002.1_36;Eramulus21|PWE86849.1;Era
mulus2789STDY|CUM90376.1;EramulusMGYG01456|CABKSU010000018.1_66;E
ramulusATCC|ERK42916.1;Erectale|ACR75980.1 
clust
er107
1 
6 
Q8R
B77 
GO:0009847; P:spore 
germination; IEA:UniProtKB-
UniRule 
EramulusMGYG02278|CABMEW010000003.1_170;Eramulus21|PWE88042.1;Era
mulus2789STDY|CUM77476.1;EramulusMGYG01456|CABKSU010000098.1_29;E
ramulusATCC|ERK46788.1;Erectale|ACR75363.1 
90 
 
clust
er108
7 
6 
P375
58 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000024.1_18;Eramulus21|PWE86103.1;Era
mulus2789STDY|CUN21500.1;EramulusMGYG01456|CABKSU010000021.1_24;Er
amulusATCC|ERK42695.1;Erectale|ACR74321.1 
clust
er109
0 
6 
B0K9
G3 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000008.1_33;Eramulus21|PWE86964.1;Era
mulus2789STDY|CUN19136.1;EramulusMGYG01456|CABKSU010000122.1_35;Er
amulusATCC|ERK43707.1;Erectale|ACR76304.1 
clust
er109
7 
6 
P408
68 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000008.1_50;Eramulus21|PWE86977.1;Era
mulus2789STDY|CUN18942.1;EramulusMGYG01456|CABKSU010000122.1_23;Er
amulusATCC|ERK43768.1;Erectale|ACR74879.1 
clust
er112
3 
6 
O34
765 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000004.1_48;Eramulus21|PWE87796.1;Era
mulus2789STDY|CUM97308.1;EramulusMGYG01456|CABKSU010000038.1_42;E
ramulusATCC|ERK50468.1;Erectale|ACR75424.1 
clust
er114
3 
6 
P241
41 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000023.1_14;Eramulus21|PWE86396.1;Era
mulus2789STDY|CUM92553.1;EramulusMGYG01456|CABKSU010000009.1_19;E
ramulusATCC|ERK50833.1;Erectale|ACR74743.1 
clust
er116
8 
6 
C0Q
YX7 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:InterPro 
EramulusMGYG02278|CABMEW010000002.1_140;Eramulus21|PWE87685.1;Era
mulus2789STDY|CUM73190.1;EramulusMGYG01456|CABKSU010000006.1_9;Er
amulusATCC|ERK43329.1;Erectale|ACR75729.1 
clust
er117
9 
6 
P062
22 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000002.1_33;Eramulus21|PWE86846.1;Era
mulus2789STDY|CUM90327.1;EramulusMGYG01456|CABKSU010000018.1_69;E
ramulusATCC|ERK42919.1;Erectale|ACR75984.1 
clust
er118
1 
6 
P408
67 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000008.1_49;Eramulus21|PWE86978.1;Era
mulus2789STDY|CUN18958.1;EramulusMGYG01456|CABKSU010000122.1_24;Er
amulusATCC|ERK43769.1;Erectale|ACR74831.1 
clust
er121
0 
6 
P497
80 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000002.1_77;Eramulus21|PWE86761.1;Era
mulus2789STDY|CUM90965.1;EramulusMGYG01456|CABKSU010000018.1_35;E
ramulusATCC|ERK43016.1;Erectale|ACR75974.1 
clust
er121
1 
6 
P391
51 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000017.1_17;Eramulus21|PWE85582.1;Era
mulus2789STDY|CUN25808.1;EramulusMGYG01456|CABKSU010000016.1_9;Era
mulusATCC|ERK50672.1;Erectale|ACR74765.1 
91 
 
clust
er123
2 
6 
P621
82 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000018.1_60;Eramulus21|PWE86450.1;Era
mulus2789STDY|CUM78110.1;EramulusMGYG01456|CABKSU010000098.1_11;E
ramulusATCC|ERK46768.1;Erectale|ACR75560.1 
clust
er129
6 
6 
P351
50 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000004.1_207;Eramulus21|PWE86694.1;Era
mulus2789STDY|CUM75745.1;EramulusMGYG01456|CABKSU010000091.1_14;E
ramulusATCC|ERK51326.1;Erectale|ACR75369.1 
clust
er132
0 
6 
P152
81 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000001.1_326;Eramulus21|PWE85793.1;Era
mulus2789STDY|CUN11272.1;EramulusMGYG01456|CABKSU010000113.1_4;Era
mulusATCC|ERK45983.1;Erectale|ACR74407.1 
clust
er132
3 
6 
P497
84 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000002.1_81;Eramulus21|PWE86758.1;Era
mulus2789STDY|CUM91043.1;EramulusMGYG01456|CABKSU010000018.1_31;E
ramulusATCC|ERK43012.1;Erectale|ACR75970.1 
clust
er134
1 
6 
P499
39 
GO:0009847; P:spore 
germination; IEA:InterPro 
EramulusMGYG02278|CABMEW010000017.1_14;Eramulus21|PWE85585.1;Era
mulus2789STDY|CUN25779.1;EramulusMGYG01456|CABKSU010000016.1_6;Era
mulusATCC|ERK50669.1;Erectale|ACR74763.1 
clust
er134
7 
6 
P497
81 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000002.1_78;Eramulus21|PWE86760.1;Era
mulus2789STDY|CUM90990.1;EramulusMGYG01456|CABKSU010000018.1_34;E
ramulusATCC|ERK43015.1;Erectale|ACR75973.1 
clust
er135
0 
6 
P178
96 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000003.1_118;Eramulus21|PWE88063.1;Era
mulus2789STDY|CUM70758.1;EramulusMGYG01456|CABKSU010000082.1_72;E
ramulusATCC|ERK47288.1;Erectale|ACR75943.1 
clust
er135
4 
6 
P218
87 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000012.1_40;Eramulus21|PWE86249.1;Era
mulus2789STDY|CUN12557.1;EramulusMGYG01456|CABKSU010000004.1_7;Era
mulusATCC|ERK43473.1;Erectale|ACR74749.1 
clust
er141
1 
6 
P375
54 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000010.1_27;Eramulus21|PWE85639.1;Era
mulus2789STDY|CUM94881.1;EramulusMGYG01456|CABKSU010000021.1_40;E
ramulusATCC|ERK42713.1;Erectale|ACR76879.1 
clust
er142
5 
6 
Q01
367 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000002.1_75;Eramulus21|PWE86763.1;Era
mulus2789STDY|CUM90929.1;EramulusMGYG01456|CABKSU010000018.1_37;E
ramulusATCC|ERK43018.1;Erectale|ACR75976.1 
92 
 
clust
er144
6 
6 
Q00
758 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000011.1_26;Eramulus21|PWE85970.1;Era
mulus2789STDY|CUM85205.1;EramulusMGYG01456|CABKSU010000025.1_86;E
ramulusATCC|ERK42356.1;Erectale|ACR75193.1 
clust
er145
3 
6 
P241
36 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000023.1_16;Eramulus21|PWE86398.1;Era
mulus2789STDY|CUM92503.1;EramulusMGYG01456|CABKSU010000009.1_21;E
ramulusATCC|ERK50835.1;Erectale|ACR74741.1 
clust
er151
1 
6 
P065
34 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000003.1_109;Eramulus21|PWE88053.1;Era
mulus2789STDY|CUM70574.1;EramulusMGYG01456|CABKSU010000082.1_80;E
ramulusATCC|ERK47297.1;Erectale|ACR75910.1 
clust
er151
7 
6 
Q81
SW4 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IDA:UniProtKB 
EramulusMGYG02278|CABMEW010000002.1_68;Eramulus21|PWE86873.1;Era
mulus2789STDY|CUM90795.1;EramulusMGYG01456|CABKSU010000018.1_44;E
ramulusATCC|ERK43026.1;Erectale|ACR75583.1 
clust
er154
7 5 
P267
64 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000008.1_34;Eramulus21|PWE86963.1;Era
mulus2789STDY|CUN19119.1;EramulusMGYG01456|CABKSU010000122.1_34;Er
amulusATCC|ERK43706.1 
clust
er155
9 5 
P351
57 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000029.1_13;Eramulus21|PWE87422.1;Era
mulus2789STDY|CUM82200.1;EramulusMGYG01456|CABKSU010000037.1_15;E
ramulusATCC|ERK41665.1 
clust
er161
5 5 
P351
58 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000029.1_19;Eramulus21|PWE87408.1;Era
mulus2789STDY|CUM82178.1;EramulusMGYG01456|CABKSU010000037.1_16;E
ramulusATCC|ERK41666.1 
clust
er164
9 5 
P604
95 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000005.1_186;Eramulus21|PWE86926.1;Era
mulus2789STDY|CUM88927.1;EramulusMGYG01456|CABKSU010000064.1_48;E
ramulusATCC|ERK49434.1 
clust
er172
0 5 
B1H
VK6 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-UniRule 
EramulusMGYG02278|CABMEW010000007.1_89;Eramulus21|PWE85503.1;Era
mulus2789STDY|CUN04108.1;EramulusMGYG01456|CABKSU010000104.1_13;Er
amulusATCC|ERK46513.1 
clust
er187
7 5 
P710
44 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000002.1_101;Eramulus21|PWE87186.1;Era
mulus2789STDY|CUN15166.1;EramulusMGYG01456|CABKSU010000112.1_26;Er
amulusATCC|ERK46178.1 
93 
 
clust
er192
7 5 
Q7W
Y77 
GO:0030435; P:sporulation 
resulting in formation of a cellular 
spore; IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000005.1_187;Eramulus21|PWE86925.1;Era
mulus2789STDY|CUM88907.1;EramulusMGYG01456|CABKSU010000064.1_49;E
ramulusATCC|ERK49435.1 
94 
 
Table S3.6. Protein list for each orthologous gene clusters for the genomes of E. oxidoreducens, E. rectale, E. ramulus 21, and E. ramulus 
MGYG02278. 
# 
clust
er_na
me 
protei
n_nu
mber 
swis
s_pr
ot_id 
go_annotation protein_list 
cluste
r1564 
5 
P398
53 
GO:0045227; P:capsule 
polysaccharide biosynthetic 
process; IEA:UniProtKB-
UniPathway 
EramulusMGYG02278|CABMEW010000009.1_19;Eoxidoreducens|SDB21266.1;Er
ectale|ACR76350.1;EramulusMGYG02278|CABMEW010000005.1_142;Eramulus2
1|PWE87843.1 
cluste
r2123 
4 
Q0P
8J8 
GO:0045227; P:capsule 
polysaccharide biosynthetic 
process; IEA:UniProtKB-
UniPathway 
EramulusMGYG02278|CABMEW010000007.1_62;Eoxidoreducens|SDB17934.1;Er
amulus21|PWE87642.1;Erectale|ACR76339.1 
cluste
r1564 5 
P398
53 
GO:0045227; P:capsule 
polysaccharide biosynthetic 
process; IEA:UniProtKB-
UniPathway 
EramulusMGYG02278|CABMEW010000009.1_19;Eoxidoreducens|SDB21266.1;Er
ectale|ACR76350.1;EramulusMGYG02278|CABMEW010000005.1_142;Eramulus2
1|PWE87843.1 
cluste
r2123 4 
Q0P
8J8 
GO:0045227; P:capsule 
polysaccharide biosynthetic 
process; IEA:UniProtKB-
UniPathway 
EramulusMGYG02278|CABMEW010000007.1_62;Eoxidoreducens|SDB17934.1;Er
amulus21|PWE87642.1;Erectale|ACR76339.1 
cluste
r381 
7 
P710
57 
GO:0000271; P:polysaccharide 
biosynthetic process; 
IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000007.1_60;Eoxidoreducens|SDB06730.1;Er
amulus21|PWE87643.1;Erectale|ACR76357.1;Eoxidoreducens|SDB06792.1;Eoxid
oreducens|SDB06813.1;Eoxidoreducens|SDB30699.1 
cluste
r2102 
4 
P710
55 
GO:0000271; P:polysaccharide 
biosynthetic process; 
IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000007.1_64;Eoxidoreducens|SDB21844.1;Er
amulus21|PWE87640.1;Erectale|ACR76356.1 
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cluste
r2117 
4 
P141
84 
GO:0009103; 
P:lipopolysaccharide 
biosynthetic process; 
IEA:UniProtKB-KW 
EramulusMGYG02278|CABMEW010000007.1_42;Eramulus21|PWE87588.1;Erect
ale|ACR76380.1;Eoxidoreducens|SDB15620.1 
cluste
r2190 
4 
Q58
466 
GO:0000271; P:polysaccharide 
biosynthetic process; 
IBA:GO_Central 
EramulusMGYG02278|CABMEW010000009.1_15;Eramulus21|PWE87842.1;Erect
ale|ACR76349.1;Eoxidoreducens|SDB15544.1 
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Table S3.7. Protein list for each orthologous gene clusters for the genomes of F. plautii YL31, F. plautii 2789STDY5834932, F. plautii ATCC 
29863, F. plautii An248. 
# 
cluster
_nam
e 
protei
n_num
ber 
swiss
_prot
_id go_annotation protein_list 
cluster
2635 4 
Q892
D0 
GO:0046336; P:ethanolamine catabolic 
process; IEA:UniProtKB-UniPathway 
2789STDY5834932|CUP71372.1;An248|OUO82145.1;YL31|ANU41982.
1;ATCC_29863|EHM42371.1 
cluster
2683 4 
Q9ZF
V2 
GO:0046336; P:ethanolamine catabolic 
process; IEA:UniProtKB-UniPathway 
2789STDY5834932|CUP71298.1;An248|OUO82147.1;YL31|ANU41984.
1;ATCC_29863|EHM42369.1 
cluster
2711 4 
P0AEJ
7 
GO:0046336; P:ethanolamine catabolic 
process; IEA:UniProtKB-UniPathway 
2789STDY5834932|CUP71331.1;An248|OUO82146.1;YL31|ANU41983.
1;ATCC_29863|EHM42370.1 
cluster
2744 4 
Q892
D0 
GO:0046336; P:ethanolamine catabolic 
process; IEA:UniProtKB-UniPathway 
2789STDY5834932|CUQ41078.1;An248|OUO83463.1;YL31|ANU42383.
1;ATCC_29863|EHM47953.1 
cluster
2792 4 
P7655
2 
GO:0046336; P:ethanolamine catabolic 
process; IEA:UniProtKB-UniPathway 
2789STDY5834932|CUP71884.1;An248|OUO82132.1;YL31|ANU41970.
1;ATCC_29863|EHM42337.1 
cluster
2801 4 
P7727
7 
GO:0046336; P:ethanolamine catabolic 
process; IEA:UniProtKB-UniPathway 
2789STDY5834932|CUP71680.1;An248|OUO82137.1;YL31|ANU41975.
1;ATCC_29863|EHM42332.1 
cluster
2809 4 
Q9ZF
V4 
GO:0046336; P:ethanolamine catabolic 
process; IEA:UniProtKB-UniPathway 
2789STDY5834932|CUP71597.1;An248|OUO82139.1;YL31|ANU41977.
1;ATCC_29863|EHM42330.1 
cluster
2881 4 
P7654
1 
GO:0046336; P:ethanolamine catabolic 
process; IEA:UniProtKB-UniPathway 
2789STDY5834932|CUP71414.1;An248|OUO82144.1;YL31|ANU41981.
1;ATCC_29863|EHM42372.1 
cluster
2965 4 
P0AB
F5 
GO:0046336; P:ethanolamine catabolic 
process; IEA:UniProtKB-UniPathway 
2789STDY5834932|CUP71451.1;An248|OUO82143.1;YL31|ANU41980.
1;ATCC_29863|EHM42373.1 
cluster
3013 4 
P7655
2 
GO:0046336; P:ethanolamine catabolic 
process; IEA:UniProtKB-UniPathway 
2789STDY5834932|CUP57828.1;An248|OUO83125.1;YL31|ANU42625.
1;ATCC_29863|EHM49955.1 
cluster
3062 4 
P1926
4 
GO:0046336; P:ethanolamine catabolic 
process; IBA:GO_Central 
2789STDY5834932|CUQ41065.1;An248|OUO83464.1;YL31|ANU42382.
1;ATCC_29863|EHM47952.1 
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cluster
2633 4 
E3PY9
9 
GO:0006591; P:ornithine metabolic 
process; TAS:UniProtKB 
2789STDY5834932|CUQ29162.1;An248|OUO83539.1;YL31|ANU42311.
1;ATCC_29863|EHM54568.1 
cluster
2723 4 
C1FW
08 
GO:0006591; P:ornithine metabolic 
process; IDA:UniProtKB 
2789STDY5834932|CUQ29280.1;An248|OUO83532.1;YL31|ANU42318.
1;ATCC_29863|EHM54561.1 
cluster
2827 4 
E3PY9
7 
GO:0006591; P:ornithine metabolic 
process; IDA:UniProtKB 
2789STDY5834932|CUQ29196.1;An248|OUO83537.1;YL31|ANU42313.
1;ATCC_29863|EHM54566.1 
cluster
2982 4 
E3PY9
8 
GO:0006591; P:ornithine metabolic 
process; IDA:UniProtKB 
2789STDY5834932|CUQ29181.1;An248|OUO83538.1;YL31|ANU42312.
1;ATCC_29863|EHM54567.1 
cluster
2731 4 
P0A1
D2 
GO:0031469; C:polyhedral organelle; 
IEA:InterPro 
2789STDY5834932|CUP71147.1;An248|OUO82151.1;YL31|ANU41988.
1;ATCC_29863|EHM42365.1 
cluster
2871 4 
P0A1
D2 
GO:0031469; C:polyhedral organelle; 
IEA:InterPro 
2789STDY5834932|CUP99707.1;An248|OUO83195.1;YL31|ANU42686.
1;ATCC_29863|EHM52290.1 
cluster
2952 4 
P0A1
D2 
GO:0031469; C:polyhedral organelle; 
IEA:InterPro 
2789STDY5834932|CUP99735.1;An248|OUO83196.1;YL31|ANU42687.
1;ATCC_29863|EHM52288.1 
cluster
2244 5 
P2344
6 
GO:0071978; P:bacterial-type 
flagellum-dependent swarming 
motility; IBA:GO_Central 
2789STDY5834932|CUP86983.1;An248|OUO84117.1;YL31|ANU40129.
1;An306|OUO41293.1;ATCC_29863|EHM53550.1 
cluster
2270 5 
P3906
3 
GO:0071978; P:bacterial-type 
flagellum-dependent swarming 
motility; IBA:GO_Central 
2789STDY5834932|CUP87040.1;An248|OUO84119.1;YL31|ANU40131.
1;An306|OUO41291.1;ATCC_29863|EHM53552.1 
cluster
2305 5 
P2450
1 
GO:0071978; P:bacterial-type 
flagellum-dependent swarming 
motility; IBA:GO_Central 
2789STDY5834932|CUP86639.1;An248|OUO84107.1;YL31|ANU40119.
2;An306|OUO41301.1;ATCC_29863|EHM53539.1 
cluster
2336 5 
P2344
6 
GO:0071978; P:bacterial-type 
flagellum-dependent swarming 
motility; IBA:GO_Central 
2789STDY5834932|CUP87427.1;An248|OUO84131.1;YL31|ANU40143.
1;An306|OUO41279.1;ATCC_29863|EHM53564.1 
cluster
2463 5 
P2450
0 
GO:0071978; P:bacterial-type 
flagellum-dependent swarming 
motility; IBA:GO_Central 
2789STDY5834932|CUP86599.1;An248|OUO84106.1;YL31|ANU40118.
1;An306|OUO41302.1;ATCC_29863|EHM53538.1 
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cluster
2194 5 
Q0AX
B7 
GO:0006935; P:chemotaxis; 
IEA:UniProtKB-UniRule 
2789STDY5834932|CUP86231.1;An248|OUO84097.1;YL31|ANU40110.
1;An306|OUO31958.1;ATCC_29863|EHM38114.1 
cluster
2239 5 
Q9X0
06 
GO:0006935; P:chemotaxis; 
IEA:UniProtKB-KW 
2789STDY5834932|CUP87493.1;An248|OUO84133.1;YL31|ANU40145.
1;An306|OUO41277.1;ATCC_29863|EHM53566.1 
cluster
2240 5 
P2181
3 
GO:0006935; P:chemotaxis; 
IEA:UniProtKB-KW 
2789STDY5834932|CUP86340.1;An248|OUO84100.1;YL31|ANU40113.
1;An306|OUO31960.1;ATCC_29863|EHM38117.1 
cluster
2319 5 
P2345
3 
GO:0050918; P:positive chemotaxis; 
IMP:CACAO 
2789STDY5834932|CUP87107.1;An248|OUO84121.1;YL31|ANU40133.
2;An306|OUO41289.1;ATCC_29863|EHM53554.1 
cluster
2350 5 
Q0AY
K9 
GO:0006935; P:chemotaxis; 
IEA:UniProtKB-UniRule 
2789STDY5834932|CUP87524.1;An248|OUO84134.1;YL31|ANU40146.
1;An306|OUO41276.1;ATCC_29863|EHM53567.1 
cluster
2437 5 
Q9W
Y63 
GO:0006935; P:chemotaxis; 
IEA:UniProtKB-KW 
2789STDY5834932|CUP86742.1;An248|OUO84110.1;YL31|ANU40122.
1;An306|OUO41299.1;ATCC_29863|EHM53542.1 
cluster
2210 5 
O677
50 
GO:0009306; P:protein secretion; 
IEA:InterPro 
2789STDY5834932|CUP87233.1;An248|OUO84125.1;YL31|ANU40137.
1;An306|OUO41285.1;ATCC_29863|EHM53558.1 
cluster
2343 5 
P3562
0 
GO:0009306; P:protein secretion; 
IEA:InterPro 
2789STDY5834932|CUP87365.1;An248|OUO84129.1;YL31|ANU40141.
1;An306|OUO41281.1;ATCC_29863|EHM53562.1 
cluster
2363 5 
P3553
5 
GO:0009306; P:protein secretion; 
IEA:InterPro 
2789STDY5834932|CUP87266.1;An248|OUO84126.1;YL31|ANU40138.
1;An306|OUO41284.1;ATCC_29863|EHM53559.1 
cluster
2453 5 
P3553
8 
GO:0009306; P:protein secretion; 
IEA:InterPro 
2789STDY5834932|CUP87336.1;An248|OUO84128.1;YL31|ANU40140.
1;An306|OUO41282.1;ATCC_29863|EHM53561.1 
cluster
1763 7 
P8058
3 
GO:0071973; P:bacterial-type 
flagellum-dependent cell motility; 
IEA:InterPro 
2789STDY5834932|CUP86109.1;An248|OUO84093.1;YL31|ANU40106.
1;An306|OUO41062.1;ATCC_29863|EHM38107.1;An306|OUO39651.1;
An306|OUO31954.1 
cluster
2130 5 
P3981
0 
GO:0071973; P:bacterial-type 
flagellum-dependent cell motility; 
IEA:InterPro 
2789STDY5834932|CUQ42182.1;An248|OUO85163.1;YL31|ANU40099.
1;An306|OUO42493.1;ATCC_29863|EHM43411.1 
cluster
2207 5 
A1SE
Q0 
GO:0071973; P:bacterial-type 
flagellum-dependent cell motility; 
IEA:InterPro 
2789STDY5834932|CUP86675.1;An248|OUO84108.1;YL31|ANU40120.
1;An306|OUO41312.1;ATCC_29863|EHM53540.1 
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cluster
2220 5 
P2407
3 
GO:1902021; P:regulation of bacterial-
type flagellum-dependent cell motility; 
IMP:CACAO 
2789STDY5834932|CUP87135.1;An248|OUO84122.1;YL31|ANU40134.
1;An306|OUO41288.1;ATCC_29863|EHM53555.1 
cluster
2486 5 
Q8K9
K4 
GO:0071973; P:bacterial-type 
flagellum-dependent cell motility; 
IEA:InterPro 
2789STDY5834932|CUP87460.1;An248|OUO84132.1;YL31|ANU40144.
1;An306|OUO41278.1;ATCC_29863|EHM53565.1 
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Table S3.8. Protein list for each orthologous gene clusters for the genomes of Flavonifractor sp. An4, Flavonifractor sp. An9, 
Flavonifractor sp.  An82, Flavonifractor sp. An306. 
# 
cluster_
name 
protein_
number 
swiss_p
rot_id go_annotation protein_list 
cluster2
102 5 
Q2RGL
2 
GO:0006777; P:Mo-molybdopterin cofactor 
biosynthetic process; IEA:UniProtKB-UniRule 
An82|OUN22106.1;An4|OUO17000.1;An10|OUQ81968
.1;An306|OUO42827.1;An306|OUO41792.1 
cluster2
541 5 P44902 
GO:0006777; P:Mo-molybdopterin cofactor 
biosynthetic process; IEA:UniProtKB-KW 
An4|OUO16999.1;An82|OUN22107.1;An10|OUQ81967
.1;An306|OUO42828.1;An306|OUO41791.1 
cluster3
168 4 B6IQ15 
GO:0006777; P:Mo-molybdopterin cofactor 
biosynthetic process; IEA:UniProtKB-UniRule 
An4|OUO16998.1;An82|OUN22108.1;An10|OUQ81966
.1;An306|OUO42829.1 
cluster3
210 4 Q8YY90 
GO:0006777; P:Mo-molybdopterin cofactor 
biosynthetic process; IEA:UniProtKB-KW 
An4|OUO16450.1;An82|OUN21730.1;An306|OUO4179
5.1;An10|OUQ83256.1 
cluster3
198 4 
Q5WH0
8 
GO:0009231; P:riboflavin biosynthetic process; 
IEA:UniProtKB-UniRule 
An4|OUO17295.1;An82|OUN22005.1;An10|OUQ80892
.1;An306|OUO44622.1 
cluster3
201 4 B2V4J4 
GO:0009231; P:riboflavin biosynthetic process; 
IEA:UniProtKB-UniRule 
An4|OUO17294.1;An82|OUN22004.1;An10|OUQ80891
.1;An306|OUO44623.1 
cluster3
206 4 P50854 
GO:0009231; P:riboflavin biosynthetic process; 
IEA:UniProtKB-UniPathway 
An4|OUO17296.1;An82|OUN22006.1;An10|OUQ80893
.1;An306|OUO44621.1 
cluster3
212 4 Q97EZ4 
GO:0006012; P:galactose metabolic process; 
IEA:UniProtKB-UniRule 
An4|OUO16988.1;An82|OUN20983.1;An10|OUQ83371
.1;An306|OUO41913.1 
cluster3
213 4 
A5VME
2 
GO:0006012; P:galactose metabolic process; 
IEA:UniProtKB-UniRule 
An4|OUO16990.1;An82|OUN20981.1;An10|OUQ83373
.1;An306|OUO41915.1 
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Table S3.9. Ids for Eut and Pdu proteins for Flavonifractor spp.  
Protein YL31 
ATCC_29
863 
2789STD
Y5834932 
An248 An306 An82 An10 An4 
First Eut operon                 
AlcDH 
ANU3994
3.1 
EHM4105
3.1 
CUP4542
7.1 
OUO8506
0.1 
OUO3946
3.1 
OUN2249
7.1 
OUQ8324
9.1 
OUO1185
1.1 
EutA 
ANU3994
4.1 
EHM4105
2.1 
CUP4546
5.1 
OUO8506
1.1 
OUO3946
2.1 
OUN2249
8.1 
OUQ8324
8.1 
OUO1185
0.1 
EutB 
ANU3994
5.1 
EHM4105
1.1 
CUP4549
9.1 
OUO8506
2.1 
OUO3946
1.1 
OUN2249
9.1 
OUQ8324
7.1 
OUO1184
9.1 
EutC 
ANU3994
6.1 
EHM4105
0.1 
CUP4553
7.1 
OUO8506
3.1 
OUO3946
0.1 
OUN2250
0.1 
OUQ8324
6.1 
OUO1184
8.1 
EutL 
ANU3994
7.1 
EHM4104
8.1 
CUP4557
3.1 
OUO8506
4.1 
OUO3945
9.1 
OUN2250
1.1 
OUQ8324
5.1 
OUO1184
6.1 
AldDH 
ANU3994
8.1 
EHM4107
8.1 
CUP4561
5.1 
OUO8506
5.1 
OUO3945
8.1 
OUN2250
2.1 
OUQ8324
4.1 
OUO1184
5.1 
EutM 
CP015406
.2: 
490,436-
491,117 
EHM4107
7.1 
CUP4568
8.1  
NFJM010
00001.1:2
55050-
255725 
OUO3949
2.1 
OUN2264
6.1 
OUQ8342
5.1 
OUO1185
7.1 
EutT 
ANU3994
9.1 
EHM4107
6.1 
CUP4572
2.1 
OUO8506
6.1 
OUO3945
7.1 
OUN2250
3.1 
OUQ8324
3.1 
OUO1184
4.1 
PTAC 
ANU3995
0.1 
EHM4107
5.1 
CUP4576
1.1 
OUO8506
7.1 
OUO3945
6.1 
OUN2250
4.1 
OUQ8324
2.1 
OUO1184
3.1 
36% identity with ethanolamine 
utilization protein 
ANU3995
1.1 
EHM4107
4.1 
CUP4579
4.1 
OUO8506
8.1 
OUO3945
5.1 
OUN2250
5.1 
OUQ8324
1.1 
OUO1184
2.1 
EutN 
ANU3995
2.1 
EHM4107
3.1 
CUP4582
8.1 
OUO8506
9.1 
OUO3945
4.1 
OUN2250
6.1 
OUQ8324
0.1 
OUO1184
1.1 
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EutH 
ANU3995
3.1 
EHM4107
2.1 
CUP4585
9.1 
OUO8507
0.1 
OUO3945
3.1 
OUN2250
7.1 
OUQ8323
9.1 
OUO1184
0.1 
EutQ 
ANU3995
4.1 
EHM4107
1.1 
CUP4590
1.1 
OUO8507
1.1 
OUO3945
2.1 
OUN2250
8.1 
OUQ8323
8.1 
OUO1183
9.1 
         
Pdu Operon         
PduV 
ANU4151
4.1 
EHM4004
7.1 
CUP3087
7.1 
OUO8275
3.1 
OUO3764
7.1 
OUN2035
2.1 
  
PduU 
ANU4151
5.2 
EHM4004
6.1 
CUP3090
4.1 
OUO8294
4.1 
OUO3765
6.1 
OUN2040
7.1 
  
oxidoreductase 
ANU4151
6.1 
EHM4004
4.1 
CUP3096
5.1 
OUO8275
2.1 
OUO3764
5.1 
OUN2035
0.1 
  
PduT 
ANU4151
7.1 
EHM4004
3.1 
CUP3099
0.1 
OUO8275
1.1 
OUO3764
4.1 
OUN2034
9.1 
  
hypothetical protein 
ANU4151
8.1 
EHM4004
2.1 
CUP3102
0.1 
OUO8275
0.1 
OUO3765
5.1 
OUN2034
8.1 
  
PduS 
ANU4151
9.1 
EHM4004
1.1 
CUP3105
3.1 
OUO8274
9.1 
OUO3764
3.1 
OUN2034
7.1 
  
AldDH 
ANU4152
0.1 
EHM4004
0.1 
CUP3108
1.1 
OUO8274
8.1 
OUO3764
2.1 
OUN2034
6.1 
  
PduO 
ANU4152
1.1 
EHM4003
9.1 
CUP3111
0.1 
OUO8274
7.1 
OUO3764
1.1 
OUN2034
5.1 
  
PduN 
ANU4152
2.1 
EHM4003
8.1 
CUP3113
6.1 
OUO8274
6.1 
OUO3764
0.1 
OUN2034
4.1 
  
PduM 
ANU4152
3.1 
EHM4003
7.1 
CUP3116
4.1 
OUO8274
5.1 
OUO3763
9.1 
OUN2034
3.1 
  
PTAC 
ANU4152
4.1 
EHM4003
5.1 
CUP3122
0.1 
OUO8274
3.1 
OUO3763
7.1 
OUN2034
1.1 
  
PduA 
ANU4152
5.1 
EHM4003
4.1 
CUP3125
8.1 
OUO8274
2.1 
OUO3763
6.1 
OUN2034
0.1 
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PduJ 
ANU41526.
1 
EHM40033.
1 
CUP31293.
1 
OUO82741.
1 
OUO37635.
1 
OUN20339.
1 (contig 
break) 
 
PduH 
ANU4152
7.1 
EHM4003
2.1 
CUP3132
6.1 
OUO8274
0.1 
OUO3763
4.1 
OUN1883
7.1 
  
PduG 
ANU4152
8.1 
EHM4003
1.1 
CUP3135
5.1 
OUO8273
9.1 
OUO3763
3.1 
OUN1883
8.1 
  
PduE 
ANU4152
9.1 
EHM4003
0.1 
CUP3139
2.1 
OUO8273
8.1 
OUO3763
2.1 
OUN1883
9.1 
  
PduD 
ANU4153
0.1 
EHM4002
9.1 
CUP3143
6.1 
OUO8273
7.1 
OUO3763
1.1 
OUN1884
0.1 
  
PduC 
ANU4153
1.1 
EHM4002
8.1 
CUP3149
1.1 
OUO8273
6.1 
OUO3763
0.1 
OUN1884
1.1 
  
PduB 
ANU4153
2.1 
EHM4002
7.1 
CUP3154
4.1 
OUO8273
5.1 
OUO3762
9.1 
OUN1884
2.1 
  
PduJ 
ANU4153
3.1 
EHM4002
6.1 
CUP3158
5.1 
OUO8273
4.1 
OUO3762
8.1 
OUN1884
3.1 
  
AlcDH 
ANU4153
4.1 
EHM4002
5.1 
CUP3163
1.1 
OUO8273
3.1 
OUO3762
6.1 
OUN1884
4.1 
  
Regulator 
ANU4153
5.1 
EHM4002
4.1 
CUP3166
9.1 
OUO8273
2.1 
OUO3762
5.1 
OUN1884
5.1 
  
Histidine kinase  
ANU4153
6.1 
EHM4002
3.1 
CUP3172
7.1  
OUO8273
1.1 
OUO3762
4.1 
OUN1884
6.1 
  
Kinase 
ANU4153
7.1 
EHM4002
1.1  
CUP3177
7.1 
OUO8273
0.1 
contig 
break 
contig 
break 
  
         
Second Eut operon         
EutQ 
ANU4196
9.1 
EHM4233
8.1 
CUP7191
8.1 
OUO8213
1.1 
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EutH 
ANU4197
0.1 
EHM4233
7.1 
CUP7188
4.1 
OUO8213
2.1 
    
BMC protein 
ANU4197
1.1 
EHM4233
6.1 
CUP7185
1.1 
OUO8213
3.1 
    
PduS homolog, cobalamin reductase 
ANU4197
2.1 
EHM4233
5.1 
CUP7180
5.1 
OUO8213
4.1 
    
EutN 
ANU4197
3.1 
EHM4233
4.1 
CUP7176
1.1 
OUO8213
5.1 
    
36% identity with PduM 
ANU4197
4.1 
EHM4233
3.1 
CUP7172
4.1 
OUO8213
6.1 
    
EutJ 
ANU4197
5.1 
EHM4233
2.1 
CUP7168
0.1 
OUO8213
7.1 
    
PTAC 
ANU4197
6.1 
EHM4233
1.1 
CUP7163
3.1 
OUO8213
8.1 
    
EutT 
ANU4197
7.1 
EHM4233
0.1 
CUP7159
7.1 
OUO8213
9.1 
    
EutM 
ANU4197
8.1 
EHM4232
9.1 
CUP7155
1.1 
OUO8214
0.1 
    
EutM 
ANU4197
9.1 
EHM4232
8.1 
CUP7151
1.1 
OUO8214
1.1 
    
EutM 
ANU4198
0.1 
EHM4237
3.1 
CUP7145
1.1 
OUO8214
3.1 
    
EutL 
ANU4198
1.1 
EHM4237
2.1 
CUP7141
4.1 
OUO8214
4.1 
    
EutC 
ANU4198
2.1 
EHM4237
1.1 
CUP7137
2.1 
OUO8214
5.1 
    
EutB 
ANU4198
3.1 
EHM4237
0.1 
CUP7133
1.1 
OUO8214
6.1 
    
EutA 
ANU4198
4.1 
EHM4236
9.1 
CUP7129
8.1 
OUO8214
7.1 
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pdtaS; two-component system, sensor 
histidine kinase PdtaS [EC:2.7.13.3] 
ANU4198
5.1 
EHM4236
8.1 
CUP7125
2.1 
OUO8214
8.1 
    
pdtaR; two-component system, 
response regulator PdtaR 
ANU4198
6.1 
EHM4236
7.1 
CUP7121
9.1 
OUO8214
9.1 
    
EutP 
ANU4198
7.1 
EHM4236
6.1 
CUP7118
5.1 
OUO8215
0.1 
    
EutS 
ANU4198
8.1 
EHM4236
5.1 
CUP7114
7.1 
OUO8215
1.1 
    
AlcDH/AldDH 
ANU4198
9.1 
EHM4236
4.1 
CUP7111
4.1 
OUO8215
2.1 
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Table S3.10. Distance Matrix for Pdu Operon in F. plautii YL31 with the one in Salmonella enterica subsp. enterica serovar Typhimurium 
str. LT2. 
F. plautii YL31  Salmonella enterica  Distancea 
ANU41514.1 NP 461001.1 PduV 1.124 
ANU41515.2 NP 461000.1 PduU 0.431 
ANU41517.1 NP 460999.1 PduT 0.856 
ANU41519.1 NP 460998.1 PduS 0.856 
ANU41520.1 NP 460996.1 PduP 0.431 
ANU41521.1 NP 460995.1 PduO 0.744 
ANU41522.1 NP 460994.1 PduN 0.744 
ANU41524.1 NP 460992.1 PduL 0.470 
ANU41525.1 NP 460983.1 PduA 0.255 
ANU41526.1 NP 460990.1 PduJ 0.393 
ANU41527.1 NP 460989.1 PduH 0.916 
ANU41528.1 NP 460988.1 PduG 0.693 
ANU41529.1 NP 460987.1 PduE 0.322 
ANU41530.1 NP 460986.1 PduD 0.431 
ANU41531.1 NP 460985.1 PduC 0.105 
ANU41532.1 NP 460984.3 PduB 0.357 
ANU41533.1 NP 460990.1 PduJ 0.223 
ANU41534.1 NP 460997.1 PduQ 0.393 
aEstimates of Evolutionary Divergence between Sequences, the number of amino acid substitutions per site from between sequences are shown. Analyses were conducted using 
the Poisson correction model (Zuckerkandl & Pauling, 1965). The analysis involved 42 amino acid sequences. All positions containing gaps and missing data were eliminated. There 
were a total of 40 positions in the final dataset. Evolutionary analyses were conducted in MEGA6. 
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Table S3.11. Blast results for Enoate Reductase (ERED) for Eubacterium spp.  
Description  Score  eValue  Identities  Positives  Gaps 
lcl|E. ramulus 2789STDY|CUN25748.1  1404 0 100 100 0 
lcl|E. ramulus MGYG01456|CABKSU010000016.1_3  1399 0 99 99 0 
lcl|E. ramulus ATCC|ERK50666.1  1399 0 99 99 0 
lcl|E. ramulus MGYG02278|CABMEW010000007.1_31  1322 0 95 98 0 
lcl|E. ramulus 21|PWE87608.1  1321 0 95 98 0 
lcl|E. oxidoreducens|SDB03427.1  1118 0 79 88 0 
 
 
Table S3.12. Blast results for Phloretin Hydrolase (Phy) for Eubacterium spp.  
Description Score eValue Identities Positives Gaps 
lcl|E. ramulus ATCC|ERK50757.1  565 0 99 99 0 
lcl|E. ramulus MGYG01456|CABKSU010000011.1_31  553 0 99 99 0 
lcl|E. ramulus 2789STDY|CUN27723.1  550 0 99 99 0 
lcl|E. ramulus MGYG02278|CABMEW010000016.1_10  520 0 91 96 0 
lcl|E. oxidoreducens|SDB04098.1  403 5.00E-142 72 83 1 
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Table S3.13. Blast results for NADH oxidase for Flavonifractor spp. 
Description  Score  eValue  Identities  Positives  Gaps 
lcl|2789STDY5834932|CUQ36251.1  1353 0 99 99 0 
lcl|ATCC_29863|EHM51844.1  1330 0 99 99 0 
lcl|YL31|ANU42126.2  1328 0 99 99 0 
lcl|An248|OUO81996.1  1300 0 98 98 0 
lcl|An306|OUO41927.1  1259 0 92 97 0 
lcl|An82|OUN23292.1  1251 0 93 96 0 
 
Table S3.14. Blast results for Phloretin Hydrolase (Phy) for Flavonifractor spp. 
Description  Score  eValue  Identities  Positives  Gaps 
lcl|ATCC_29863|EHM54196.1  550 0 100 100 0 
lcl|2789STDY5834932|CUQ29647.1  550 0 100 100 0 
lcl|YL31|ANU42335.1  550 0 100 100 0 
lcl|An248|OUO83512.1  547 0 99 99 0 
lcl|An10|OUQ80369.1  507 0 91 95 0 
lcl|An82|OUN23291.1  473 2.00E-169 85 91 0 
lcl|An306|OUO41926.1  472 4.00E-169 86 90 0 
lcl|An4|OUO11830.1  469 4.00E-168 83 90 0 
 
109 
 
Appendix 4. Advances in Gut Microbiome Research, Opening New Strategies to Cope with a 
Western Lifestyle 
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sulfide (H2S), IL-1 receptor antagonist (IL-1ra), interleukin-10 (IL-10), interleukin-1β (IL-1β), 
interleukin-6 (IL-6), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), 
lipopolysaccharides (LPS), Nonalcoholic steatohepatitis (NASH), Nuclear Factor kappa beta (NF-
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necrosis factor-α (TNF-α), trimethylamine-N-oxide (TMAO), ω-3 polyunsaturated fatty acids (-3 
PUFAs), ω-6 polyunsaturated fatty acids (ω-6 PUFA).  
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Abstract 
The 'westernization' of global eating and lifestyle habits is associated with the growing 
rate of chronic diseases, mainly cardiovascular diseases, cancer, type 2 diabetes mellitus, and 
respiratory diseases. The primary prevention approach is to make nutritional and behavioral 
changes, however, there is another important determinant of our health that only recently has 
been considered and is the presence of beneficial microorganisms and their products in our 
gastrointestinal tract. Microorganisms living in our body can alter the fate of food, drugs, 
hormones, and xenobiotics, and recent studies point to the use of microorganisms that can 
counteract the harmful effects of certain compounds introduced or produced endogenously in 
our body. This review considers the effects of the western lifestyle on adiposity, glucose 
metabolism, oxidative markers and inflammation profile, emphasizes on the studies that have 
investigated bacterial strains and products of their metabolism that are beneficial under this 
lifestyle, and examines the screening strategies that recent studies are using to select the most 
promising probiotic isolates. In addition, we consider the relevance of studying the microbiota of 
metabolically healthy people under a western lifestyle for the understanding of the key 
components that delay the development of chronic diseases.  
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Introduction 
Our modern societies have settled on large urban arrangements that have changed behavior and 
alimentary patterns. The establishment of new alimentary habits has been influenced by industrialization 
and technological advances which have minimized the time for preparing and consuming meals, reduced 
the cost of livestock, dairy, and sugar-sweetened products, vegetable oils, and flours, and increased the 
availability of these foods, especially, to low-income families[1]. Nowadays, the trend in nutritional 
epidemiology is the analysis of dietary patterns (i.e. through food-frequency questionnaires) to assess 
habits in food consumption. In this line, several studies have focused on identifying the main dietary 
factors that are common to the modern diet. For instance, Hu et al. (1998) identified a 'western dietary 
pattern' through factor analysis of dietary patterns among cohorts in the United States. The authors 
described this dietary pattern as a diet with a “higher intake of processed meat, red meat, butter, high-
fat dairy products, eggs, and refined grains”. Likewise, Slattery et al. (1999) identified a similar dietary 
pattern with “high levels of red meat, processed meat, fast food, refined grains, and sugar- containing 
foods, and low levels of vegetables (other than potatoes) and fruits, with the predominant fruit being 
canned fruit”[2], [3]. Importantly, the 'western diet' is no longer restricted to western societies, 
globalization and urbanization are increasing the worldwide exposition to this dietary pattern. For 
example, a Japanese study found a 'westernized Japanese pattern' associated with “high intakes of bread, 
meat, processed meat, fruit juice, coffee, black tea, soft drinks, sauces, mayonnaise, and dressing”[4]. 
Overall, the 'western diet' can be understood as a dietary pattern with a high intake of refined sugars, 
refined vegetable oils, and livestock products, and low intake of fresh fruits and vegetables[5].  
Concerns with the modern alimentary pattern can be traced back to the scientific literature of 
1939, when Weston Price published his findings on modern degeneration related to the modernized 
diet[6]. Currently, not only the modern dietary habits are of concern but also low-activity high-stress 
occupations, sedentarism, alcohol binge drinking, and smoking. These behavior and alimentary patterns 
will be defined from now on as the 'western lifestyle'[7]–[9]. This lifestyle is increasingly being associated 
with several conditions, including: obesity, alzheimer's disease[10], cardiovascular disease, type 2 
diabetes mellitus[11], non-alcoholic fatty liver disease[12], hypertension[13], osteoporosis[14], 
autoimmunity[15], and cancer[16]. There are several risk factors for developing chronic diseases, 
including genetic, environmental, demographic, social and other factors that are not the scope of this 
review, instead the objective of this review is to relate the research made in the fields of microbiology, 
immunology, and nutrition to explain the role of gut microbiota as a risk factor of 'western lifestyle'-
related chronic conditions, and then the strategies that are being developed to shift the gut microbiota 
from a risk factor toward a more protective state that helps ameliorate the effects of this lifestyle. 
The Healthy Western Microbiota  
The concept of the human microbiota, as first described by Joshua Lederberg, is defined as “the 
ecological community of commensal, symbiotic, and pathogenic microorganisms that literally share our 
body space”[17]. Major efforts are being made worldwide in order to understand the composition and 
functional states of the healthy gut microbiota. So far, projects like the Human Microbiome Project 
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Consortium among others[18]–[20] have found that the gut microbiome of healthy individuals varies 
significantly and only a few species from the dominant bacterial phyla have been consistently described, 
these are Firmicutes, Bacteroidetes and Actinobacteria, with Proteobacteria and Verrucomicrobia also 
present in lower abundance. Other studies also evidence that the microbiome of healthy and non-healthy 
states can be distinguished, as it is the case for ulcerative colitis, Crohn´s disease[20], chronic fatigue 
syndrome[21], rheumatoid arthritis[22], type I diabetes[23], and type II diabetes[24]; nevertheless, one 
study warns that the patient's treatment can exert changes in the microbiota[25].  
Although not a single marker can be identified as representative of a healthy gut microbiome, a 
higher proportion of butyrate-producing and mucin-degrading bacteria has been mentioned in some 
studies[23], [26], [27]. Butyrate is a short chain fatty acid produced mainly by bacterial fermentation of 
non-digestible fiber in the colon, and a correct balance of a butyrate-producing microbiota may induce 
the synthesis of mucin in the gut epithelium thus maintaining gut integrity[23], [28]. Studies have shown 
that butyrate can enhance the assembly of tight junction proteins through regulation of AMP-activated 
protein kinase (AMPK), however the mechanism of AMPK activation is unknown[29]. Butyrate also has 
anti-inflammatory and anti-carcinogenesis effects, mainly by two mechanisms: activation of GPCRs 
(GPR41 and GPR43) and inhibiton of histone deacetylase (HDAC). Some of the effects of butyrate that 
have been observed are enhancement of the expression of certain pro-apoptotic genes in malignant cells 
and suppression of the pro-inflammatory pathway of Nuclear Factor kappa beta (NF-)[30]. It is 
estimated that butyrate producers represent approximately 25% of all human faecal bacteria[31]. 
Meanwhile, bifidobacteria is another important group for colon health, they represent about <5% of the 
microbiota in adult subjects. In disease states like Clostridium difficile associated diarrhea, a 3 log10 
reduction of this group of bacteria can occur[32]. Bifidobacteria contributes to colon health through the 
production of organic acids, like acetate and lactate, that are then used by butyrate-producing bacteria. 
Thus, a high abundance of butyrate-producers, mucin-degraders, and bifidobacteria could be an indicator 
of good health. 
Another common feature in some studies is greater gut diversity in healthy states. In lean twins, 
a greater bacterial diversity has been observed compared to their obese twins[33], in patients with morbid 
obesity subjected to a gastric bypass an increased richness of gut microbiota was also observed after the 
surgery along with positive health outcomes[34],  and another study analyzed the microbiota of non-colic 
and colic infants finding a higher microbiota diversity in non-colic infants during the first weeks after 
birth[35]. Hence, a high bacterial diversity can be another indicator of a healthy gut microbiota. 
In terms of western diet, Yatsunenko et al. (2012) observed that American microbiomes were enriched 
with genes degrading simple sugars and amino acids[36]. As mentioned earlier, a western diet is 
characterized by a higher intake of processed meat and red meat, thus individuals following this diet may 
benefit from a Bacteroides-rich microbiota instead of a Prevotella-rich microbiota. This last type of 
microorganisms produces more trimethylamine from L-carnitine, a nutrient in red meat, which is then 
converted to pro-atherosclerotic trimethylamine-N-oxide (TMAO), increasing the risk of atherosclerosis. 
A study by Lozupone et al. (2014) evidenced that the immune dysfunction of HIV-infected individuals 
compromises their ability to select for bacteria that match their diet, thus HIV-positive individuals 
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following a western diet, instead of having a Bacteroides-rich microbiota have a Prevotella-rich 
microbiota, which is normally present in individuals consuming a plant-based diet, in consequence, these 
HIV-positive subjects have an increased incidence of several health risks, including cardiovascular 
disease[37]–[39]. Therefore, a Bacteroides-rich microbiota is of benefit under a western diet, as it has 
been associated with reduced cardiovascular risk. 
In order to reveal the key components that make a healthy western microbiota, studies at the 
strain-level are needed. Evidence points that different strains have distinct effects, as it is the case with 
strains belonging to a genus enriched in people following a western diet, Lactobacillus[40]–[42]. For 
example, the administration of Lactobacillus reuteri ATCC PTA 4659 was associated with weight decrease 
in mice, whereas the administration of L. reuteri L6798 was associated with weight gain[43]. Differential 
effects have also been observed on the type of immunological response that the strain elicits, for example, 
Lactobacillus salivarius CECT5713 induced the anti-inflammatory cytokine IL-10, while Lactobacillus 
fermentum CECT5716 induced pro-inflammatory cytokines[44]. Studying the intestinal microbiota at the 
strain-level has been proved challenging due to the great variability at this taxonomic level among 
individuals and the lack of reliable, easy to use tools for accurate identification of bacteria at strain level, 
however, these studies indicate that the insights obtained at the phylum-level are limited and that the 
understanding of the functionality of strains can help delineate the boundaries of a healthy gut 
microbiota.  
Metabolic healthy subjects under a western lifestyle 
In order to better understand the healthy western microbiota, metabolic healthy individuals 
following a western lifestyle must be investigated. One potential group of people to be examined is 
metabolically healthy obeses. The prevalence of obesity in the United States has increased by 75% since 
1980 along with the acquisition of a western diet, and is associated with an increased incidence of 
cardiovascular disease, type 2 diabetes mellitus, hypertension, stroke, dyslipidemia, osteoarthritis, and 
some cancers[45], [46]. However, 10 to 30% of obese individuals are metabolically healthy and even 
have a lifelong health[47]. The physiological factors that characterized a metabolically healthy obese are 
decreased visceral and liver fat, number of macrophages in adipose tissue, mean adipocyte size, 
circulating C-reactive protein; while having an increase in serum adiponectin, and adipocyte insulin 
sensitivity[48]. The genetic background might play an important part in this scenario, as it has been 
observed that some ethnic groups at a higher body mass index (BMI) accumulate less liver fat, a factor 
that affects the metabolic outcome of the individual[49]. A study revealed that liver fat content is higher 
among Japanese than non-Hispanic whites despite a lower mean BMI, and the difference becomes more 
robust with a small increase in BMI; this might explain why obesity-related complications in Asians occur 
at a lower BMI[50].  
In African Americans, high rates of fructose malabsorption have been associated with reduced 
liver fat[51]. African-Americans also appear to be more resistant to hypertriglyceridemia (high blood levels 
of triglycerides) associated with insulin resistance[52]. Geographical factors might be also involved; 
migrants from lower-to-higher chronic disease areas (i.e., Japaneses that migrate to the United States) 
acquire a higher risk of developing a chronic disease[53]. But even under a similar background, differences 
are observed. Naukkarinen et al. (2014) studied 16 Finnish pairs of identical twins in which one twin was 
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obese and the other lean, they found that despite all twin pairs being of the same age, had similar age of 
onset of obesity and weight difference, half of the obese co-twins were metabolically as healthy as their 
lean co-twins while the other half of the obese co-twins exhibited a typical response to obesity, this was 
increased insulin production and resistance, dyslipidaemia, fatty liver, and higher blood pressure; they 
also observed that the one factor that best predicted the metabolic outcome was the level of liver fat[49]. 
It is now recognized that the gut microbiota can influence liver fat in the host, thus the microbiota 
might be one of the factors modulating the individual susceptibility to chronic disease. A study that 
observed an association of microbiota and liver fat accumulation demonstrated that gut microbiota 
directly induced non-alcoholic fatty liver disease (NAFLD) in mice. The authors performed fecal 
transplantations from mice that developed, or not, liver steatosis (responders and non-responders, 
respectively) during a 16 week period of high-fat diet (HFAD) to receiver mice. The responder-receiver 
mice developed a higher level of liver steatosis and had higher levels of branched-chain fatty acids from 
bacterial amino acid fermentation than non-responder-receiver mice[54]. Similarly, nonalcoholic 
steatohepatitis (NASH) (severe hepatic steatosis and liver inflammation) patients had an increase in ester 
compounds and endogenous alcohol most likely produced from bacterial metabolism compared to 
patients with simple steatosis (fatty liver) and healthy volunteers. It is worth mentioning that healthy 
subjects and obese non-NASH patients had similar blood-ethanol concentrations[55], [56] (for a review 
see [57]), thus indicating that even under an obese state, non-NASH patients may harbor a microbiota 
whose functionality resembles the one on a healthy state. In addition, the administration of probiotics 
can exert a positive effect on liver fat accumulation, which will be mentioned later. One potential 
mechanism for liver fat accumulation is that bacteria can suppress the expression of a lipoprotein lipase 
inhibitor, the fasting-induced adipose factor (Fiaf), thus increasing the lipase activity in the gut and 
affecting the outflow of free fatty acids to the liver[58]. In order to advance our understanding of the 
factors influencing metabolic health during a western diet, it is important to explore the microbiome of 
metabolically healthy individuals following a western diet which stay healthy at an advanced age, such 
studies might reveal components of the microbiome that can counteract the accumulation of liver fat, 
protecting the host from further health outcomes.  
 
The Western Lifestyle and Inflammation 
Nowadays in the modern societies, an unbalanced diet, stress, and smoking can onset the 
inflammatory response daily, leading to a chronic low-grade systemic inflammation. Inflammation is the 
process through which the body limits pathogen invasion and controls tissue damage after injury. It is 
mediated by many soluble factors essential to signal immune cells to eliminate the aggressor and initiate 
tissue repair. Among these factors are secreted polypeptides called cytokines, which include tumor 
necrosis factor- (TNF-), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10), IL-1 receptor 
antagonist (IL-1ra), and soluble TNF- receptor (sTNF-R). TNF- and IL-1 are pro-inflammatory cytokines, 
IL-6 has both anti- and pro-inflammatory properties, while IL-10, IL-1ra and sTNF-R are anti-inflammatory 
cytokines. In acute inflammation, the levels of cytokines rapidly increase several fold and decrease when 
the infection is controlled or the injury is healed. However, acute inflammation does not always subside, 
and can become a chronic low-grade inflammation characterized by a two- to three-fold increase in the 
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concentrations of cytokines and C-reactive protein, a molecule produced by the liver in response to 
inflammation[59].  
One way the western lifestyle can cause inflammation is by increasing the number of compounds 
and microbial products with inflammatory capability (Fig. 4.1). Among these are: lipopolysaccharides (LPS) 
or endotoxins, D-lactate, acetaldehyde, hydrogen sulfide, toxic products of bacterial protein metabolism, 
and oxidative radicals, as described below. A role of antibiotics is also discussed.  
Figure 4.1. Comparison of a system suffering from western-related conditions (right, in red) and 
a system with amelioration of western-related conditions (left, in orange). One aspect of a western 
lifestyle is the higher intake of ω-6 PUFA (depicted as FFA), this enhances the formation of 
chylomicrons allowing the translocation of LPS, these then activate basolateral TLR which 
initiates a pro-inflammatory response, one overall consequence is the alteration of the gut 
epithelium and its permeability (depicted as deteriorated epithelium and compromised tight 
junctions), exacerbating inflammation by allowing the translocation of more LPS, pro-
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inflammatory cytokines, FFA, among other luminal compounds (1). LPS/ pro-inflammatory 
cytokines/ FFA can enter portal and systemic circulation, one consequence is the alteration of fat 
metabolism, thus enhancing fat accumulation in liver (2), and in adipose tissue, adipocytes increase 
in size, FFA synthesis is enhanced (depicted as FFA in circulation), and an elevated pro-
inflammatory state occurs (depicted as increased infiltration of macrophages and production of 
pro-inflammatory cytokines) (3). The western lifestyle includes higher intake of simple sugars and 
red-meat, lower intake of antioxidants (depicted as presence of oxidants), and sedentarism 
(depicted as low production of sIgA), some of the consequences are lower-capacity for antigen 
neutralization (depicted as LPS not bound to sIgA) and damage to the DNA of epithelial cells 
(depicted as DNA strand breakage) (4). For the amelioration of these conditions, a person can take 
different approaches, these include exercise (depicted as high production of sIgA), intake of dietary 
nutrients (i.e. polyphenols and -3 PUFAs) (depicted as antioxidants), probiotics, prebiotics, and 
SCFA (depicted as fiber, bacterial active compounds and probiotics) (5). Some of the effects of 
these approaches include the reestablishment of gut epithelium permeability and a decrease in LPS 
translocation, TLR activation, chylomicron formation, presence of LPS/cytokines/FFA in portal 
and systemic circulation (6), liver fat (7), adipocyte size, FFA synthesis, macrophage infiltration 
in adipose tissue (8), and an overall amelioration of the inflammatory state (depicted as a higher 
concentration of anti-inflammatory cytokines compared to pro-inflammatory cytokines  [6 and 8]). 
FFA, free fatty acids. For more details see the text. 
 
Lipopolysaccharides (LPS) 
LPS are part of the outer membrane of Gram-negative bacteria and are one of the most important 
compounds that can induce a low-grade inflammation. LPS is bound by Toll like receptors (TLR) in cell 
surfaces, specifically TLR-4. Particularly in intestinal epithelial cells, these receptors mediate the 
inflammatory response triggering different mechanisms depending on its membrane location, apical or 
basolateral. Apical TLR are normally exposed to luminal antigens, including bacteria and their LPS, and 
their stimulation results in a homeostatic response and tolerance but not inflammation. In contrast, 
basolateral TLR are exposed to antigens only if these have crossed important epithelial barriers, and are 
potentially infectious. Therefore, basolateral TLR stimulation triggers the activation of the transcription 
factor NF-, one of the most important mediators of the pro-inflammatory response[60]. Extra-luminal 
LPS can also reach the bloodstream, and subsequently, bind TLR on the surface of other cells, like blood 
vessel, muscle, joint, adipose, and hepatic Kupffer cells. Their activation affects processes like insulin 
signaling, adipose tissue differentiation, lipogenesis, and it has been suggested that the interaction LPS-
adipocyte–macrophage can amplify the low-grade inflammation to the level of influencing metabolic 
disorders[61]. Thus, inflammation is a mechanism vital to set a prompt response to pathogens, however, 
LPS can onset a low-grade inflammatory response that may alter the metabolic status of the host by 
unknown molecular mechanisms[62]. LPS are being increasingly associated with a number of conditions 
summarized in Table 4.1.
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Table 4.1. Conditions associated with high levels of plasmatic LPS. 
Disease/Condition Association with LPS 
Depression and 
Neurodegenerative 
diseases 
Peripheral inflammation can chronically activate brain microglia to 
produce elevated pro-inflammatory factors(Maes et al., 2013; L. Qin 
et al., 2007; Suffredini & Noveck, 2014).  
Cardiovascular Disease 
and Atherosclerosis  
Macrophages with a pro-inflammatory profile induced by TLR 
accumulate in blood vessel walls eventually forming a 
plaque(Caesar et al., 2010; Wiedermann, 1999).  
Chronic Fatigue 
Syndrome  
Serum levels of antibodies directed against LPS correlate to the level 
of fatigue(Maes & Leunis, 2008).  
Cancer 
LPS have been shown to increase the inflammatory activity of 
immune cells that generate oxidative radicals incrementing the 
chance of DNA damage in proliferating cells(Coussens & Werb, 
2002), and they also increase the adhesiveness and metastatic 
capacity of cancer cells(Hsu et al., 2011). 
Type 2 Diabetes Mellitus 
LPS decreased insulin sensitivity in healthy subjects that had a 
reduced response to insulin 24h after a LPS infusion protocol(Mehta 
et al., 2010).  
Obesity  
LPS are identified as a triggering factor since a 4-week treatment of 
LPS in mice resulted in a similar whole-body, liver, and adipose 
tissue weight gain as in a HFAD(Cani et al., 2007).  
Autism  
The higher the level of LPS, the worse the social interaction of the 
patient(Emanuele et al., 2010).  
Systemic Lupus 
Erythematosus disease  
LPS increase systemic nucleosome release due to an enhancement 
of apoptosis and a decrease in the clearance of apoptotic cells(Licht, 
Van Bruggen, Oppers‐Walgreen, Rijke, & Berden, 2001).  
HIV-1  
LPS lead to neurological dysfunctions since the increase of cytokine 
production affects the permeability of the blood-brain barrier 
allowing the trespassing of the virus into the brain(Dohgu & Banks, 
2008).  
Retinal pathologies 
LPS are an underlying factor for their progression due to the 
sensitivity of the retinal pigment epithelium cells to inflammatory 
stress(Leung, Barnstable, & Tombran-Tink, 2009).  
Autoimmune Joint 
Inflammation 
An oral administration of LPS can exacerbate arthritis in animal 
models and antibiotics can suppress the recurrence of the 
disease(Yoshino, Sasatomi, Mori, & Sagai, 1999).  
118 
 
Several behaviors associated with the western lifestyle can affect the levels of plasmatic LPS. 
Among these are sedentarism, smoking, stress, and an unhealthy diet. Lira et al. (2010) showed that 
sedentary people had higher levels of plasmatic LPS than highly trained people at rest[63]. Pace et al. 
(2008) observed that cigarette smoke increased the expression of TLR4 and LPS binding[64]. Furthermore, 
it has been demonstrated that stress hormones stimulate the growth of LPS-containing bacteria such as 
Yersinia enterocolitica and Escherichia coli, and indeed, stress hormones achieved a 100,000-fold increase 
in viable E. coli in the cecum of mice within 24h and promote the synthesis of an autoinducer of bacterial 
growth[65]–[68]. Meanwhile, Cani et al. (2007) observed that a 4-week high-fat diet (HFAD) chronically 
increased plasma LPS concentration two to three times[69].  
Among the factors that increase the abundance of plasmatic LPS, diet is the best studied. It is 
recognized that HFADs induce high levels of LPS in the blood through the stimulation of chylomicron 
(droplets of fat) formation in intestinal epithelial cells, this facilitates LPS transcellular transport across the 
gut epithelium and subsequently, LPS reach the bloodstream[70]. However, several investigations point 
that not every type of HFADs increases the concentration of plasmatic LPS. HFADs consisting of oils rich in 
-6 polyunsaturated fatty acids (-6 PUFA), like safflower oil, cause a markedly increase in the 
concentration of plasmatic LPS and pro-inflammatory cytokines compared to diets rich in coconut oil or 
fish oil, which instead are protective against a LPS challenge[71], [72]. Meanwhile, a high-fructose diet 
(HFUD) promotes a more pronounced increase in plasmatic LPS concentration than diets rich in glucose. 
The mechanism for this is unknown, but evidence suggests that HFUD effects are related to the gut 
microbiota, since observations that oral non-absorbable antibiotics (antibiotics that act locally in the gut) 
can prevent the increase of plasmatic LPS, while the knockout of the LPS receptor TLR-4 greatly decreases 
lipid peroxidation, expression of TNF-, and accumulation of fat in the liver that occurs in fructose-fed 
mice[73]. In humans, HFUD is also associated with non-alcoholic fatty liver disease[74],[75]. The distinct 
effects of different fats and sugars might explain some of the variability of diet response among studies.  
Diet-dependent products of bacterial metabolism 
Bacterial products of metabolism released in our gut depend heavily on diet, host secretions and 
digestive enzymes, local conditions of pH, oxygen and hydrogen, gut transit time, and the composition 
and activity of the microbiota, among other factors[76]. Undigested dietary residues that arrive to the 
large intestine are the main substrates of bacterial metabolism, along with diet-independent substrates 
like endogenous host secretions. Undigested carbohydrates are fermented mainly to short-chain fatty 
acids (SCFAs) (such as butyrate, acetate, and propionate) and gases (mainly carbon dioxide, hydrogen, and 
methane)[77]. However, an excessive consumption of carbohydrates can also increase the concentration 
of toxic compounds derived from microbial metabolism, as it is the case of D-lactate, which is produced 
during carbohydrate fermentation by D-lactic acid bacteria. This compound inhibits the transport of L-
lactate and pyruvate, both essential for mitochondrial energy production[78]. Several conditions have 
been associated with high concentration of D-lactate, among these are chronic fatigue syndrome, 
diarrhea, short bowel syndrome, and diabetes[79]–[81]. Another toxic compound that has been 
associated with the excessive consumption of carbohydrates and alcoholic drinks is acetaldehyde. This 
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compound is produced by ethanol-oxidizing bacteria and yeast, and is formed during ethanol metabolism. 
When acetaldehyde is metabolized, oxidative radicals are generated, altering the permeability of the 
intestinal epithelium facilitating the translocations of luminal contents to the bloodstream[82]. 
Acetaldehyde is also a known carcinogenic compound[83], [84].  
While carbohydrates are fermented in the proximal colon, amino acids are fermented in the distal 
colon and this results in branched-chain fatty acids and potentially toxic metabolites such as ammonia, 
phenols, indoles, amines, TMAO, and volatile sulfur compounds[85], some of which are associated with 
the increased incidence of colorectal cancer[86], [87] and atherosclerosis[88] in high-red meat diets, fresh 
or processed. In the case of ammonia, higher levels of this compound in the blood can enter the brain and 
cause conditions like hepatic encephalopathy. Ammonia is a concern in subjects with chronic diseases in 
the thyroid gland, kidneys, lungs, and liver, and it is been increasingly associated with diabetes, extreme 
obesity[89], and tumor promotion[86]. Interestingly, the evidence suggests that white meat (poultry and 
fish) do not have the same detrimental effects of red meat. A possible explanation is the higher content 
of dietary haem in red meat, which will provide a source of iron for some proteins that can form toxic 
nitrosating agents from nitric oxide under anaerobic conditions[90].  
Another toxic compound of bacterial protein or carbohydrate metabolism is hydrogen sulfide 
(H2S). This is produced by sulphate-reducing bacteria during the oxidation of a wide range of substrates 
found in the large intestine[91]. In western countries there is a high incidence of people with a sulphate-
reducing bacteria, 50-70% compared to 10-20% of rural black Africans. The H2S produced by this group of 
bacteria can cause DNA damage in susceptible subjects with genetic predisposition that compromises 
DNA repair, as it is observed in patients suffering from ulcerative colitis and colorectal cancer[92]. The 
concentration of these toxic compounds of bacterial protein and carbohydrate metabolism in the 
intestinal lumen might be the result of interplay between the microbiota capacity to produce them and 
the host capacity to clear them up; in addition, the metabolic effect of these compounds would depend 
on the host susceptibility.  
Oxidative radicals 
Oxidative radicals are normally produced in high concentrations during food digestion and are 
also generated during cigarette smoking.  Ingestion of food with antioxidants can control the exposure to 
these compounds, consequently diets with low levels of antioxidants will not subside the constant 
oxidative stress that occur in the gut and lung epitheliums[93]–[95]. Overnutrition also increases the 
oxidative stress in the endoplasmatic reticulum, this activates a mediator of inflammation normally 
inactive in the hypothalamus, the kinase IKK, which regulates NF- through the phosphorylation of its 
inhibitor IB[96]. Oxidative stress also increases the activity of the PI 3-kinase and the myosin light chain 
kinase promoter that regulate the opening of the intestinal tight junction barrier. Thus oxidative stress 
mediates the enlargement of the spaces in the gut epithelium allowing the translocation of normally non-
invasive bacteria or their toxic products and components, which will induce the activation of NF-κβ 
perpetuating a vicious cycle of NF-κβ activation and impairment of the tight junction barrier[97],[98]. 
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In summary, the NF-κβ pathway that mediates inflammation can be activated by several cellular 
stresses, including LPS and compounds that generate cellular damage, like D-lactate, acetaldehyde, and 
H2S. Importantly, the activation of NF-κβ in parts of the body different from the gastrointestinal tract 
might eventually alter the permeability of the intestinal epithelium, facilitating the translocation of 
luminal materials, including LPS, which will exacerbate the low-grade inflammation state.  
Antibiotics 
The use of antibiotics in the modern era, including the extensive and inappropriate use in humans 
and animals, has changed the gut microbiota and this has diverse health implications. Broad-spectrum 
antibiotics can impact the gut microbiota causing a dysbiosis (“a pathological imbalance in a microbial 
ecological niche”[99]) which can alter the microbiota capacity to prevent the colonization and growth of 
pathogens and pathobionts with inflammatory capability. Two meta-analyses, one in >56,000 patients 
with C. difficile infection and the other in >7,000 inflammatory bowel disease (IBD) patients showed that 
antibiotics were a high risk factor for the development of these diseases[100], [101]. Depending on the 
class of antibiotic, the dosage, time of administration, and other antibiotic-independent factors, like 
genetic predisposition, sex, diet, physical activity, disease and environmental toxicants, antibiotics can 
exert effects on the weight (underweight and overweight states) and metabolic profile (pro-diabetic and 
anti-diabetic effect) of an individual (for a review see [102]). Antibiotic use carries other risks, like the 
dissemination of bacterial resistant genes and the alteration of the well established host-microbiota 
symbiosis through the eradication of important susceptible strains[103]. Recently, Moeller et al. (2016) 
demonstrated the cospeciation of certain symbiotic bacterial strains with hominids, including 
humans[104]. This unique set of symbionts might provide beneficial health effects to the host and could 
be under selective pressure by the modern use of antibiotics.  
Approaches that Counteract the Western Lifestyle 
The approaches that can effectively counteract the effects of the western lifestyle are the ones 
that mitigate the translocation of LPS, prevent toxic microbial metabolism, and modulate the pro-
inflammatory response and oxidative stress. Among these approaches are: exercise, dietary compounds, 
probiotics, prebiotics, and short chain fatty acids (SCFAs) (Fig. 4.1 and Table 4.2), as described below. 
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Table 4.2. Summary of beneficial factors under a western lifestyle. 
Disease/Condition Association with LPS 
Depression and 
Neurodegenerative 
diseases 
Peripheral inflammation can chronically activate brain microglia to 
produce elevated pro-inflammatory factors (Maes et al., 2013; L. Qin et 
al., 2007; Suffredini & Noveck, 2014).  
Cardiovascular Disease and 
Atherosclerosis  
Macrophages with a pro-inflammatory profile induced by TLR 
accumulate in blood vessel walls eventually forming a plaque (Caesar et 
al., 2010; Wiedermann, 1999).  
Chronic Fatigue Syndrome  
Serum levels of antibodies directed against LPS correlate to the level of 
fatigue(Maes & Leunis, 2008).  
Cancer 
LPS have been shown to increase the inflammatory activity of immune 
cells that generate oxidative radicals incrementing the chance of DNA 
damage in proliferating cells(Coussens & Werb, 2002), and they also 
increase the adhesiveness and metastatic capacity of cancer cells(Hsu et 
al., 2011). 
Type 2 Diabetes Mellitus 
LPS decreased insulin sensitivity in healthy subjects that had a reduced 
response to insulin 24h after a LPS infusion protocol(Mehta et al., 2010).  
Obesity  
LPS are identified as a triggering factor since a 4-week treatment of LPS 
in mice resulted in a similar whole-body, liver, and adipose tissue weight 
gain as in a HFAD(Cani et al., 2007).  
Autism  
The higher the level of LPS, the worse the social interaction of the 
patient(Emanuele et al., 2010).  
Systemic Lupus 
Erythematosus disease  
LPS increase systemic nucleosome release due to an enhancement of 
apoptosis and a decrease in the clearance of apoptotic cells(Licht, Van 
Bruggen, Oppers‐Walgreen, Rijke, & Berden, 2001).  
HIV-1  
LPS lead to neurological dysfunctions since the increase of cytokine 
production affects the permeability of the blood-brain barrier allowing 
the trespassing of the virus into the brain(Dohgu & Banks, 2008).  
Retinal pathologies 
LPS are an underlying factor for their progression due to the sensitivity 
of the retinal pigment epithelium cells to inflammatory stress(Leung, 
Barnstable, & Tombran-Tink, 2009).  
Autoimmune Joint 
Inflammation 
An oral administration of LPS can exacerbate arthritis in animal models 
and antibiotics can suppress the recurrence of the disease(Yoshino, 
Sasatomi, Mori, & Sagai, 1999).  
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Exercise  
Regular moderate doses of physical activity can ameliorate the effect of an LPS insult. In addition, 
it has been shown that exercise: controls the levels of pro-inflammatory cytokines, is associated with less 
liver fat[105], [106], protects against insulin resistance[107], and increases the levels of SCFAs. The main 
SCFAs are butyrate, acetate and propionate, and these have anti-carcinogenic as well as anti-
inflammatory properties and are essential for colon health[108]. Exercise can also modulate the 
microbiota, mice who exercised had lower intestinal and systemic bacterial loads than the group of 
sedentary mice, and had higher total and specific intestinal secretory immunoglobulin A (sIgA) which are 
the antibodies that control luminal antigens[109]. 
Dietary compounds 
Dietary compounds can also be introduced to prevent the negative effects of a western lifestyle. 
Among these are: dietary polyphenols and ω-3 PUFAs. Polyphenols can be found in wine, cocoa, 
cranberry, grape, curcumin, propolis, coffee, and tea; they function as antioxidants[110], strengthen 
intestinal barrier function[111], prevent endotoxemia (presence of LPS in the blood), the loss of some 
beneficial bacterial strains, and the development of diabetes[112]–[114]. The other compounds are ω-3 
PUFA, which are found in fish and olive oil, their addition to a high ω-6 PUFA diet can reverse some of the 
inflammatory effects of ω-6 PUFA, like immune cell infiltration and NF- activation[115]. It is possible 
that the beneficial effects of some of these dietary compounds are exerted through the modulation of the 
microbiota. For example, the administration of cranberry extract and grape polyphenols is associated with 
an increased abundance of the beneficial genus Akkermansia even under a high sucrose and/or HFAD, 
while ω-3 PUFA have been shown to enrich Lactobacillus and Bifidobacteria[113], [115]–[117].  
Probiotics 
A probiotic can be defined as “a live microorganism that, when administered in adequate 
amounts, confers a health benefit on the host”[118]. Several recent studies have evaluated the benefits 
of probiotic supplementation in the absence of lifestyle changes[119]. One example is the study of Park 
et al. (2013) who observed that mice following a HFAD for 8 weeks and supplemented with Lactobacillus 
curvatus HY7601 and Lactobacillus plantarum KY1032 for another 10 weeks gained 38% less weight than 
the unsupplemented controls[120]. The same group also demonstrated that L. curvatus HY7601 and L. 
plantarum KY1032 at high (1010 cfu/d) or low dosage (109 cfu/d) lowered plasma glucose, insulin, 
triglycerides, and oxidative stress levels in rodents fed a HFUD, while only at high doses lower liver mass 
and liver cholesterol were achieved[121].  
The bacteria Akkermansia muciniphila and Bacteroides uniformis have also been evaluated under 
a HFAD. Everard et al. (2013) showed that A. muciniphila reduced plasma levels of LPS, adiposity, insulin 
resistance, body weight (without changing food intake), hyperglycemia, increased adipocyte 
differentiation and lipid oxidation. The supplementation of live cells of A. muciniphila also prevented the 
thinning of the mucus layer that occurred when mice were fed a HFAD[122]. Meanwhile, Cano et al. (2012) 
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showed that an oral administration of B. uniformis CECT 7771 significantly reduced total body weight gain, 
liver fat, levels of cholesterol and triglycerides. Furthermore, B. uniformis CECT 7771 improved glucose 
metabolism, insulin and leptin sensitivity, and immune function of macrophages and dendritic cells. The 
authors also measured the number of fat micelles per enterocyte as an indicator of intestinal lipid 
absorption which contributes to adiposity, and B. uniformis CECT 7771 also achieved a significant 
reduction in this aspect[123]. It was also demonstrated, in meat-fed rats, that Lactobacillus acidophilus 
strains NCFM and N-2 promoted a significantly lower production of free amines[124] and lowered 
significantly, in rats and subjects, the activity of cecal bacterial ß-glucuronidase, nitro-reductase, and 
azoreductase enzymes which are responsible for the generation of potential precarcinogenic 
compounds[125]. 
Studies have not only evaluated probiotic effects under a particular nutritional environment but 
have examined their effect on the treatment of alcohol-drinking and smoking induced diseases. Several 
studies have shown an improvement of alcohol-induced liver injury in mice and human subjects. For 
example, Kirpich et al. (2008) performed a pilot study evaluating the effect of a 5-day probiotic 
supplementation consisting of Bifidobacterium bifidum and L. plantarum 8PA3 on 66 alcoholic individuals, 
the subjects under the probiotic treatment had significantly lower alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) activity than those treated with standard therapy (abstinence plus 
vitamins)[126]. Then again, the same group demonstrated that a Lactobacillus rhamnosus GG 
supplementation during the last 2-weeks of a 8-week diet containing 5% alcohol significantly improved 
liver function and reduced alcohol-induced endotoxemia, and hepatic steatosis in mice[127]. Meanwhile, 
Naruszewicz et al. (2002) determined that the administration of L. plantarum 299v to heavy smokers for 
6 weeks with no changes in lifestyle led to the significant reduction in systolic blood pressure, leptin, 
fibrinogen, IL-6, and monocytes adhesion to vein endothelial cells, thus reducing their risk of 
cardiovascular disease[128]. 
Prebiotics and SCFAs 
Prebiotics are non-digestible fiber that promotes the growth of beneficial microorganisms in the 
gastrointestinal tract. Some examples are: inulin, fructooligosaccharides, resistant starch, pectin, among 
others. These are metabolized to SCFAs, mainly propionate, acetate and butyrate, which as mentioned 
earlier exert many beneficial health outcomes. SCFAs activate the SCFA receptor GPR43 that reduces 
insulin sensitivity in adipose tissue and hence its fat accumulation, thereby reducing the uptake, synthesis, 
and oxidation of toxic fatty acids in other tissues[129], [130]. They also increase proliferation and inhibit 
apoptosis of intestinal cells[131], hinders intestinal secretion of chylomicron into the circulation[132], and 
limits inflammation perhaps through inhibition of the NF- pathway[133]. Galisteo et al. (2008) analyzed 
several studies that showed that prebiotics reduce all the abnormalities clustered in the metabolic 
syndrome, including: body weight gain, dyslipidemia, inflammation, hypertension, and insulin 
resistance[134].  
One drawback of prebiotics is that they can cause intestinal tract discomfort in individuals with 
limited microbial capacity to ferment the prebiotic. Thus, novel approaches to deliver the benefits of 
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prebiotics have been developed. Chambers et al. (2014) designed an improved prebiotic compound linked 
to a SCFA, propionate, which exploits the benefits of prebiotics while reducing the amount to be 
administrated. SCFAs have many health benefits, but if they are supplemented orally, they will be 
absorbed in the upper part of the small intestine where their benefits are limited. In contrast, this new 
compound ensures the delivery of the SCFA directly to the colon and at the same time, reduces the patient 
complains about prebiotics (e.g. gas production and bloating). Only 10 grams of the inulin-propionate 
ester achieved a 2.5-fold increase in colonic propionate, this in consequence, prevented weight gain, 
abdominal adiposity, liver fat, and reduced insulin resistance significantly more than in the prebiotic-only 
control group[135], [136].  
Probiotics and prebiotics are already been used clinically for the improvement of fatty liver[137], 
minimal hepatic encephalopathy[138], diabetes[139], abdominal adiposity[140], chronic fatigue 
syndrome[98], diarrhea, and Clostridium difficile disease[141], among others. Their supplementation is 
one alternative that is simple, safe, and that improves several health parameters simultaneously.  
 
Mechanism-based Screening Strategies for the Identification of Beneficial Strains  
There is great interest in developing commercial probiotic formulations that include new 
beneficial strains. Thus, several studies focus on different screening strategies to find promising strains 
that can favorably shape host pathways. These strains can act directly or indirectly on the cells of the 
immune system, epithelial cells, adipocytes, beta pancreatic cells, and can also control pathobionts. For 
instance, Cano et al. (2012) screened for the immunomodulation capabilities among different strains of 
Bacteroides spp., they carefully selected for a specific strain that had the lowest inflammatory potential 
on macrophages in vitro, specifically, low TNF- and high IL-10 production[123]. Poutahidis et al. (2013) 
also demonstrated that L. reuteri protected the host from obesity through an immunomodulatory 
mechanism, specifically, L. reuteri had an effect on the IL-10-dependent function of CD4+ T cells. 
Interestingly, the researchers could replicate the phenotype of the probiotic-supplemented mice in naïve 
recipient rodents by transferring only the purified CD4+ T cells[40]. Meanwhile, Ito et al. (2003) screened 
the inhibitory activity of 49 lactic bacterial strains on lipid peroxidation in vivo and in vitro[142]. While 
Kullisaar et al. (2011) measured the capacity of L. fermentum ME-3 to reduce oxidative stress, blood 
triglyceride levels, and lipoprotein status postprandially (2h after a meal) in a randomized double-blind 
placebo-controlled study with 100 healthy subjects[143]. Lastly, Chung et al. (2016) screened for a FFAs-
absorbing strain, L. reuteri JBD30 l, in a fecal sample of a healthy lean subject. The administration of this 
strain to experimental animals and human subjects under a clinical trial lowered the concentration of FFAs 
in the fluid of the small intestine thus increasing fecal fat excretion, the efficacy was comparable to the 
one obtained for orlistat, a FDA-approved pharmaceutical that also increases the content of fat in 
feces[144].  
There are other reported mechanisms that can guide screening studies, among these are the 
increment in the expression of lectins against Gram-positive bacteria, e.g. A. muciniphila produces 
RegIII[122]; the inhibition of T cell activation, e.g. S. boulardii produces a <3 kDa protein that has this 
effect[145]; production of phosphatases that can dephosphorylate LPS, as it has been observed also in S. 
boulardii[146]; upregulation of the expression of cytoprotective heat shock proteins that increase the 
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protection against oxidative damage and gut barrier loss in intestinal cells, e.g. Bacillus subtilis produces 
a quorum-sensing signal molecule, the competence- and sporulation-stimulating factor, which induces 
the heat shock protein Hsp27[147]; inhibition of the hydrogen peroxide-induced epithelial barrier 
disruption, e.g. L. rhamnosus GG produces two soluble proteins, p40 and p75, that control this 
aspect[148]; inhibition of NF- pathway[149]; and enhancement of SCFA production[129], [130].  
 
Conclusions 
The western lifestyle causes the overproduction of inflammation signals and underprovides the 
means to block them, driving the body into a chronic low inflammation state. To avoid some negative 
consequences, people can introduce light exercise, simple dietary compounds, probiotics, prebiotics 
and/or SCFAs into their daily routine. Interestingly, several recent studies have proved that the effects of 
probiotics and prebiotics can even be exploited under a HFAD and smoking conditions, providing a way to 
extend the health of a person with a western lifestyle. The presence of probiotics in dairy products has 
made them well accepted and recognized by their health benefits on the gastrointestinal tract, and given 
that the clinical evidence points that they also have benefits on the lipid and glucose metabolism, gut 
permeability, mood, and immune system, it is foresighted that this field will keep introducing new 
probiotic strains to the market, perhaps specific formulations depending on the desired benefit. We 
proposed that for the advancement of this field, it is important to understand if there is a microbiological 
component that is extending the health of asymptomatic lean, overweight and obese people following a 
western diet, and the factors that increase the fitness of these strains in the western microbiome. 
Ultimately, considering that in western countries the most prevalent diseases are inflammatory in nature, 
it will be important that in the near future, inflammation markers would be routinely screened in the 
clinical setup and anti-inflammatory probiotics administered as an alternative preventive measure.  
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